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ABSTRACT
N-linked protein glycosylation is characterized by the formation of a -glycosylamine
linkage to an asparagine residue within the Asn-Xaa-Ser/Thr consensus sequence. This
modification is found in organisms from eukaryotic, archaeal and bacterial domains and is
implicated in numerous cellular processes.
Recently, a system of N-linked glycosylation was characterized in a gram-negative
bacterium, Campylobacter jejuni. Glycosylation in this organism involves the transfer of a
heptasaccharide from an undecaprenyl-pyrophosphate (Und-PP) carrier onto the asparagine side-
chain of a protein. The genes in the 'pgl gene cluster' encode all of the proteins necessary for the
biosynthesis of the glycan donor and its ultimate transfer to protein. The heptasaccharide donor
has been characterized as GalNAc-al,4- GalNAc-al,4-(Glcp1,3)-GalNAc-al,4-GalNAc-al,4-
GalNAc-al,3-Bac-al ,PP-Und, where Bac is bacillosamine (2,4-diacetamido-2,4,6-
trideoxyglucose). A synthetic route was developed to access bacillosamine-phosphate, which
was incorporated into UDP-bacillosamine (UDP-Bac) and undecaprenyl-pyrophosphate-
bacillosamine (Und-PP-Bac), which are substrates for the Pgl enzymes. Using the synthetic
UDP-Bac, the role of the PglC glycophosphoryltransferase was elucidated in vitro. The activities
of the Pgl glycosyltransferases, PglA, PglJ, PglH and PglI were validated using the synthetic
Und-PP-Bac substrate and it was discovered that PglH is a polymerase that catalyzes the transfer
of the three terminal GalNAc residues. PglB is the oligosaccharyl transferase of the bacterial
system. Using the synthetic glycan donor, PglB was shown to act in vitro on a short peptide
substrate. This in vitro system enables detailed mechanistic investigations into the action of this
intriguing enzyme.
N-linked glycosylation in eukaryotes is catalyzed by oligosaccharyl transferase (OT), a
multimeric protein complex localized in the lumen of the endoplasmic reticulum. The Stt3p
protein of the eukaryotic OT cluster is homologous to the bacterial PglB enzyme. With the goal
of inhibiting OT in a cellular environment, a family of peptidomimetic inhibitors with nanomolar
affinity was synthesized. These inhibitors were evaluated for cellular inhibition of OT using a
novel, high-throughput assay that monitors the production of a reporter glycoprotein, secreted
alkaline phosphatase. The results from the screening yielded a hydrophobic peptidomimetic
compound as a potential candidate for further studies into the in vivo inhibition of OT.
Thesis Supervisor: Barbara Imperiali
Title: Class of 1922 Professor of Chemistry and Professor of Biology
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Chapter 1
Introduction
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Glycosylation is a complex, co- or post-translational protein modification that serves to
expand the diversity of the proteome. A vast array of carbohydrate units, together with a variety
of glycan-protein linkages, have been identified in glycoproteins originating from eukaryotic,
archaeal and bacterial organisms.1 Eukaryotic glycoproteins have been implicated in a multitude
of cellular processes including the immune response, intracellular targeting, intercellular
recognition and protein folding and stability.2 The biological role of prokaryotic glycoproteins
requires further exploration, but it is evident that glycosylation plays a vital role in pathogenicity
and evasion of the host immune system.3
This thesis focuses on N-linked protein glycosylation, which is characterized by a 3-
glycosylamine linkage to asparagine. 4' 5 This system has been extensively investigated in
eukaryotes, particularly in the yeast, Saccharomyces cerevisiae. Recently, a system of N-linked
glycosylation was discovered in a gram-negative bacterium, Campylobacterjejuni, which was
the first observation of this protein modification in the bacterial domain.6' 7 Although the 13-
glycosylamine-linkage to protein is conserved, the structure of the glycan that is transferred is
strikingly different between eukaryotic and bacterial systems.8 9 The biosynthetic machinery
responsible for this elaborate protein modification follows the same overall progression, whereby
an oligosaccharide is assembled step-wise on a polyisoprenyl-pyrophosphate carrier and
ultimately transferred to protein. Here, we provide a detailed comparison of the N-linked
glycosylation machinery of eukaryotic organisms, exemplified by Saccharomyces cerevisiae,
with the parallel process in the gram-negative bacterium, Campylobacterjejuni.
Chapters 2-4 of this thesis describes the synthesis of intermediates in the N-linked
glycosylation pathway in C. jejuni and the in vitro validation of the biosynthetic enzymes
15
involved in this process. In chapters 5 and 6, the design and evaluation of inhibitors for the
eukaryotic glycosylation process is described.
Eukaryotic glycosylation
Overview
N-linked glycosylation in eukaryotes is a co-translational process that is catalyzed by
oligosaccharyl transferase (OT), a protein complex localized in the lumen of the endoplasmic
reticulum (ER). °10 Proteins in the secretory pathway encode a signal sequence that is recognized
by the signal recognition particle (SRP) (Figure 1-1).l l 12 The SRP directs the growing
polypeptide chain to the translocon machinery, whereby transport across the ER membrane
occurs.3, 14 The signal peptidase complex, containing the essential Sec l p protein, then cleaves
the signal sequence,1 5 which moves the polypeptide to the compartment where OT-mediated
glycosylation takes place. OT transfers a tetradecasaccharide 'core' unit (GlcNAc2Man9Glc3) to
the polypeptide chain. Approximately 14-residues of the newly-translated polypeptide have to
clear the luminal surface of the ER-membrane for glycosylation to occur. 16 Since the protein is
still being translated by the ribosome during this process, global folding and tertiary structure of
the protein are not important determinants in the recognition events leading to glycosylation.
However, as discussed later, the local secondary structure around the site of glycosylation is a
vital determinant in this enzymatic process.
16
Figure 1-1. Co-translational glycosylation of proteins in the secretory pathway.
The process of protein translocation and glycosylation is a well-characterized eukaryotic
phenomenon. Significant work has been done on the role of the translocon, the signal peptidase
and oligosaccharyl transferase in this protein modification process. The exact machinery
involved in bacterial N-linked glycosylation is poorly defined. The glycosylation process is
thought to occur in the periplasm of bacteria, which is the functional equivalent of the ER in
eukaryotes. Currently, there is no conclusive evidence to demonstrate either the co-translational
or post-translational nature of N-Iinked glycosylation in the bacterial periplasm. If the C. jejuni
machinery functions post-translationally, on fully-folded proteins, it could potentially be one of
the most significant differences between the eukaryotic and prokaryotic processes of N-linked
glycosylation.
After OT -catalyzed glycosylation, the newly-synthesized glycoproteins undergo a series
of processing reactions including the enzymatic cleavage of the glucose residues and several of
the mannose residues on the tetradecasaccharide.17 Upon trimming of the two terminal glucose
residues, by glucosidase I and II, the protein enters a folding cycle mediated by two ER-resident
lectins with chaperone function, calnexin (membrane-bound) and calreticulin (soluble) (Figure 1-
17
2). 18-20 These lectins function together with the co-chaperone Erp57 (a thiol-oxidoreductase), to
facilitate the folding process.21 22 Dissociation of the glycoprotein-calnexin/calreticulin complex
is mediated by glucosidase II, by cleavage of the remaining glucose residue. In the case of
misfolded proteins, a UDP-glucose:glycoprotein glucosyltransferase (UGGT) acts to re-
glucosylate the protein, which can re-enter the calnexin/calreticulin cycle. The fully-folded
proteins that are released by the glycoprotein chaperones are acted on by ER mannosidases,
before transport to the Golgi with the aid of the ERGIC-53 lectin. Quality control at this stage,
ensures that non-native conformations are recognized by mannosidase-like lectins (Mnllp,
EDEM) to initiate the ER-associated degradation (ERAD) pathway.23 The fully-folded
glycoproteins that are transported to the Golgi, undergo further transformation involving glycan
trimming and elaboration, catalyzed by a series of glycosidases/glycosyltransferases, to afford
the plethora of diverse carbohydrate units that are present on eukaryotic glycoproteins.
The calnexin/calreticulin cycle exemplifies the intricate mechanisms by which eukaryotic
cells maintain protein quality control to prevent the release of misfolded proteins into the extra-
cellular milieu. Such a complex system of glycoprotein folding has not been demonstrated in the
bacterial system, and the processes by which these organisms maintain glycoprotein quality is a
prevailing question. The glycan structures displayed on all N-linked glycoproteins of C. jejuni
are identical, lacking the immense diversity of eukaryotic N-linked glycoproteins. This is due to
the lack of the glycan trimming/elaboration steps that occur post-glycosylation in the Golgi of
eukaryotic cells. Since bacterial cells lack the extensive compartmentalization present in
eukaryotic cells, there is no functional equivalent of the Golgi, where such elaboration steps can
take place.
18
Goigi...
Folded protein
Glucosidase
1/
ERAD IMist.lded p.... ln
G,UCOSidasel r Glucosyl
1/ Transferase
(UGGT)
Glucosidase
"
Glucosidase
I
Figure 1-2. The calnexin-calreticulin cycle.
The Dolichol Pathway
The glycan that is transferred to the asparagine side chain of a nascent protein IS a
tetradecasaccharide (Glc3Man9GlcNAcz) that is highly conserved in higher order eukaryotic
systems (Figure 1_3).5 In trypanosomes, truncated analogs (Man6,7,9GIcNAcz) have been shown
to be transferred to protein.24 The tetradecasaccharide is assembled in the ER membrane on a
dolichyl-pyrophosphate carrier by a series of glycosyltransferases, in a process known as the
dolichol pathway,8 The pathway begins with dolichyl-phosphate (Dol-P); the dolichols constitute
a family of a-saturated, (S)-polyisoprenyl-phosphates containing 14-17 isoprene units that are
biosynthesized from famesyl-pyrophosphate on the cytoplasmic face of the ER?S Dol-P is then
elaborated on the cytoplasmic side to form a dolichyl-pyrophosphate-linked heptasaccharide
(Dol-PP-GlcNAczMans) by a series of glycosyltransferases that utilize the nucleotide-activated
19
sugar donors, UDP-N-acetylglucosamine (UDP-GlcNAc) and GDP-mannose (GDP-Man). This
heptasaccharide is then flipped to the luminal face of the ER membrane by the flippase, Rft 1p, 26
where further elaboration occurs to yield the tetradecasaccharide (Dol-PP-GlcNAc2Man9Glc3).
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Figure 1-3. Structure of the tetradecasaccharide (Glc3Man9GlcNAc2) transferred to protein in
eukaryotic N-linked glycosylation.
The reactions on the cytoplasmic face of the ER begin with AIg7, an N-
acetylglucosamine-phosphate transferase that elaborates Dol-P to Dol-PP-GlcNAc (Figure 1-
4).27 AIg7 is inhibited by tunicamycin, which is a microbial natural product that acts as a
transition-state inhibitor for this step and is currently the only cellular inhibitor that affects N-
20
linked protein glycosylation.28 Recent bioinformatics studies have determined that the addition of
the second GlcNAc residue is catalyzed by a hetero-oligomeric protein classified as Algl3/14.29
Further in vivo experiments have demonstrated that the transmembrane-bound Algl4 recruits the
30 31
soluble AlgI3, containing a predicted catalytic domain, to the ER membrane for catalysis.g 3
The role of Algl, which catalyzes the first mannosylation step, has been extensively
characterized in vitro due to the advantageous formation of the chemically challenging f3(1-4)-
mannosidic linkage, which may be useful in chemoenzymatic syntheses.32 33 Two mannosyl-
transferases, Alg2 and Alg 11 are implicated in the remaining cytosolic glycosylations in the
dolichol pathway,34 36 yet their precise roles in this process remains to be rigorously validated.
Biochemical and genetic assays have shown that Algl interacts with both Alg2 and AlgI 1,
suggesting a role for protein-complex formation in maintaining the fidelity of the early steps in
the dolichol pathway.3 7
On the luminal face of the ER membrane, the glycan donors are the dolichyl-phosphate
linked Dol-P-Man and Dol-P-Glc. These donors are synthesized from the corresponding
nucleotide-linked sugar donors, GDP-Man or UDP-Glc, by a Dol-P-Man synthase (DPM1)3 8 and
a Dol-P-Glc synthase (Alg5),39 which act on the cytoplasmic face of the ER membrane and
flipped into the lumen. Four mannosyltransferases and three glucosyltransferases are involved in
the completion of the dolichyl-pyrophosphate-linked tetradecasaccharide. All of the 'luminal'
glycosyltransferases in the dolichol pathway have now been identified and are all highly
hydrophobic, basic proteins (MW 65-75 kDa) that include multiple transmembrane domains with
small hydrophilic loops.8 Recently, the bi-functional nature of Alg9 was demonstrated, whereby
Alg9 catalyzes the addition of both the seventh and the ninth mannose residue (both a-1,2-
21
mannosyllinkages).4o Once the entire tetradecasaccharide has been assembled in the lumen of
the ER, it is utilized by OT, which catalyzed transfer of the oligosaccharide to protein.41
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Figure 1-4. The dolichol pathway of N-linked glycosylation in Saccharomyces cerevisiae.
Oligosaccharyl Transferase (OT)
The OT complex is a multimeric, membrane-associated enzymc that is localized in the
membrane of the lumen of the endoplasmic reticulum, with the active site disposed to the
luminal compartment.41.42 This enzyme complex has been most extensively investigated in the
yeast Saccharomyces cerevisiae and comprises at least eight membrane-bound protein subunits
(Figure 1-5) that exist in three sub-complexes, Ost 1p-Ost5p, Ost2p-Swp Ip-Wbp 1p, and Stt3p-
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Ost4p-Ost3p/Ost6p. Genetic-knockout experiments have revealed that five of these subunits
(Ost2p, Ostlp, Stt3p, Swplp and Wbplp) are absolutely essential for yeast viability.4 3 -46 Recent
data indicate that there are two, functionally-distinct OT complexes in vivo.47' 48 These
complexes differ in one of the subunits, containing either Ost3p or Ost6p, which are highly
homologous proteins. The two complexes vary in specificity and function and are thought to be
responsible for fine-tuning the N-linked glycosylation process.48 Three of the essential subunits
(Ostlp, Wbplp and Stt3p) are known to be glycosylated in vivo and recent studies have shown
that glycosylation of Ostlp and Wbplp is not essential for activity.49 Stt3p is the largest of the
essential proteins in the complex and is hypothesized to be the catalytic subunit of OT.50' 51
Disrupting the two adjacent glycosylation sites on Stt3p (N535NT and N5 39NT) resulted in major
growth defects.49
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Figure 1-5. Subunit composition of the yeast (S. cerevisiae) oligosaccharyl transferase complex.
The boxed subunits are essential for yeast viability.
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Stt3p is a highly-conserved transmembrane protein that is found in all eukaryotic
organisms. Site-directed mutagenesis combined with photo-crosslinking experiments show that
Stt3p is directly involved in the catalytic process.51' 52 The S. cerevisiae Stt3p comprises 11-13
transmembrane segments and a hydrophilic C-terminal domain. A detailed topology mapping
study using engineered glycosylation sites, established that the N-terminus of Stt3p is in the
cytosol and the C-terminus in the lumen, and places most of the highly-conserved residues on the
luminal face of the ER membrane, which is in accord with the lumen being the site of catalysis.53
A highly-conserved WWDYGY amino acid sequence is present in all homologs of Stt3p in
organisms that contain a system for N-linked glycosylation. A bacterial protein from
Campylobacterjejuni, PglB, is homologous to Stt3p, and N-linked glycosylation in this organism
is abolished with the loss of PglB.7 54 Mutations within this conserved WWDYGY motif result
in the loss of glycosylation activity, suggesting that this sequence includes residues that are
essential for catalysis in PglB and Stt3p.5 4
Mechanism of OT
The glycosylation step catalyzed by OT involves the transfer of a pre-assembled
tetradecasaccharide from a dolichyl-pyrophosphate carrier onto the side chain of asparagine,
within the Asn-Xaa-Ser/Thr sequon (Scheme 1-1), where Xaa can be any amino acid except
proline. 55
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Scheme 1-1. Reaction catalyzed by oligosaccharyl transferase (OT).
The enhanced nucleop~ilicity of the amide nitrogen in this glycosylation reaction is a
prevailing mechanistic question and several mechanisms have been proposed to explain this
amide reactivity. The first model by Marshall (Figure 1-6 A), proposes that a hydrogen bond
between the hydroxyl group of the Ser/Thr residue and the carbonyl of the Asn side chain
promotes deprotonation of the amide nitrogen, resulting in nucleophilic attack.56 In a second
model, Bause (Figure 1-6 B) suggests that the amide group of asparagine functions as a
hydrogen-bond donor and the hydroxyl group as a hydrogen-bond acceptor, resulting in amide
activation.57 In the fmal model by Imperiali (Figure 1-6 C), an Asx-turn motif is believed to be
an important element in the glycosyl transfer mechanism. The hydrogen-bonding network in the
Asx-turn may facilitate deprotonation of the nitrogen to afford a neutral imidol species. This
intermediate could then react with the dolichyl-pYrophosphate-linked oligosaccharide donor to
form the p-linked glycopeptide. 58, 59
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Figure 1-6. The proposed mechanisms of OT. (A) Marshall. (B) Bause. (C) Imperiali.
The fact that proline is not accepted at the Xaa site within the Asn-Xaa-Ser/Thr sequon,
coupled with the observation that 10-30% of potential glycosylation sites are not glycosylated,
suggests that local conformational effects play an important role in the process of N-linked
glycosylation.60 The peptide can bind to the OT active site in two distinct conformations - an
Asx-turn or a P3-turn conformation. A 3-turn is characterized by hydrogen bonding between
backbone amide groups.6 1 On the other hand, in an Asx-tum, the side-chain amide of the
asparagine partakes in hydrogen-bonding interactions with the backbone resulting in a more open
61peptide conformation (Figure 1-7).6 Using NMR studies it was demonstrated that an
unglycosylated peptide based on a short sequence of hemagglutinin, adopts an Asx-turn
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conformation, but upon glycosylation, undergoes a chain reversal to induce a compact type-I-f3-
turn conformation.62 63
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Figure 1-7. Structure of (A) P-tum motif. (B) Asx-turn motif.
In vitro, a short peptide sequences containing the Asn-Xaa-Ser/Thr motif can be
glycosylated by OT. In support of the Asx-turn motif being an important determinant in N-linked
glycosylation site-specificity, a tripeptide substrate was synthesized with a carbon macrocyle
pre-organizing the sequence into an Asx-turn. This resulted in a substrate with a significantly
greater affinity for OT (Figure 1-8).64
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Figure 1-8. Effect of cyclization on enzyme affinity. (A) Linear substrate KM 800 pM. (B)
Cyclized substrate KM 78 M.
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In order to derive a mechanistic picture, several peptides in which the asparagine was
replaced by various isosteres, were synthesized and assayed for activity against OT (Table 1-
1).59, 65, 66 These asparagine analogs demonstrate different ionization properties, as well as
varying hydrogen-bonding capacities and therefore add insight into the mechanism of the
glycosylation process. Compounds 2-5 (Table 1-1) were synthesized in the Imperiali group.59
Replacing the Asn with a negatively charged Asp moiety (2) resulted in complete loss of
glycosylation with no competitive binding, suggesting that the active-site residues do not tolerate
a negative charge. The incorporation of a methyl ester (3) also diminishes binding, suggesting
the importance of a proton-donor at the Asn-position. The thioasparagine-containing peptide (4)
is a substrate for OT, but with a lower rate of turnover, possibly due to the reduced basicity and
hydrogen-bonding capacity of sulfur. Finally, replacing the Asn with a diaminobutyric-acid
residue (Dab) (5) competitively inhibits OT with a Ki that is comparable to the KM of the
substrate. Compounds 6-8, were synthesized by Coward et al. The diazoketone (6) was proposed
to target a catalytic nucleophile such as a cysteine thiolate, but showed no catalytic turnover or
inhibition of OT.66 The methyl ketone (7) and sulfoxide (8) could be substrates for N-
glycosylation if the mechanism involved amide deprotonation, however neither of these
compounds acted as substrates or inhibitors. Finally, compounds 9-12 were synthesized by Bause
et al, 6 5 and demonstrated that the hydroxamide (10) group resulted in a weak inhibitor and the
hydroxyasparagine (12) was a poor substrate for OT. The biological characterization of all of
these asparagine analogs, provides clues to the mechanism of OT catalyzed glycosylation, but
does not conclusively support either of the proposed mechanisms.
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Table 1-1. Kinetic analysis of substrates/inhibitors containing asparagine analogs.
Inhibitors of OT
The discovery that a tripeptide containing the Dab amino acid is a competitive inhibitor
of OT, sparked the field of OT inhibitor development. This observation, coupled with the pre-
organization of potential inhibitors into the bio-active Asx-turn conformation, resulted in
inhibitors with low-nanomolar affinity for OT. The most potent of these inhibitors are illustrated
in Figure 1-964 67
Although potent inhibitors of OT exist, none of these compounds function within a
cellular environment. An inhibitor that can selectively target OT in cells can enable
investigations into the downstream effects of glycosylation on various cellular functions. The
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no binding
no binding
no binding
weak inhibitor
no binding
poor substrate
focus of chapters 5 and 6 of this thesis is the modification of the current inhibitors to afford
peptidomimetic structures as potential in vivo inhibitors of OT.68
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Figure 1-9. The most potent OT inhibitors to date.
N-linked glycosylation in eukaryotic systems is an extremely complex process involving
a multitude of enzymes acting in concert to biosynthesize the dolichyl-pyrophosphate-linked
tetradecasaccharide and facilitate the ultimate transfer of the glycosyl moiety to protein. All of
the proteins involved in this process are highly hydrophobic, membrane-associated proteins,
which complicate detailed in vitro biochemical and biophysical characterization. In order to
understand this complex process of N-linked protein glycosylation, it would be ideal to have
access to a parallel system that is more amenable to biochemical characterization. The recent
discovery of a system of N-linked protein glycosylation in the gram-negative bacterium,
Campylobacterjejuni, has provided us with a parallel, yet simpler system that is more suitable
for in-depth biochemical characterization, and can potentially shed light on the more complex
eukaryotic process.
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Prokaryotic glycosylation
Overview
Investigations into glycosylation systems in eukaryotic organisms have prevailed since
the late 1930's, yet for many decades it was assumed that bacteria and archaea were devoid of
this important protein modification.6 9 The discovery of surface layer (S-layer) glycoproteins in
the gram-negative halophile, Halobacterium salinarium, was the first such system to be found
outside of the eukaryotic domain.7T ' These S-layer glycoproteins in archaea have the unique
feature of assembling into two-dimensional crystalline arrays on the cell wall of halobacteria and
are characterized by a variety of glycans and a diverse array of linkages to protein.7' Since this
initial report of S-layer glycoproteins in halobacteria, several characterizations of similar
glycosylated proteins in the bacterial domain have also surfaced.72 These glycoproteins are
integrated into cell-surface appendages, such as pili and flagella.6 9 The pili of pathogenic
bacteria, such as Neisseria meningitidis and Campylobacterjejuni/coli contain O-linked glycans
that involve unusual sugars such as pseudaminic acid (a nine-carbon sugar that resembles sialic
acid) and 2,4-diacetamido-2,4,6-trideoxyhexose (DATDH) (Figure 1-10).73' 74 The flagella of
gram-negative bacteria have also been shown to include O-linked pseudaminic acid analogs.7 5 76
OHp OH AcHNCH3 , o
o COOH AcHN
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Pseudaminic acid 2,4-diacetamido-2,4,6-trideoxyhexose
(DATDH)
Figure 1-10. Structures of pseudaminic acid and DATDH sugars.
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The first system of N-linked protein glycosylation to be discovered in gram-negative
bacteria comes from Campylobacter jejuni, a human-gut mucosal pathogen that is implicated in
gastroenteritis (Figure 1-11).7Campylobacter enteritis is characterized by acute abdominal pain
and inflammatory diarrhea,77 hence, understanding the pathogenicity of C. jejuni could
potentially lead to better prevention and infection-control strategies. The sequencing of the C.
jejuni genome, together with detailed genetic maps have facilitated genetic characterization of
various strains of this organism and the majority of the work described herein specifically
focuses on the strain C.jejuni NCTC 11168.78,7980
Figure 1-11. Electron micrograph of Campylobacter jejuni bacterial cells.
(Figure taken from www.niwa.co.nz/ .../ bacteria2 lar!!e.iDf!!view).
In 1999, it was discovercd that C. jejuni contains a gene locus that is involved in the
biosynthesis of a number of highly immunogenic glycoproteins.6 This cluster was tcrmcd the
'pgl gene cluster' and contained the gcnes pglA to pglG, which demonstrate significant
homology to enzymes involved in bactcrial lipopolysaccharide (LPS) and capsular
polysaccharide (CPS) biosynthesis. Mutagenesis of key residues in this cluster resulted in no
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discernible effect on CPS or LPS levels but caused a dramatic reduction in the immunoreactivity
of numerous C.jejuni proteins.
Soybean agglutinin (SBA) is a plant lectin known to bind terminal GalNAc residues. The
highly immunogenic C. jejuni proteins affected by mutations in the pgl gene cluster bind
strongly to the SBA lectin. This allowed the identification of PEB3 and CgpA, two highly
immunoreactive glycoproteins in C. jejuni.81 The glycan attached to these proteins was not
affected by p-elimination, which generally removes 0-linked glycans, thus suggesting a linkage
via a glycosyl amide to an asparagine residue.9 Through the action of specific exoglycosidases,
the oligosaccharide was shown to include one or more a-linked GalNAc residues.81 The PEB3
glycoprotein was partially purified and analyzed by mass spectrometry and shown to be modified
via an Asn-linked glycan with a mass of 1406 Da. Using nano-NMR techniques on very small
quantities of isolated glycan, the structure of the glycan was determined to be the
heptasaccharide, GaINAc-a-l ,4-GaINAc-al ,4-(Glcp 1,3)-GaINAc-al ,4-GaINAc-al ,4-GaINAc-
al,3-Bac-pl,N-Asn where Bac is bacillosamine (2,4-diacetamido-2,4,6-trideoxyglucose) (Figure
1-12).9Furthermore, this heptasaccharide structure was shown to be conserved throughout all C.
, jejuni strains.82
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Figure 1-12. The 'glycan transferred to protein in C.jejuni N-linked glycosylation.
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The C. jejuni heptasaccharide is structurally very different from the tetradecasaccharide
transferred in eukaryotic N-linked glycosylation. Bacteria utilize a wide variety of amino- and
deoxy-sugars that are not found in eukaryotic systems. 83 This is exemplified by the N-linked
glycan in C. jejuni that incorporates bacillosamine, a diacetamido-trideoxy-sugar found in
several bacterial strains such as Neisseria and Pseudomonas. Chapter 2 of this thesis is dedicated
to the chemical synthesis of bacillosamine and various analogs that can be used to investigate the
Pgl pathway in vitro. 84
The Pgl pathway
Computational analysis of the pgl gene cluster (Figure 1-13), suggested that the locus
encodes five putative glycosyltransferases (PglA, PglC, PglH, PglI and PglJ), three putative
integral membrane proteins (PglB, WlaB and PglG) and three enzymes involved in sugar
biosynthesis (PglD, PglE and PglF). The wlaB gene encodes a putative ABC transport protein
and the galE gene encodes a UDP-glucose 4-epimerase that converts UDP-glucose to UDP-
galactose. 81
Li P [~~ ~. P 1 '\ P
Glycosyl Bacillosamine Oligosaccharyl
transferase 1biosynthesis transferase
Figure 1-13. The pgl gene cluster from Campylobacterjejuni.
This pgl gene cluster in C. jejuni is very similar to a cluster found in the genome of
Nesseria meningitides that is known to be responsible for the O-linked glycosylation of pilin
(Figure 1-14). Pilin glycosylation involves an O-modified serine with a Gal-31,3-Gal-al,3-
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DATDH modification (DATDH = 2,4-diacetamido-2,4,6-trideoxyhexose). 73The stereochemistry
of the DATDH sugar in pilin glycosylation has not been unambiguously determined, but is most
likely to be bacillosamine. Bioinformatic analysis of the pgl gene cluster was greatly facilitated
by the fact that several homologous genes in the N. meningitides cluster were already
functionally annotated. Analogs of the sugar modifying enzymes, PgID, PgIE and PgIF are
present in the N. meningitides cluster, and are attributed to the biosynthesis of bacillosamine.
There is no homolog of the pglB gene inN. meningitides but a homologous protein to pglC (Nm
pglB) is a glycosyltransferase responsible for transferring the first sugar phosphate onto a
polyisoprene-phosphate carrier (Nm pglB codes for a bi-functional protein demonstrating both
glycosyltransferase and acetyltransferase activity).73The pglA gene in C. jejuni is homologous to
Nm pglA, which is responsible for the Gal-al,3-Bac linkage. The other putative
glycosyltransferase genes in C. jejuni are pglH, pglI and pgU, but the bioinformatics data is
insufficient to assign GaINAcal,4- or Glcpl,3-transferase function to these genes.9
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Figure 1-14. The pilin glycosylation locus of Neisseria meningitides and its comparison to the
Campylobacter jejuni pgl gene cluster.
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In critical work by Aebi and coworkers, the pgl gene cluster was functionally transferred
to E. coli and a C. jejuni periplasmic protein, AcrA, was shown to be glycosylated in this
modified E. coli system.54 This suggests that the pgl cluster contains all of the genes necessary
for the biosynthesis of the polyisoprenyl-pyrophosphate-linked heptasaccharide and its eventual
transfer to protein. It is postulated that the prokaryotic oligosaccharide is constructed on a
polyisoprenyl-pyrophosphate in a manner similar to the assembly of dolichyl-pyrophosphate
linked oligosaccharide in eukaryotes. The polyisoprene used is undecaprenol (also known as
bactoprenol), and contains 11 isoprene units, where the a-isoprene is unsaturated, in contrast to
the a-saturated nature of dolichol.54 Analysis of Campylobacter isolates using the SBA lectin,
which binds GalNAc residues, resulted in the isolation of up to 38 proteins that were identified
as possibly containing this N-linked glycan.9 These glycoproteins are predominantly annotated as
periplasmic proteins, which suggest that the glycosylation machinery is specific for periplasmic
substrates. An AcrA mutant that lacks the periplasmic signal sequence is not glycosylated,
further supporting the identification of the periplasm as the site of modification.85
Through mutational studies of the pgl gene cluster in E. coli, the exact roles of various
pgl genes were explored using structural analysis of the glycan transferred to protein. 6 As
predicted by bioinformatics, the pglA, pglJ, pglH and pglI genes were shown to encode specific
glycosyltransferases responsible for sequential addition of monosaccharides to form the ultimate
heptasaccharide donor. The pglA mutant, showed transfer of monosaccharide to protein,
verifying the earlier observation that PglA transfers the al,3-GalNAc to bacillosamine. The pgUJ
mutant showed transfer of disaccharide, suggesting that PglJ is responsible for the first a-1,4-
GalNAc linkage to afford the trisaccharide. The pglH mutant, showed transfer of a trisaccharide
to protein, suggesting a role for PglH in the transfer of the second al,4-GalNAc sugar. Finally,
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the pglI mutant showed transfer of a linear hexasaccharide, suggesting its role as a
glucosyltransferase, adding the final branching glucose residue (Figure 1-15). While this study
provided crucial information on the role of several Pgl glycosyltransferases, it did not provide
information on the identity of the transferases responsible for the addition of the two terminal a-
1,4-GalNAc residues. Therefore, the suggested scenarios were that PglH added all three terminal
GalNAc residues or that PglH and PglJ acted alternately, adding two GalNAc residues each to
form the hexasaccharide.
The role of each of these enzymes was unambiguously validated through in vitro
biochemical analysis, using chemically-synthesized Und-PP-Bac and purified Pgl
glycosyltransferases (Chapter 3). 84 ' 87 These data provided further evidence to support the
bioinformatics and mutational analyses above and also demonstrated that PglH is a sugar
polymerase, adding three GalNAc residues to the undecaprenyl-pyrophosphate-linked glycan.
Reconstitution of the sequence of enzymatic steps in vitro also provided valuable insight into
how these enzymes function together at a membrane interface.87
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Figure 1-15. The PgI pathway of N-linked glycosylation in Campy/obacter jejuni.
The PgI pathway shares striking similarities with the cukaryotic dolichol pathway. The
oligosaccharide substrate for the oligosaccharyl transferase is built up sequentially on a
polyisoprenyl-pyrophosphate carricr (undecaprenol in C. jejuni, dolichol in S. cerevisiae) by a
series of glycosyltransferase that utilize nucleotide-activated sugar donors or dolichol-phosphate
activated donors. This sequence of biosynthetic transformations occurs in the periplasmic
membrane of C. jejuni, which is the functional equivalent of the ER membrane in yeast.
Interestingly, in both systems, thc glycan is built up to a heptasaccharide structure on the
cytoplasmic face and then flipped to the other side of the membrane, either the ER lumen or the
periplasm, by a flippase. The flippase in the C. jejuni system, WlaB, has been annotated to be an
ABC (ATP-binding cassette) transporter, whereas the Rftl p protein in the dolichol pathway is
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non-ATP driven. In the dolichol pathway, this heptasaccharide is further elaborated to the
tetradecasaccharide, whereas in C. jejuni, no further elaboration occurs. Both pathways contain
at least one enzyme that catalyzes the transfer of multiple glycans (PglH in C. jejuni, Alg9 in
yeast). One striking difference is that the ALG genes in yeast encode highly hydrophobic
proteins, which all include at least one transmembrane domain. Although the Pgl
glycosyltransferases function on similar isoprene-bound intermediates, they contain no predicted
transmembrane domains. This renders the Pgl enzymes more amenable to detailed biochemical
analysis. Both pathways are examples of multistep enzymatic transformations that occur at a
membrane interface. Studies devoted to understanding the interactions that occur amongst the
Pgl glycosyltransferases at the membrane interface, can provide clues on how the corresponding
Alg enzymes maintain the fidelity of the dolichol pathway.
PglB: The oligosaccharyl transferase of C. jejuni
The PglB gene shares significant homology with the STT3 gene that codes for the largest
subunit of the yeast, S. cerevisiae, oligosaccharyl transferase (OT) cluster.5 ' 54 PglB contains a
highly conserved amino acid motif WWDYGY that is present in all putative OT homologs. This
conserved sequence is located on the hydrophilic C-terminal portion of PglB. In a pglB mutant
strain, PEB3 and AcrA, both known glycoproteins from C. jejuni, were found to be
unglycosylated. 9, 54 When functionally reconstituted in E. coli, the pgl cluster containing a
mutation in the 457WWDYGY 46 2 motif of PglB (W458A, D459A), resulted in unglycosylated
protein.54 This suggests the direct involvement of PglB in the glycosylation process whereby
PglB facilitates the transfer of the heptasaccharide onto the side-chain of asparagine.
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There are significant similarities between the Pgl pathway and the biosynthesis of the O-
antigen lipopolysaccharide (LPS), where sequential addition of glycans results in an isoprenyl
pyrophosphate-bound oligosaccharide that is transferred to the Lipid A core.88 When the O-
antigen ligase in E. coli was replaced with PglB, various O-antigen glycans were transferred to
acceptor proteins (Figure 1-16).89 This illustrates the substrate flexibility of PglB, which can
accept a diverse array of undecaprenyl-linked oligosaccharide substrates.89
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Figure 1-16. Diverse O-antigen glycans transferred to protein by PglB.
The OT cluster in S. cerevisiae and PglB in C. jejuni, both catalyze a similar reaction, the
transfer of an oligosaccharide from a polyisoprenyl-pyrophosphate-linked glycan to an
asparagine side chain. Yet, the S. cerevisiae system requires at least 8 proteins to efficiently
catalyze this process, whereas the bacterial system appears to use only a single protein. In the
yeast system, OT is required to interact with multiple other protein complexes such as the
translocon and the signal peptidase, for efficient co-translational glycosylation. It is hypothesized
that some of the OT subunits play a role in these interactions. A predominant area of research
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currently is to purify PglB to homogeneity in order to discern if it is solely responsible for
catalysis. Regardless, the simplicity of the PglB mediated process provides us a great opportunity
to investigate the mechanism of this intriguing enzymatic reaction in more depth.
The OT complex in S. cerevisiae shows a high degree of specificity with regards to the
dolichyl-pyrophosphate-linked glycan substrate and accepts very few truncated and non-native
structures.9 0 PglB on the other hand, appears to display much greater glycan flexibility by
accepting various O-antigen structures as well as glycans of varying length and structure
(Chapter 4). The glycans are however limited to those containing a C-2 N-acetamido-group on
the proximal sugar, which suggests a role of the N-acetamido group in the catalytic mechanism
of both OT and PglB. This substrate promiscuity of PglB suggests great promise for the potential
of using the bacterial glycosylation system in engineering humanized glycoproteins.
Mechanism of PglB
All the glycosylated proteins identified in C. jejuni, were shown to contain the Asn-Xaa-
Ser/Thr sequon.81 Other proteins in the genome also contain this sequon but do not appear to be
glycosylated. Hence, similar to the eukaryotic system, it appears that the N-X-S/T sequon is a
necessary but not absolute determinant of glycosylation. The Thr-sequon in C. jejuni occurs at
43% of the sites.9 Detailed investigation of the glycosylation sequon illustrated that similar to the
eukaryotic process, proline is not accepted as the X amino acid, hence indicating the importance
of peptide conformation in the glycosylation process.85 In vitro studies using an E. coli cell
membrane fraction expressing PglB, showed that similar to the yeast OT system, PglB can
accept a truncated peptide substrate in place of a full length protein. Initial studies indicate that
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the recognition sequence for PglB may require determinants in addition to the canonical
tripeptide substrate for yeast OT (Chapter 4).
Inhibitors of PglB
The glycosyl modifications synthesized by the pgl genes are highly immunogenic.6
Mutations in pglB and pglE resulted in a significant reduction in adherence to, and invasion of,
INT407 cells in vitro, and a reduced ability to colonize the intestinal tract of mice, suggesting a
role for these N-linked glycans in Campylobacter virulence.9' Recently it was demonstrated that
the N-linked glycans in C. jejuni plays a direct role in complex protein assembly. VirB10 is an
N-linked glycoprotein that is present in the type IV secretion system (T4SS) of C. jejuni. Lack of
VirB10 glycosylation results in C. jejuni cells containing a competence defect due to lack of
protein complexation.9 2 Interestingly, the closest homolog of the VirB 10 glycoprotein is found in
Wolinella succinogenes, which is the only other bacterium known to contain a putative N-linked
92glycosylation system similar to the pgl system.92
Due to the essential role played by the C. jejuni N-glycans in bacterial adherence and
pathogenicity, PglB and the Pgl pathway as a whole appear to be interesting potential targets for
antibacterial therapeutics. The extensive work done on the synthesis of inhibitors for the
eukaryotic OT system93 can now be applied toward the design of potent inhibitors of PglB. The
periplasmic location of PglB also makes it a much more accessible target than the OT complex
that is located in the ER lumen.
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Conclusion
Due to the similarities between the dolichol (Alg) pathway and the Pgl pathway, as well
as the parallels between the Stt3p-catalyzed glycosylation with the PglB reaction, the eukaryotic
and prokaryotic systems are greatly intertwined. Our knowledge accumulated over decades of
research devoted to understanding eukaryotic N-linked glycosylation can now be applied to the
recently discovered prokaryotic system. Hopefully, the reduced complexity of the C. jejuni
glycosylation process will allow for detailed biochemical and biophysical characterization that is
currently virtually impossible with the eukaryotic system. Hence, the knowledge that can be
gained from understanding the prokaryotic process will be invaluable in shedding light on the
mechanism and function of the eukaryotic glycosylation system.
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Chapter 2
Synthesis of bacillosamine and its derivatives for investigating the enzymes involved in N-linked
glycosylation in Campylobacterjejuni
A significant portion of the work described in this chapter has been published in:
Weerapana, E; Glover, K. J.; Chen, M. M.; Imperiali, B. Investigating Bacterial N-Linked
Glycosylation: Synthesis and Glycosyl Acceptor Activity of the Undecaprenyl Pyrophosphate-
Linked Bacillosamine. J. Am. Chem. Soc. 2005, 127, 13766-13767.
Mark Chen scaled-up the synthesis of bacillosamine and provided NMR characterization of
several intermediates.
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Introduction
The process of N-linked glycosylation in Campylobacter jejuni displays significant
similarities to the analogous process in eukaryotes.1-3 A series of glycosyltransferases act
sequentially to assemble a glycan donor on a polyisoprenyl carrier (undecaprenyl pyrophosphate
(Und-PP)), which is transferred to the asparagine side chain of proteins at the Asn-Xaa-Ser/Thr
(N-X-S/T) consensus sequence.4 In C. jejuni, the glycan donor has been identified as the Und-PP
linked heptasaccharide GalNAc-al 1,4- GalNAc-al,4-(Glcf 1 ,3)-GalNAc-al,4-GalNAc-al,4-
GalNAc-al,3-B3ac-al,PP-Und (1) (Figure 2-1), where Bac is the unusual sugar bacillosamine
(2,4-diacetamidco-2,4,6-trideoxyglucose) that is only found in specific bacterial systems.5
HC
Figure 2-1. The undecaprenyl-pyrophosphate-linked heptasaccharide donor.
Bioinformatic and mutagenesis data suggest that the pgl gene cluster contains all of the
enzymes required for the biosynthesis of the polyisoprenyl-linked heptasaccharide and its
ultimate transfer to protein.4 6' 7 The proposed biosynthetic route to the heptasaccharide substrate
begins in the cytoplasmic side of the periplasmic membrane with a UDP-HexNAc (either UDP-
53
GlcNAc or UDP-GaINAc) that is converted to UDP-Bacillosamine (UDP-Bac) by the action of
three enzymes PgI F, E and D, which code for a dehydratase, an aminotransferase and an
acetyltransferase, respectively. PgIC, a glycophosphoryltransferase then transfers the
bacillosamine from UDP-Bac to Und-P to form Und-PP-Bac, which is the first membrane
associated substrate in the pathway. This substrate is then elaborated to the heptasaccharide by
the action of four glycosyltransferases, PgI A, H, J and I and then flipped to the periplasm where
it is utilized by PgIB, which is the oligosaccharyl transferase of the bacterial system (Figure 2-
.Q).8,9
UDP__ •
PgIH.J;
D.
D.
UDP__ •
PglA
UDP__
PglC •
Perlplasm
A HexNAc- Baclllosamine r(- N-Acetylgalactosamlne• Glucose
pp Pyrophosphate ~
Und Undecaprenol (ess Isoprenoid) PglB
Cytoplasm
UDP-A P9IFED.
Figure 2-2. The PgI pathway.
Our goal is to investigate the activity of the PgI enzymes in vitro to validate their
proposed activity and study their substrate specificity. Validation of enzyme activity in vitro
involves the overexpression and purification of the PgI proteins and the use of chemically-
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defined substrates. The substrates for the Pgl enzymes all include bacillosamine, an unusual
carbohydrate that is only found in specific bacterial systems. These compounds are only present
in very small quantities in the native C. jejuni system, making purification from the natural
source an unrealistic endeavor. Furthermore, extraction from C. jejuni is complicated by the fact
that it is an extremely pathogenic strain of bacteria that requires specialized handling. Chemical
synthesis provides an alternative to isolating the substrates from the natural source and allows
access to milligram quantities of the desired substrates and other related derivatives in extremely
pure form.
The substrates for the Pgl enzymes all incorporate bacillosamine either as the nucleotide
diphosphate or polyisoprenyl-pyrophosphate forms. In order to study the activity of the
glycophosphoryltransferase PglC, the nucleotide linked UDP-Bac substrate is required. To
extend the study to the PglA, H, J and I glycosyltransferases, highly pure undecaprenyl
pyrophosphate linked bacillosamine (Und-PP-Bac) is essential. Employing chemical synthesis,
we can access the desired milligram quantities of UDP-Bac and Und-PP-Bac for biochemical
studies of the glycosyltransferases. Here we report the synthesis of a protected bacillosamine-
phosphate derivative (Bac-P) (2) and its subsequent coupling to UMP-morpholidate to form
UDP-Bac (3) and to undecaprenyl phosphate to form Und-PP-Bac (4), both of which are key
intermediates in the Pgl pathway of N-linked glycosylation (Figure 2-3).
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Figure 2-3. Retrosynthetic analysis of substrates for the Pgl enzymes.
Synthesis of Uridine-diphosphobacillosamine (UDP-Bac) (3) and undecaprenyl-pyrophosphate
bacillosamine (Und-PP-Bac) (4) from 3-O-benzoyl bacillosamine-a- 1-phosphate (Bac-P) (2).
Results and Discussion
Synthesis of 3-O-benzoyl-bacillosamine-a-1-phosphate (Bac-P) (2)
Several nucleotide linked derivatives of 6-deoxyhexose glycans similar to bacillosamine
have been synthesized using enzyme-based approaches,' 0- 2 however the biosynthetic enzymes
responsible for the synthesis of bacillosamine are yet to be validated and utilized in a preparative
manner. The first chemical synthesis of bacillosamine was reported by Liav et al. from 2-
acetamido-2-deoxy-glucose in a >15 step procedure.13 Bundle et al. also reported a synthesis of a
derivative of bacillosamine, methyl 2-acetamido-4-amino-2,4,6-trideoxy-q-D-glucopyranoside
using a novel chlorosulfation procedure.' 4 Other similar syntheses of 2,4-diacetamido-2,4,6-
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trideoxy sugars have also been published' 5 '9, yet none of these synthetic routes are easily
adapted towards the synthesis of bacillosamine phosphate. Here we describe the first chemical
synthesis of the a-phosphate of bacillosamine at the anomeric center and its application to the
synthesis of UDP-Bac and Und-PP-Bac, which are intermediates in the Pgl pathway (Scheme 2-
1).
Our synthesis of bacillosamine began with benzyl 2-acetamido-2-deoxy-J3-D-
galactopyranoside (5), which was prepared from commercially available D-galactosamine
hydrochloride using the method of Matta et a.20 Briefly, this procedure involved selectively
accessing the [3-anomeric benzyl configuration via the oxazoline. Intermediate 5 was then
modified via a selective benzoylation to produce benzyl 2-acetamido-3,6-di-O-benzoyl-2-deoxy-
,-D-galactopyranoside (6) using 2.2 mol equivalents of benzoyl chloride in pyridine at -60 C.
Inversion of configuration at C-4 was achieved by triflation followed by subsequent
displacement with sodium azide resulting in 7. Debenzoylation of 7 with sodium methoxide
yielded benzyl 2-acetamido-4-azido-2,4-deoxy-1-D-glucopyranoside (8). Selective tosylation of
the resulting primary hydroxyl afforded 9, which was followed by substitution of the tosyloxy
group with iodide to afford the 6-iodo derivative 10. Simultaneous reduction of the azido group
and de-iodination occurred by catalytic hydrogenation on Pd(OH)2/C. The presence of N, N-
diisopropylethylamine in the hydrogenation reaction ensured that this reduction occurred without
affecting the anomeric benzyl protecting group. Subsequent acetylation of both the amino and
hydroxyl functionalities resulted in benzyl 2-4-acetamido-3-O-acetyl-2,4,6-trideoxyglucose (11).
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Scheme 2-1. Synthetic route to 3-O-benzoyl bacillosamine-a-1-phosphate (2).a
aReagents and conditions: (a) benzoyl chloride, pyridine, -40 C-->0 °C, 70%; (b) Tf2O,
CH2Cl2/pyridine, 0 °C->rt; (c) NaN3 , DMF, rt, 62% over 2 steps; (d) NaOMe, MeOH, rt, 80%;
(e) TsCI, pyridine, 0 C->rt, 75%; (f) NaI, MeCN, 80 C, 70%; (g) H2, Pd(OH)2/C, DIPEA,
MeOH, 32 C; (h) Ac 2O, pyridine, rt, 65% over 2 steps; (i) NaOMe, MeOH, 90%; (j) BzCl,
pyridine, 60%; (k) H2, Pd(OH) 2/C, MeOH, 32 C, 86%; (1) LiHMDS, -68 C; then
[(BnO)2P(O)]20, -68 °C->0 °C, 50%; (m) H2, Pd/C, MeOH, 99%.
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d
Deprotection of the anomeric benzyl group in 11 by hydrogenation resulted in a 1:1 a::
mixture of 2-4-diacetamido-3-O-acetyl-2,4,6-trideoxyglucopyranoside. Attempts to
phosphorylate this compound using tetrabenzylpyrophosphate, resulted in very low yields due to
poor solubility. To circumvent this issue, the C-3 protection was changed to a benzoyl group to
afford 13. This was achieved by sodium methoxide treatment of 11 to form intermediate 12,
followed by treatment with benzoyl chloride at 0 °C to yield 2,4-diacetamido-3-O-benzoyl-2,4,6-
trideoxyglycopyranoside (13). Catalytic hydrogenation in the presence of Pd(OH)2/C resulted in
14 as an anomeric mixture. Phosphorylation of the more soluble benzoyl protected analog was
successfully achieved in 50% yield. This phosphorylation reaction proceeds with >16:1
selectivity in favor of the a-phosphate 15. The benzyl protection on the phosphate was removed
by hydrogenation to yield the phosphorylated bacillosamine derivative 2. A minor (<15%)
impurity in the product is observed, and this impurity cannot be separated by chromatography.
This minor product may result from epimerization at the anomeric center.
Synthesis of uridine diphospho-bacillosamine (UDP-Bac) (3)
PglC is the membrane-bound enzyme that facilitates the transfer of bacillosamine
phosphate from UDP-Bac to undecaprenyl phosphate to form Und-PP-Bac in C. jejuni.8 9 In
order to validate the activity of PglC in vitro, it is necessary to access the UDP-Bac substrate.
UDP-Bac was chemically synthesized via the coupling of the benzoyl-protected bacillosamine
phosphate derivative (Bac-P, 2) to UMP-morpholidate. This coupling was performed in dry
pyridine in the presence of IH-tetrazole to yield the protected UDP-Bac derivative (16).21 22 The
benzoyl protection on this intermediate was then removed with sodium methoxide to afford the
fully deprotected UDP-Bac (3) substrate for PglC (Scheme 2-2).
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Scheme 2-2. Synthesis of UDP-Bac (3).a
aReagents and conditions: (a) 4-morpholine-N-N'-dicyclohexylcarboxamidinium uridine 5'-
monophosphonrmorpholidate; H-tetrazole, pyridine, rt, 3 days, 50%, (b) NaOMe, MeOH, rt,
68%.
Synthesis of undecaprenyl-pyrophosphate-linked bacillosamine (Und-PP-Bac) (4)
The glycosyltransferases in the Pgl pathway function on polyisoprenyl-pyrophosphate-
linked glycan substrates that are anchored to the membrane. Similar to the dolichol pathway of
eukaryotic glycosylation, the glycans are bound to the isoprene via a pyrophosphate linkage and
are elaborated on the isoprene by a series of glycosyltransferases. Undecaprenol is an abundant
polyisoprene found in bacterial systems and consists of 11 isoprene units. In C. jejuni, the
glycosyltranferases, Pgl A, J, H and I, all function on undecaprenyl pyrophosphate linked glycan
substrates. In order to further investigate the activities of these glycosyltransferases, it is
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necessary to access milligram quantities of the undecaprenyl-linked substrates. We chose to
access Und-PP-Bac (4), which is the first polyisoprenyl-linked substrate in the pathway, and the
substrate for the glycosyltransferase, PglA by chemical synthesis. Using this substrate,
investigations into PglA activity as well as the later glycosyltransferases can be undertaken.
Und-PP-Bac is synthesized via the coupling of Bac-P to undecaprenyl phosphate (Und-
P), which was synthesized from undecaprenol using phosphoramidite chemistry as previously
reported.23 ' 24 The coupling to Bac-P was afforded using 1,1'-carbonyldiimidazole (CDI) as a
coupling reagent to yield the protected Und-PP-Bac derivative (17) (Scheme 23).24 25 In the
final step, the C-3 benzoyl protection was removed with sodium methoxide to yield the final
target molecule, Und-PP-Bac (4).
NHAC
IvIC
AcHNBzO
AcHN
2
Scheme 2-3. Synthesis of Und-PP-Bac (4).a
aReagents and conditions: (a) carbonyl diimidazole, DMF; then Und-P, 50%; (b) NaOMe,
MeOH, 99%.
Exploring the glycan specificity of the Pgl enzymes
Since the synthesis of bacillosamine involves a multi-step reaction sequence, we were
interested to determine if the Pgl enzymes would accept different glycans in place of
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bacillosamine. If the enzymes recognized a synthetically simpler glycan substrate, it would
greatly facilitate future studies into this system. Furthermore, studying the glycan specificity
would also provide valuable insight into the interactions occurring at the enzyme active sites. In
order to investigate the substrate specificity of the Pgl enzymes, two other undecaprenyl
pyrophosphate linked glycans were synthesized. These were Und-PP-6-hydroxybacillosamine
(Bac-6-OH), which differs from bacillosamine by the presence of a C-6 hydroxyl moiety (18)
and Und-PP-GlcNAc, which additionally lacks the C-4 N-acetyl group (19) (Figure 2-3).
GlcNAc is an abundant glycan present in most bacterial systems hence we were interested in
studying the specificity of the Pgl enzymes for bacillosamine over the more abundant GIcNAc.
The Bac-6-OH derivative is an intermediate that is accessed in fewer synthetic steps than
bacillosamine, and could act as a useful Bac substitute in future studies. Moreover, this
derivative would provide valuable information regarding the importance of the 4-acetamido
group over the 6-deoxy moiety.
NHAc
Figure 2-4. Substrates to explore the glycan specificity.
Und-PP-6-hydroxybacillosamine (Und-PP-Bac-6-OH) (18) and Und-PP-GlcNAc (19).
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Compounds 18 and 19 were synthesized using a procedure similar to that for the
synthesis of Und-PP-Bac (4). The synthesis involved the activation of the corresponding sugar
phosphate (Bac-6-OH-P (23) or GIcNAc-P) with carbonyl diimidazole (CDI) followed by
coupling to Und-P to form the pyrophosphate linkage. GlcNAc-P was synthesized according to a
previous procedure25 while Bac-6-OH-P (23) was synthesized from an intermediate in the
synthesis of Bac-P. Intermediate 7 in the synthesis of Bac-P (2) (Scheme 2-1) was elaborated
according to Scheme 2-4. A catalytic hydrogenation of 7 with Pd(OH) 2 /C in the presence of
diisopropylethylamine resulted in the reduction of the C-4 azido group without affecting the
anomeric benzyl group. This intermediate was subsequently acetylated with acetic
anhydride/pyridine to yield 20. The anomeric benzyl protection was removed with catalytic
hydrogenation to afford 21 and phosphorylated with lithium hexamethyldisilazide treatment
followed by tetrabenzylpyrophosphate to yield the a-anomeric phosphate 22. The benzyl
protection on the phosphate was removed with catalytic hydrogenation using Pd/C to afford Bac-
6-OH-P (23), which was coupled to Und-P without further purification.
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Scheme 2-4. Synthesis of 6-hydroxy-bacillosamine phosphate (23).a
a Reagents and conditions: (a) (i) H2, Pd(OH) 2 /C, DIPEA, MeOH, 32 0C; (ii) Ac 2 O, pyridine, 'I,
70% over 2 steps; (b) IH2, Pd(OH) 2 /C, MeOH, 32 0 C, 79%; (c) (i). LiHMDS, -68 0 C; (ii).
[(BnO) 2 P(O)] 2 0, -68 0 C-0 0C, 65%; (d) H2 , Pd/C, MeOH, 99%.
Exploring the polyisoprene specificity of the Pgl enzymes
Some of the difficulties associated with studying the glycosyltransferases in the Pgl
pathway are related to problems with obtaining and handling the hydrophobic undecaprenol. The
-- Nm AcHIN 0-} AcHN
C55 (11 isoprene units) carbon chain tends to aggregate and assays using undecaprenyl-
pyrophosphate linked substrates require organic co-solvents, detergents and other additives.O-P-OBn O-P-O-
22 OBn 23 o0-
Undecaprenol is also a very expenthesives of 6-hydroting material ($250 for mg). For these reasons, it
would bents advantageous to identify a more convenient substrate for the P()gl enzymes. Fort,
example, if the enzymes accept polyisoprene-pyrophosphate-linked intermediates that are shorter70%and/or easier to access, studying systems such as these would be greatly facilitated.[(BnO)2P(O)]20, -68 °C-->0 °C, 65%; (d) H2, Pd/C, MeOH, 99%.
ExIn plorder to investigate the polyisoprene specificity of the Pgl enzymes, several different
polyisoprene-pyrophosphate-linked associatedlogs were synthesized (Figure 2-4). Commercially   
   
pyrophosphate linked substrates require organic co-solvents, detergents and other additives.
Undecaprenol is also a very expensive starting material ($250 for 5mg). For these reasons, it
would be advantageous to identify a more convenient substrate for the Pgl enzymes. For
example, if the enzymes accept polyisoprene-pyrophosphate-linked intermediates that are shorter
and/or easier to access, studying systems such as these would be greatly facilitated.
In order to investigate the polyisoprene specificity of the Pgl enzymes, several different
polyisoprene-pyrophosphate-linked analogs were synthesized (Figure 2-4). Commercially
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available geranylgeraniol was used to afford geranylgeranyl-pyrophosphate-Bac-6-OH (24). This
substrate includes a shorter chain isoprene than the native undecaprenol and would provide
insight into the chain length specificity of the Pgl enzymes. Geranylgeraniol comprises 4
isoprene units (C20) and is far more readily available compared to its undecaprenol counterpart.
The other substrate that was synthesized was the dolichyl-pyrophosphate-Bac-6-OH (25).
Dolichol is a longer polyisoprene that comprises 16-18 isoprene units. Unlike undecaprenol and
geranylgeraniol, which are fully unsaturated polyisoprenols, dolichol contains a saturated
isoprene unit at the hydroxyl-terminus. This Dol-PP-Bac-6-OH derivative would provide insight
into the ability of the Pgl enzymes to accept longer chain lengths as well as the effect of a
terminal saturated isoprene unit.
Figure 2-5. Substrates to explore the polyisoprene specificity.
Geranylgeranylpyrophosphate-Bac-6-OH (24) and Dolichylpyrophosphate-Bac-6-OH (25).
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Conclusion
Bacillosamine is the first sugar found in the heptasaccharide moiety that is transferred to
the asparagine side chain of proteins in C. jejuni. Studies into the activities of the enzymes
involved in this N-linked glycosylation pathway have been hindered by the lack of substrates,
since bacillosamine and its derivatives are difficult to isolate from natural sources. For this
reason, it is important to devise a synthetic route that allows access to bacillosamine and its
derivatives. In this chapter, the first chemical synthesis of bacillosamine phosphate is outlined.
This crucial intermediate is then incorporated into two of the critical substrates for the Pgl
enzymes, UDP-Bac and Und-PP-Bac. A bacillosamine derivative, Bac-6-OH (containing a C-6
hydroxyl group), is also synthesized and this analog, together with the more readily available
GlcNAc is used to investigate the specificity of the Pgl enzymes. Strategies to link these different
sugar phosphates to polyisoprene phosphates are discussed in the synthesis of undecaprenyl,
geranylgeranyl and dolichol-linked glycan substrates, which can be used to explore the
specificity of the Pgl enzymes towards the polyisoprene. Altogether, a plethora of native and
non-native substrates for the enzymes in the Pgl pathway have been synthesized and can now be
used to shed light on the elusive process of N-linked glycosylation in C. jejuni.
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Experimental
General Procedures
All chemicals were purchased from Sigma/Aldrich unless otherwise noted. Undecaprenol
and 3H-UDP-GalNAc were purchased from American Radiolabeled Chemicals Inc. Analytical
thin layer chromatography (TLC) was performed on Merck silica gel 60 F2 54 plates (0.25 mm).
All compounds were visualized on TLC by UV irradiation or cerium sulfate-ammonium
molybdate staining. Flash column chromatography was carried out using forced flow of the
indicated solvent on AdTech Flash Silica Gel, 32-63 lim particle size, 60 A pore size (Adedge
technologies). Proton, carbon and phosphorous NMR spectra were recorded on a Bruker Avance
400 NMR Spectrometer (400 MHz). Chemical shifts (6) are reported in parts per million (ppm)
with chemical shifts referenced to internal standards: CDCl3 (7.26 ppm for H, 77.0 ppm for 13C),
CD 3OD (4.78 ppm for 1H, 49.15 ppm for 13C). 31p spectra are reported in 6 values relative to
H 3PO 4 (0.0 ppm). Coupling constants (J) are reported in Hertz (Hz) and multiplicities are
abbreviated as singlet (s), doublet (d), triplet (t), multiplet (m), broadened singlet (brs) and
doublet of doublets (dd). The term apparent triplet (tapp) is used to denote a doublet of doublets
(dd) with two similar coupling constants and apparent quartet (qapp) is used for a doublet of
doublet of doublets (ddd) with three similar coupling constants. High resolution Mass Spectra
(HRMS) were obtained at the Mass Spectrometry Facility at MIT (Cambridge, MA). The
negative ion ESI mass spectrum of undecaprenyl-pyrophosphate bacillosamine was obtained at
the Mass Spectrometry Facility, University of Illinois at Urbana-Champaign.
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Synthesis of benzyl 2-acetamido-3,6-di-O-benzoyl-2-deoxy-p-D-galactopyranoside
HO OBz
BzO OBn
NHAc
6
Benzyl 2-acetamido-2-deoxy-f3-D-galactopyranoside (5) (1.8 g, 5.7 mmol, 1.0 eq) was
dissolved in pyridine (10 mL) and the solution cooled to -40 C in a dry ice/acetonitrile bath.
Benzoyl chloride (1.4 mL, 12.5 mmol, 2.2 eq) was added dropwise and the solution was allowed
to warm to room temperature overnight. The pyridine was removed under vacuum and the
resulting crude mixture was purified by column chromatography (5% MeOH in CH2Cl2) to yield
2.1 g of 6 as a white solid (70%). Rf = 0.35 (CH2Cl2:MeOH 95:5). 1H NMR (400 MHz, CDCl3):
6 1.87 (s, 3H), 4.00 (m, 1H), 4.24 (brs, 1H), 4.46 (qapp, J= 8.8 Hz, 1H), 4.66 (m, 4H), 4.94 (d, J
= 12.2 Hz, 1H), 5.34 (dd, J = 11.5, <1.0 Hz, 1H), 5.52 (d, J 8.8 Hz, 1H), 7.50 (m, 6H), 7.61
(m, 3H), 8.07 (m, 4H), 8.12 (m, 2H). 13C NMR (100 MHz, CDCl3): 6 27.0, 52.7, 52.9, 53.1,
53.3, 53.5, 53.8, 54.5, 67.7, 70.7, 74.5, 76.9, 78.2, 104.0, 132.2, 132.4, 132.6, 132.8, 133.5,
133.9, 134.1, 137.6, 137.8, 141.3, 171.0. HRMS calcd for [C 29 H2 9 NO 8 + Na] + requires m/z
542.1785. Found 542.1777 (ESI+).
Synthesis of benzyl 2-acetamido-4-azido-3,6-di-O-benzoyl-2,4-deoxy-p-D-glucopyranoside
OBz
N3
BzO OBn
NHAc
The dibenzoylated compound 6 (5.2 g, 10 mmol, 1 eq) was dissolved in CH2Cl2 (10 mL)
with pyridine (1 mL). The solution was cooled to 0 C and trifluoromethane sulfonic anhydride
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(3.4 mL, 20 mmol, 2 eq) was added dropwise. The solution was stirred at 0 °C for 3 hours. The
solvent was removed under vacuum and the resulting residue was dissolved in EtOAc. The
solution was washed with H20 (1 x 5 mL), 1M HCl (2 x 5 mL), H2 0 (1 x 5 mL), saturated NaCl
(1 x 5 mL) and dried over anhydrous MgSO4. After filtering, the solvent was removed under
vacuum to afford a yellow oil, which was used without further purification.
The triflate derivative from above was dissolved in DMF (10 mL) and sodium azide (3.3
g, 50 mmol, 5 eq) was added and stirred at room temperature overnight. The solvent was
removed under vacuum and the residue dissolved in EtOAc, washed with H20 (2 x 5 mL) and
saturated NaCl (1 x 5 mL). After drying over anhydrous MgSO4, the solvent was removed and
the compound purified by recrystallization in EtOAc/Hexanes to afford 3.4 g of 5 as a white
solid (62% over 2 steps). Rf= 0.35 (CH2Cl2:MeOH 95:5). 1H NMR (400 MHz, CDCl3): 6 1.79
(s, 3H), 3.77 (, H), 3.99 (tapp, J = 9.9 Hz, 1H), 4.44 (qapp, J = 9.3 Hz, I H), 4.64 (m, 2H), 4.73
(m, 2H), 4.88 (d, = 12.2 Hz, 1H), 5.52 (tapp, J 10.1 Hz, 1H), 6.60 (d, J = 9.4 Hz, 1H), 7.26
(min, 5H), 7.45 (m, 4H), 7.60 (m, 2H), 8.06 (d, J 7.7 Hz, 2H), 8.13 (d, J = 7.7 Hz, 2H). 13C
NMR (100 MHz, CDCl3): 6 23.5, 54.4, 61.6, 64.1, 70.9, 72.8, 74.9, 100.3, 128.4, 128.4, 128.8,
129.0, 129.1, 129.2, 130.0, 130.2, 130.4, 133.8, 134.2, 137.4, 166.6, 167.1, 170.9. HRMS calcd
for [C29H28N40 7 + Na]+ requires m/z 567.1850. Found 567.1848 (ESI+)
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Synthesis of benzyl 2-acetamido-4-azido-2,4-deoxy-p-D-glucopyranoside
OH
N3
HO-O OBn
NHAc
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The azido derivative 7 (1.0 g, 1.84 mmol, 1 eq) was dissolved in MeOH (50 mL) and 100
[tL of NaOMe (25 wt% in MeOH) (0.4 mmol, 0.08 eq) was added. The mixture was stirred at
room temperature for 1 hour and the solvent neutralized with Amberlyte IR-120H ion exchange
resin. The solvent was removed under vacuum and the product was purified by column
chromatography (5% MeOH in CH2Cl2) to yield 500 mg of 8 as a white solid (80%). Rf = 0.17
(CH2Cl2:MeOH 95:5).1H NMR (400 MHz, CD3OD): 6 1.99 (s, 3H), 3.21 (, 1H), 3.48 (tapp, J =
9.6 Hz, H), 3.66 (tapp, J 9.9 Hz, H), 3.77 (, 2H), 3.88 (d,J= 12.2 Hz, H), 4.50 (d, J =8.3
Hz, 1H), 4.61 (d, J = 12.2 Hz, 1H), 4.90 (d, J =12.3 Hz, 1H), 7.30 (, 5H). 13C NMR (100 MHz,
CD 3OD): 6 22.0, 56.7, 61.5, 62.9, 70.6, 74.2, 75.3, 100.7, 127.7, 127.8, 128.4, 128.5, 138.1,
172.8. HRMS calcd for [C15H20N40 5 + Na]+ requires m/z 359.1326. Found 359.1324 (ESI+).
Synthesis of benzyl 2-acetamido-4-azido-6-tosyloxy-2,4-deoxy-p-D-glucopyranoside
OTs
N3 0
HO OBn
NHAc
9
The deprotected compound 8 from the previous step (133 mg, 0.4 mmol, 1 eq) was
dissolved in pyridine (10 mL) and cooled to 0 C. p-Toluenesulfonyl chloride (83 mg, 0.44
mmol, 1.1 eq) was added to the solution and allowed to warm up to room temperature overnight.
The pyridine was removed under vacuum and the resulting crude mixture was purified by
column chromatography (5% MeOH in CH2Cl2) to afford 9 as a yellow oil (147 mg, 75% yield).
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Rf = 0.27 (CH2CI2:MeOH 95:5). 1H NMR (400 MHz, CD3OD): 6 1.97 (s, 3H), 2.44 (s, 3H), 3.37
(m,2H), 3.66 (m, 2H), 4.29 (m, 2H), 4.44 (d, =7.8 Hz, H), 4.49 (d,J= 12.1 Hz, H), 4.75 (d, J
= 12.2 Hz, 1H), 7.34 (m, 5H), 7.47 (d, J 7.8 Hz, 2H), 7.87 (d, J 8.0 Hz, 2H). 13C NMR (100
MHz, CD3OD): 6 22.0, 23.6, 30.1, 53.9, 57.6, 61.6, 62.4, 69.2, 71.0, 71.4, 72.2, 74.9, 99.7,
124.3, 127.9, 128.1, 128.4, 128.4, 128.9, 130.4, 132.8, 136.8, 137.3, 145.6, 149.8, 172.8. HRMS
calcd for [C22H26N407S + Na]+ requires m/z 513.1414. Found 513.1425 (ESI+).
Synthesis of benzyl 2-acetamido-4-azido-6-iodo-2,4,6-deoxy-p-D-glucopyranoside
I
N3 0
HO OBn
NHAc
10
The tosylate derivative 9 (265 mg, 0.54 mmol, 1 eq) was dissolved in acetonitrile (10
mL) and sodium iodide (405 mg, 2.7 mmol, 5 eq) was added. The mixture was stirred with
heating (80 °C) for 7 hours. The acetonitrile was removed under vacuum and the resulting
residue was purified by column chromatography (5% MeOH in CH2C12) to yield 170 mg of 10 as
a white solid (70%/). Rf = 0.27 (CH 2CI 2 :MeOH 95:5). 1H NMR (400 MHz, CD 3OD): 6 1.99 (s,
3H), 3.04 (m, 1H), 3.34 (m, 1H), 3.45 (m, 1H), 3.62 (d, J = 10.9 Hz, 1H), 3.72 (m, 2H), 4.53 (d,
J= 8.2 Hz, 1H), 4.64 (d, J= 12.2 Hz, 1H), 4.89 (d, J = 12.1 Hz, 1H), 7.33 (m, 5H). 13C NMR
(100 MHz, CD 3OD): 6 5.4, 21.8, 37.0, 56.5, 67.1, 70.4, 72.9, 73.6, 99.9, 127.6, 127.8, 128.2,
137.6, 172.5. HRMS calcd for [C15H19IN407 + Na]+ requires m/z 469.0343. Found 469.0352
(ESI+).
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Synthesis of benzyl 2,4-acetamido-3-O-acetyl-2,4,6-deoxy-p-D-glucopyranoside
Me
AcHN
AcO- OBn
NHAc
11
The iodo derivative 10 (220 mg, 0.5 mmol, 1 eq) was dissolved in MeOH (10 mL). N,N-
di-isopropylethylamine (175 ptL, 1.0 mmol, 2 eq) was added together with Pd(OH)2/C (20 wt. %,
wet) (100 mg, 0.14 mmol, 0.3 eq). The solution was stirred under a hydrogen atmosphere at 32
°C for 5 hours. The palladium was filtered off and the solvent removed under vacuum to afford a
colorless oil. This crude mixture was acetylated without further purification, by dissolving in a
2:1 mixture of pyridine:acetic anhydride (10 mL) and stirred at room temperature overnight. The
solvent was removed under vacuum and the resulting residue was purified by column
chromatography (10% MeOH in CH 2 Cl2 ) to yield 120 mg of 11 as a white solid (65% over 2
steps). Rf = 0.52 (CH2Cl2:MeOH 9:1). H NMR (400 MHz, CDCl3): 6 1.33 (d, J = 5.9 Hz, 3H),
1.91 (s, 3H), 1.96 (s, 3H), 2.03 (s, 3H), 3.54 (, H), 3.70 (tapp, J = 10.0 Hz, H), 3.87 (tapp, J
9.4 Hz, H), 4.60 (d, J = 11.9 Hz, H), 4.79 (d, J = 8.5 Hz, H), 4.92 (d, J = 12.2 Hz, H), 5.35
(tapp, J = 10.0 Hz, H), 7.35 (m, 5H). 13C NMR (100 MHz, CDCl3 ): 6 18.6, 21.1, 23.1, 23.2,
56.5, 57.3, 72.2, 74.6, 101.6, 129.2, 129.8, 139.4, 172.6, 173.8, 173.8. HRMS calcd for
[C19H26N20 6 + Na]+ requires m/z 401.1683. Found 401.1696 (ESI+).
Synthesis of benzyl 2,4-acetamido-2,4,6-deoxy-p-D-glucopyranoside
Me
AcHN O
HO _ OBn
NHAc
12
Compound 11 (60 mg, 0.16 mmol, 1 eq) was dissolved in methanol (5 mL) and 20 jLL of
NaOMe (25 wto in MeOH) (0.09 mmol, 0.6 eq) was added. The mixture was stirred at room
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temperature for 1 hour and the solvent neutralized with Amberlyte IR-120H ion exchange resin.
The solvent was removed under vacuum and the product was purified by column
chromatography (5% MeOH in CH2Cl2) to yield 48 mg of 12 as a white solid (90%) Rf = 0.18
(CH2Cl2:MeOH 95:5). 1H NMR (400 MHz, CD3OD): 6 1.26 (d, J = 6.1 Hz, 3H), 1.98 (s, 3H),
2.00 (s, 3H), 3.47 (m, 1H), 3.61 (m, 2H), 3.70 (tapp, J = 8.0 Hz, 1H), 4.53 (d, J = 8.3 Hz, 1H),
4.59 (d, J = 12.1 Hz, 1H), 4.86 (d, J = 12.1 Hz, 1H), 7.30 (m, 5H). 13C NMR (100 MHz,
CD 3OD): 6, 17.3, 21.9, 57.3, 58.0, 70.7, 71.3, 100.6, 127.7, 127.8, 128.3, 138.1. HRMS calcd for
[C17H24N205 + Na]+ requires m/z 337.1758. Found 337.1755 (ESI+).
Synthesis of benzyl 2,4-acetamido-3-O-benzoyl 2,4,6-deoxy-fI-D-glucopyranoside
Me O
AcHN
BzOO4L OBn
NHAc
13
The deprotected compound 12 (36 mg, 0.11 mmol, 1 eq) was dissolved in pyridine (2
mL) and cooled to 0 C. Benzoyl chloride (26 [tL, 0.22 mmol, 2 eq) was added and the mixture
was allowed to warm to room temperature overnight. The pyridine was removed under vacuum
and the product was purified by column chromatography (5% MeOH in CH2C12) to yield 29 mg
of 13 as a white solid (60% yield). Rf = 0.28 (CH2Cl2:MeOH 95:5). 1H NMR (400 MHz,
CDCl 3 ): 6 1.38 (d, J = 6.2 Hz, 3H), 1.76 (s, H), 1.83 (s, 3H), 3.62 (m, H), 3.95 (qapp,, J = 9.0
Hz, 1H), 4.10 (qapp,J = 9.9 Hz, 1H), 4.63 (d, J = 12.2 Hz, 1H), 4.83 (d, J = 8.3 Hz, 1H), 4.94 (d,
J = 12.2 Hz, 1H), 5.65 (tapp, J = 10.0 Hz, 1H), 5.93 (d, J 8.5 Hz, 1H), 6.04 (d, J 9.3 Hz, 1H),
7.33 (, 5H), 7.46 (, 2H), 7.60 (, 1H), 8.00 (d, J = 7.1 Hz, 2H). 13C NMR (100 MHz,
CDCl3): 618.4, 23.7, 23.7, 56.0, 56.2, 70.9, 71.8, 73.5, 77.1, 77.3, 73.5, 99.4, 128.3, 128.4,
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128.9, 129.1, 129.4, 130.0, 134.1, 137.8, 168.0, 170.5, 170.8. HRMS calcd for [C 2 4H 28 N2 0 6 +
Na]+ requires m/z 463.1840. Found 463.1852 (ESI+).
Synthesis of 2,4-acetamido-3-O-benzoyl-2,4,6-deoxy--D-glucopyranoside
Me
AcHN
Bz O OH
NHAc
14
Compound 8 (25 mg, 0.06 mmol, 1 eq) was dissolved in methanol (2 mL) and Pd(OH)2/C
(20 wt. %, wet) (5 mg, 0.007 mmol, 0.1 eq) was added. The mixture was stirred under a
hydrogen atmosphere at 32 C for 7 hours. The palladium was filtered off and the product was
purified by column chromatography (10% MeOH in CH2Cl2), to yield 14 as a white solid (17
mg, 86%). Rf= 0.52 (CH2Cl2 :MeOH 9:1). 1H NMR (400 MHz, CD3OD): 6 1.22 (d, J = 6.2 Hz,
3H), 1.82 (s, 3H), 1.86 (s, 3H), 3.34 (, 1H), 4.00 (m, 1H), 4.19 (, 1H), 5.14 (d, J = 3.5 Hz,
1H), 5.47 (tapp, J =- 10.4 Hz, 1H), 7.48 (, 2H), 7.63 (m, IH), 7.99 (m, 2H). 13C NMR (100 MHz,
CD 3OD): 6 21.4, 21.5, 53.3, 53.4, 56.0, 66.0, 72.4, 91.8, 128.6, 129.8, 130.1, 133.4, 133.4,
167.0, 172.3, 172.4. HRMS calcd for [C17H22N20 6 + Na]+ requires m/z 351.1551. Found
351.1551 (ESI+).
Synthesis of dibenzylphospho-2,4-acetamido-3-O-benzoyl-2,4,6-deoxy-a-D-glucopyranoside
Me
AcHNBzO 
'I AcHN if
15 O-P-OBn
OBn
Compound 14 (15 mg, 0.04 mmol, 1 eq) was dissolved in dry THF (2 mL) and the
solution cooled to -68 C. To the cooled solution, lithium hexamethyldisilazide (LiHMDS, 1M
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solution in THF) (56 1iL, 0.05mmol, 1.3 eq) was added dropwise. After 10 minutes,
tetrabenzylpyrophosphate (30 mg, 0.06 mmol, 1.5 eq) was dissolved in dry THF (1 mL) and
added dropwise to the reaction mixture. The reaction was stirred at -68 C for 10 minutes and
slowly warmed to 0 C. The mixture was then diluted with Et2 0 (2 mL), washed with chilled
saturated NaHCO3 (2mL) and NaCl (2 mL) and dried over anhydrous MgSO4. The solvent was
removed under vacuum and the mixture purified by column chromatography (5% MeOH in
CH2Cl2) to yield the protected phosphate 15 as a colorless oil (16 mg, 50% yield). Rf = 0.27
(CH2Cl2:MeOH 95:5). H NMR (400 MHz, CDCl3): 6 1.17 (d, J = 6.2 Hz, 3H), 1.75 (s, 3H),
1.79 (s, 3H), 3.95 (, 1H), 4.23 (qapp, J = 10.2 Hz, 1H), 4.61 (, 1H), 5.08 (, 4H), 5.29 (tapp, J
= 10.5 Hz, 1H), 5.73 (dd, J = 5.45, 3.4 Hz, 1H), 6.23 (brs, 1H), 6.30 (brs, 1H), 7.25-7.80 (nm,
15H). 13C NMR (100 MHz, CDCl 3 ): 6 17.9, 23.0, 23.3, 54.6, 70.0, 70.0, 128.0, 128.1, 128.2,
128.6, 128.7, 128.9, 129.0, 129.0, 129.1, 130.1, 133.9, 168.0, 170.4, 170.6.31P NMR (162 MHz,
CDCl3): 6 -2.07. Mass spectroscopy of this intermediate is complicated by the facile 13-
elimination of the phosphotriester, which precludes observation of the molecular ion.
Synthesis of phospho-2,4-acetamido-3-O-benzoyl-2,4,6-deoxy-a-D-glucopyranoside
Me
AcHN- 0
Bz O
'I AcHN II
2 O-P-0'
0-
The protected phosphate 15 (16 mg, 0.02 mmol, 1 eq) was dissolved in MeOH (2 mL).
Pd/C (10 wt% on activated carbon) (2 mg, 0.002 mmol, 0.1 eq) was added and the mixture was
stirred under a hydrogen atmosphere for 3 hours. The palladium was filtered off and the solvent
removed to yield 12 mg of 2 as a white solid (> 99%), which was used in the coupling to UMP-
morpholidate or Und-P without further purification. H NMR (400 MHz, CD3OD): 6 1.23 (d, J =
75
6.2 Hz, 3H), 1.81 (s, 3H), 1.85 (s, 3H), 4.04 (tapp, J = 10.3 Hz, 1H), 4.19 (, 1H), 4.41 (, 1H),
5.43 (tapp, J = 10.4 Hz, 1H), 5.75 (dd, J = 6.2, 3.3 Hz, 1H), 7.46 (, 2H), 7.61 (, 1H), 7.99 (nm,
2H). 13C NMR (100 MHz, CD3OD): 6 16.8, 21.2, 21.4, 52.7, 52.7, 55.2, 68.0, 71.4, 95.3, 128.4,
129.6, 129.6, 133.3, 166.6, 172.1, 172.4. 31P NMR (162 MHz, CD 3OD): -0.014. HRMS calcd
for [C17H23N2 09P - H]- requires m/z 429.1068. Found 429.1066 (ESI-).
Synthesis of Uridin-5'-yl (2-4-diacetamido-2,4-6-trideoxy-a-D-glucopyranosyl) diphosphate
Me O
AcHN- O
HO 0 0 NH
AcHN I II IIO-P-O-P-O N O
0- 0-
3 2Et3NH OH OHOH OH
The protected bacillosamine phosphate derivative (2) (10 mg, 0.02 mmol, 1 eq) was
coevaporated several times with dry pyridine. To this dried compound, 4-morpholine-N,N'-
dicyclohexylcarboxamidinium uridine 5'-monophosphormorpholidate (17.9 mg, 0.03 mmol, 1.3
eq) was added and the mixture was coevaporated twice with dry pyridine and dried under
vaccum. The solid was then dissolved in 0.5 mL of dry pyridine and 1H-tetrazole (0.04 mmol, 2
eq, 3 mg) was added and the solution stirred at room temperature for 3 days. The solved was
removed under vaccum and the residue dissolved in water and purified by RP-HPLC (C 18) (0.05
M triethylammonium bicarbonate (TEAB) buffer; gradient 4-18% CH3CN over 30 min; flow
rate, 1 mL/min; t = 28.7 min). Benzoyl protected UDP-Bac (9 mg, 50%) was obtained as a
white solid. H NMR (400 MHz, MeOH) 6 H NMR (400 MHz, CD3OD): 6 1.25 (d, J = 6.8 Hz,
3H), 1.82 (s, 3H), 1.94 (s, 3H), 4.03 (tapp, J = 10.3 Hz, 1H), 4.22 (min, 1H), 4.28 (mn, 2H), 4.38 (inm,
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1H), 4.41 (, 2H), 4.58 (tapp, J = 4.2 Hz, 1H), 5.40 (tapp, J = 10.4 Hz, 1H), 5.75 (dd, J 7.3, 3.1
Hz, 1H), 5.85 (d, J - 8.1 Hz, 1H), 6.05 (d, J =- 5.3 Hz, 1H), 7.45 (t, J = 7.7 Hz, 2H), 7.58 (t, J=
7.6 Hz, 1H), 7.95 (d, J = 7.1Hz, 2H), 8.18 (d, J = 8.1 Hz, 1H). 31 p NMR (162 MHz, CD3OD): 6 -
10.8, -13.0. LRMS calcd for [C2 6H33N4 01 7P2 - H]- requires m/z 734.5. Found 734.4 (ESI-).
The protected UDP-Bac analog from above (5 mg, 0.007 mmol, 1 eq) was dissolved in
MeOH (0.5 mL). Sodium methoxide 1.0 L (25 wt% in MeOH) was added and the mixture
stirred at room temperature for 30 min. The solvent was removed under vacuum, the residue
dissolved in water and purified by RP-HPLC (C18) (0.05 M triethylammonium bicarbonate
(TEAB) buffer; 1 % CH3CN; flow rate, 1 mL/min; tR = 15.0 min). Compound 1 was obtained as
a white solid (3.0 mg, 68%). LRMS calcd for [C19 H29 N40 16 P2 - H]- requires m/z 630.4. Found
630.5 (ESI-).
Synthesis of undecaprenyl-pyrophosphate bacillosamine
Bacillosamine phosphate 2 (5 mg, 0.008 mmol, 1 eq) was dissolved in DMF (500 ,uL)
and carbonyl di-imidazole (CDI) (2 mg, 0.013 mmol, 1.6 eq) was added. The mixture was stirred
at room temperature for 6 hours. The excess CDI was quenched with methanol (2.3 ,uL, 0.072
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mmol, 9 eq) and stirred for 30 mins. The undecaprenyl phosphate (7 mg, 0.008 mmol, 1 eq) was
dissolved in CH2Cl2 (500 [tL) and added to the sugar phosphate. The mixture was allowed to stir
at room temperature for one week and monitored by 31p NMR. The solvent was removed under
vacuum and the mixture purified by silica gel chromatography eluting with CHCI3:MeOH:2M
NH4OH 85:14:1, to yield 5.0 mg of protected undecaprenyl pyrophosphate bacillosamine as a
colorless oil (50%). Rf= 0.48 (CHCl3:MeOH:H20 65:25:4), Rf= 0.82 (CHC13:MeOH:2M
NH4OH 9:7:2) 1H NMR (400 MHz, CD3OD): see attached spectra. 31p NMR (162 MHz,
CDCl3:CD3OD (2:1)): 6 -4.5, -7.0. LRMS calcd for [C72Hl12N2012P2-H]- requires m/z 1257.8.
Found 1257.4 (ESI-).
(a)
0
(D)
Figure Si: Thin layer chromatography of the protected Und-PP-Bac intermediate. a)
CHCl3:MeOH:2M NH4OH 9:7:2 b). CHCl3:MeOH:H20 65:25:4
The protected intermediate from above was dissolved in MeOH and I jtL of NaOMe/MeOH
was added and stirred at room temperature for 10 min. The solvent was neutralized with Dowex-
50WX8- 200 ion exchange resin (pyridinium form) and removed under vacuum to yield 4.6 mg
of 2 (99 % yield) as a colorless oil. Rf= 0.32 (CHCl3:MeOH:H20 65:25:4). LRMS calcd for
[C65 H1 0 8 N2 011P2-H]- requires m/z 1153.7. Found 1153.8 (ESI-).
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Figure S2: Thin layer chromatography of deprotected Und-PP-Bac in CHCl3 :MeOH:H20
65:25:4
Synthesis of benzyl 2,4-acetamido-3,6-O-benzoyl-2,4-deoxy-p-D-glucopyranoside
OBz
AcHN
BzO OBn
20 NHAc
Intermediate 7 in the synthesis of bacillosamine (300 mg, 0.55 mmol, 1 eq) was dissolved
in MeOH (10 mL). N,N-di-isopropylethylamine (200 1tL, 1.1 mmol, 2 eq) was added together
with Pd(OH) 2/C (20 wt. %, wet) (110 mg, 0.17 mmol, 0.3 eq). The solution was stirred under a
hydrogen atmosphere at 32 C for 5 hours. The palladium was filtered off and the solvent
removed under vacuum to afford a colorless oil. This crude mixture was acetylated without
further purification, by dissolving in a 2:1 mixture of pyridine:acetic anhydride (10 mL) and
stirred at room temperature overnight. The solvent was removed under vacuum and the resulting
residue was purified by column chromatography (10% MeOH in CH2Cl2) to yield 200 mg of 20
as a white solid (65% over 2 steps). Rf= 0.29 (CH2Cl2:MeOH 95:5). H NMR (400 MHz,
CDCl3 ): 1.75 (s, 3H), 1.76 (s, 3H), 3.94 (m, H), 4.07 (m, H), 4.42 (tapp, J = 10.2 Hz, H),
4.46 (dd,J = 12.1, 6.9 Hz, H), 4.57 (dd, J = 12.1, 2.4 Hz, H), 4.59 (d, J = 10.4 Hz, 1H), 4.76
(d, J = 8.4 Hz, H), 4.82 (d, J= 12.0 Hz, H), 5.44 (tapp, J = 10.3 Hz, H), 7.24 (m, 5H), 7.41-
8.23 (m, 10H). 13C NMR (100 MHz, CDCl 3 ): 23.1, 52.7, 56.5, 65.1, 72.3, 74.2, 75.0, 101.5,
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126.0, 128.7, 129.3, 129.4, 129.8, 129.9, 130.1, 130.1, 131.2, 131.2, 131.3, 131.6, 134.9, 135.0,
138.9, 139.1, 150.5. 168.1, 173.9. HRMS calcd for [C3 1H32 N2 08 + Na] + requires m/z 583.2051.
Found 583.2027 (ESI+).
Synthesis of 2,4-acetamido-3,6-O-acetyl-2,4-deoxy-p-D-glucopyranoside
OBz
AcHN 
BzO OH
21 NHAc
Compound 20 (200 mg, 0.34 mmol, 1 eq) was dissolved in methanol (3 mL) and
Pd(OH)2/C (20 wt. %, wet) (21 mg, 0.03 mmol, 0.1 eq) was added. The mixture was stirred
under a hydrogen atmosphere at 32 C for 7 hours. The palladium was filtered off and the
product was purified by column chromatography (10% MeOH in CH2C12), to yield 21 as a white
solid (130 mg, 79%). Rf= 0.18 (CH2Cl2:MeOH 95:5). 1H NMR (400 MHz, CD3OD): 6 1.79 (s,
3H), 1.84 (s, 3H), 4.37-4.53 (m, SH), 5.21 (d, J= 3.4 Hz, 1H). 5.57 (tapp, J= 9.9 Hz, 1H), 7.44-
8.10 (m, 10H). 13C NMR (100 MHz, CD3OD): 6 22.7, 23.0, 52.1, 53.9, 53.9, 64.7, 71.6, 71.6,
71.7, 71.7, 71.9, 72.4, 98.5, 129.2, 129.6, 129.7, 129.9, 130.0, 130.1, 130.2, 130.3, 131.0, 131.2,
131.4, 134.8, 135.1, 137.3, 167.9, 168.1, 173.8, 174.2. HRMS calcd for [C 24 H26 N20 8 + Na] +
requires m/z 493.1581. Found 493.1570 (ESI+).
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Synthesis of dibenzylphospho-2,4-acetamido-3,6-O-benzoyl-2,4-deoxy-a-D-gluco-
pyranoside
OBz
AcHN- 0
BzO 
AcHN 11O-P-OBn
22 OBn
Compound 21 (138 mg, 0.28 mmol, 1 eq) was dissolved in dry THF (3 mL) and the
solution cooled to -68 C. To the cooled solution, lithium hexamethyldisilazide (LiHMDS, 1M
solution in THF) (360 piL, 0.36 mmol, 1.3 eq) was added dropwise. After 10 minutes,
tetrabenzylpyrophosphate (194 mg, 0.42 mmol, 1.5 eq) was dissolved in dry THF (2 mL) and
added dropwise to the reaction mixture. The reaction was stirred at -68 C for 10 minutes and
slowly warmed to 0 C. The mixture was then diluted with Et2O (2 mL), washed with chilled
saturated NaHCO3 (2mL) and NaCl (2 mL) and dried over anhydrous MgSO4. The solvent was
removed under vacuum and the mixture purified by column chromatography (5% MeOH in
CH 2Cl2 ) to yield the protected phosphate 22 as a colorless oil (100 mg, 50% yield). Rf = 0.35
(CH2Cl2:MeOHF 95:5). 1H NMR (400 MHz, CDCl3): 6 1.77 (s, 3H), 1.83 (s, 3H), 4.43-4.57 (nm,
6H), 5.14, (, 4H), 5.60 (tapp, J = 10.5 Hz, 1H), 5.86 (dd, J = 3.3, 5.9 Hz, 1H), 7.37 (m, 5H),
7.47-8.07 (m, 0IOH). 13C NMR (100 MHz, CDCl3): 6 22.7, 23.0, 52.1, 53.9, 64.7, 71.6, 71.7,
71.9, 72.4, 98.5, 129.2, 129.6, 129.7, 129.9, 130.0, 130.1, 130.2, 130.3, 131.0, 131.2, 131.4,
134.8, 135.1, 137.3, 167.9, 168.1, 173.8, 174.2. 3 1 p NMR (162 MHz, CDCl 3 ): 6 -1.50. Mass
spectroscopy of this intermediate is complicated by the facile -elimination of the
phosphotriester, which precludes observation of the molecular ion.
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Synthesis of phospho-2,4-acetamido-3,6-O-benzoyl-2,4-deoxy-a-D-galacto-pyranoside
OBz
AcHN 0
BzO O
AcHN IO-P-O-
23 o0-
The protected phosphate 22 (100 mg, 0.14 mmol, 1 eq) was dissolved in MeOH (2 mL).
Pd/C (10 wt% on activated carbon) (14 mg, 0.014 mmol, 0.1 eq) was added and the mixture was
stirred under a hydrogen atmosphere for 3 hours. The palladium was filtered off and the solvent
removed to yield 12 mg of 2 as a white solid (> 99%), which was used in the coupling to UMP-
morpholidate or Und-P without further purification. H NMR (400 MHz, CD3OD): 6 1.82 (s,
3H), 1.93 (s, 31-1), 4.41 (m, 2H), 4.51 (m, 1H), 4.58 (m, 2H), 5.61 (m, 2H), 7.46-8.15 (m, I10H).
13C NMR (100 MHz, CD 3OD): 6 10.1, 23.1, 47.4, 50.1, 51.8, 54.8, 64.8, 70.6, 74.8, 95.5, 129.9,
130.0, 131.2, 131.6, 131.8, 134.7, 168.2, 168.3, 173.4, 173.9.3 P NMR (162 MHz, CD 3OD): 6 -
2.56. HRMS calcd for [C24H25N2011P - H]- requires m/z 549.1269. Found 549.1283 (ESI-).
Synthesis of Und-PP-Bac-6-OH
Bac-6-OH phosphate 23 (15 mg, 0.03 mmol, 1 eq) was dissolved in DMF (500 pL) and
carbonyl di-imidazole (CDI) (7 mg, 0.04 mmol, 1.6 eq) was added. The mixture was stirred at
room temperature for 6 hours. The excess CDI was quenched with methanol (8.6 L, 0.27 mmol,
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9 eq) and stirred for 30 mins. The undecaprenyl phosphate (7 mg, 0.008 mmol, <1 eq) was
dissolved in CH2Cl2 (500 pL) and added to the sugar phosphate. The mixture was allowed to stir
at room temperature for one week and monitored by 31p NMR. The solvent was removed under
vacuum and the mixture purified by silica gel chromatography eluting with CHCl 3:MeOH:2M
NH4OH 85:14:1, to yield 5.0 mg of protected Und-PP-Bac-6-OH as a colorless oil (50%). Rf =
0.55 (CHCl3 :MeC)H:H20 65:25:4). 31p NMR (162 MHz, CDCl 3:CD3OD (2:1)): 6 -5.7, -8.3.
The dibenzoyl protection on C-3 and C-6 was deprotected with sodium methoxide as before to
yield the deprotected Und-PP-Bac-6-OH as a colorless oil. HRMS calcd for [C65H106N2 012P2-H]-
requires m/z 1169.7232. Found 1169.7315 (ESI-).
Synthesis of Und-PP-GlcNAc
GlcNAc phosphate (15 mg, 0.03 mmol, 1 eq) was dissolved in DMF (500 ptL) and
carbonyl di-imidazole (CDI) (7 mg, 0.04 mmol, 1.6 eq) was added. The mixture was stirred at
room temperature for 6 hours. The excess CDI was quenched with methanol (8.6 pL, 0.27 mmol,
9 eq) and stirred for 30 mins. The undecaprenyl phosphate (7 mg, 0.008 mmol, <1 eq) was
dissolved in CH2C12 (500 pL) and added to the sugar phosphate. The mixture was allowed to stir
at room temperature for one week and monitored by 31p NMR. The solvent was removed under
vacuum and the mixture purified by silica gel chromatography eluting with CHCl 3:MeOH:2M
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NH4OH 85:14:1, to yield 5.0 mg of protected Und-PPGlcNAc as a colorless oil (50%). Rf= 0.40
(CHCl3:MeOH:H20 65:25:4), 31p NMR (162 MHz, CDCl 3:CD3OD (2:1)): 6 -5.0, -7.9. LRMS
calcd for [C69HlllNOs5P2-2H]2 - requires m/z 1253.7. Found 1253.5 (ESI-).
The acetyl protecting groups were removed with sodium methoxide as before to yield the
deprotected Und-PP-GlcNAc as a colorless oil.
Synthesis of Geranylgeranyl-PP-Bac-6-OH
2 24
Bac-6-OH phosphate 23 (10 mg, 0.018 mmol, 1 eq) was dissolved in DMF (500 L) and
carbonyl di-imidazole (CDI) (15 mg, 0.09 mmol, 5.0 eq) was added. The mixture was stirred at
room temperature for 6 hours. The excess CDI was quenched with methanol (5 L, 0.16 mmol, 9
eq) and stirred for 30 mins. Geranylgeranyl phosphate (6.7 mg, 0.018 mmol, 1 eq) was dissolved
in CH2C12 (500 tL) and added to the sugar phosphate. The mixture was allowed to stir at room
temperature for one week and monitored by 31p NMR. The solvent was removed under vacuum
and the mixture purified by silica gel chromatography eluting with CHCl3:MeOH:2M NH4OH
85:14:1, to yield 5.0 mg of protected geranylgeranyl-PP-Bac-6-OH as a colorless oil (50%). Rf =
0.25 (CHCl3:MeOH:H 20 65:25:4). 31 p NMR (162 MHz, CDCl 3:CD3OD (2:1)): 6 -5.0, -7.8.
LRMS calculated for [C4 4H6 0N2 014P2 -2H]- requires m/z 900.4. Found 900.4 (ESI-). The C-3 and
C-6 benzoyl protection was removed with sodium methoxide as before to yield the fully
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deprotected Geranylgeranyl-PP-Bac-6-OH as a colorless oil. LRMS calcd for [C3 0H52 N2 01 2P2-
2H]2- requires m/z 692.3. Found 692.5 (ESI-).
Synthesis of Dolichyl-PP-Bac-6-OH
)H
Bac-6-OH phosphate 23 (7 mg, 0.014 mmol, 1 eq) was dissolved in DMF (500 [LL) and
carbonyl di-imidazole (CDI) (11 mg, 0.07 mmol, 5.0 eq) was added. The mixture was stirred at
room temperature for 6 hours. The excess CDI was quenched with methanol (5 tL, 0.12 mmol, 9
eq) and stirred for 30 mins. Dolichyl phosphate (20 mg, 0.014 mmol, eq) was dissolved in
CH2Cl2 (500 AL) and added to the sugar phosphate. The mixture was allowed to stir at room
temperature for one week and monitored by 31p NMR. The solvent was removed under vacuum
and the mixture purified by silica gel chromatography eluting with CHCl3:MeOH:2M NH4OH
85:14:1, to yield 7.0 mg of protected dolichyl-PP-Bac-6-OH as a colorless oil (50%). Rf= 0.50
(CHCl3:MeOH:H20 65:25:4). 31p NMR (162 MHz, CDCl 3:CD3OD (2:1)): 6 -6.3, -8.6. The C-3
and C-6 benzoyl protection was removed with sodium methoxide as before to yield the fully
deprotected Geranylgeranyl-PP-Bac-6-OH as a colorless oil. LRMS calcd for [C95-115H158-
19 0N2 0 12P2-2H]2 - requires m/z 1579.1, 1647.2, 1715.2, 1783.3, 1851.4. Found 1579.5, 1647.6,
1715.7, 1783.6, 1850.8 (ESI-).
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Chapter 3
Investigating the glycosyltransferases in the Pgl pathway of Campylobacterjejuni
A significant portion of the work described in this chapter has been published in:
Glover, K. J., Weerapana, E., Imperiali B. In vitro assembly of the undecaprenylpyrophosphate-
linked heptasaccharide for prokaryotic N-linked glycosylation. Proc. Natl. Acad Sci. USA. 2005.
40, 14255-14259.
Glover, K. J.*, Weerapana, E.*, Chen, M. M., Imperiali B. UDP-Bacillosamine is the substrate
for the PglC glycosylphosphotransferase involved in C. jejuni N-linked glycosylation. 2005,
Manuscript in preparation.
*These authors contributed equally to this work.
Dr. K. J. Glover performed all the cloning, protein expression and purification described in this
chapter. All the radioactive and HPLC assays were a collaborative effort.
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Introduction
The undecaprenyl-pyrophosphate-linked heptasaccharide donor for N-linked
glycosylation in Campylobacterjejuni is biosynthesized on the cytosolic face of the periplasmic
membrane by a series of glycosyltransferases. The enzymes responsible for this process are
encoded by a gene cluster dubbed 'pgl' for protein glycosylation (Figure 3 1). l 2
w. vP~~~~1 Nk r '0 '\He~~~~q -Qq' '4q , Q ~8 , at atQ9q , '9q
* Glycosyl Bacillosamine Oligosaccharyl
transferase biosynthesis transferase
Figure 3-1. The pgl gene cluster from C. jejuni.
PglC is a glycophosphoryltransferase that transfers the first sugar residue of the N-linked
heptasaccharide onto the undecaprenyl-phosphate (Und-P) carrier. The exact identity of the
nucleotide-linked glycan substrate for PglC is still in question.3 Four glycosyltransferases, PglA,
PglJ, PglH and PglI are responsible for the completion of the heptasaccharide biosynthesis. The
addition of six glycans via the action of four glycosyltransferases leads to questions regarding the
exact role of each of these enzymes in this biosynthetic process. Our interests lie in validating the
activities of the Pgl enzymes in vitro, with two major goals in mind:
1. To unambiguously define the nucleotide-linked glycan donor for the glycophosphoryl-
transferase, PglC.
2. To determine how the four glycosyltransferases, Pgl A, J, H and I, facilitate the transfer of
six glycan units.
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Pg1C
PglC is a 23 kD glycophosphoryl-transferase that is postulated to catalyze the transfer of
a sugar-phosphate from a UDP-linked donor to Und-P, to form the first, membrane-associated
glycan intermediate in the pathway. PglC includes a single N-terminal transmembrane-domain
(TMHMM, ExPASY), similar to several bacterial galactose-l1-phosphoryl transferases involved
in O-antigen biosynthesis, including RfbP (WbaP) in Salmonella enterica.4' 5 Enzymes involved
in HexNAc-1-P transfer reactions such as MraY (bacterial cell wall synthesis),6 WecA (O-
antigen biosynthesis), 7 and Alg7 (the eukaryotic enzyme responsible for the first committed step
in the dolichol pathway), 8 differ topologically from PglC since they all include 11 or more
transmembrane regions.9
Currently, there are two accepted models for the role of PglC in the Pgl pathway. In the
first model (Figure 3-2 A), UDP-GlcNAc or UDP-GalNAc is converted sequentially by a
dehydratase (PglF), an aminotransferase (PglE) and an acetyltransferase (PglD) to afford uridine
diphospho-bacillosamine (UDP-Bac). This product then acts as the substrate for PglC, which
creates the membrane-associated intermediate, undecaprenyl-pyrophosphate-linked
2bacillosamine (Und-PP-Bac).
In the second model (Figure 3-2 B), PglC is proposed to utilize UDP-GlcNAc or UDP-
GalNAc to create the membrane associated intermediate Und-PP-GlcNAc/GalNAc. This
intermediate is then modified sequentially on the Und-P carrier by PglF, PglE and PglD to yield
Und-PP-Bac.1 Our interest lies in defining the precise role of PglC in order to provide vital
information regarding the early steps of the Pgl pathway.
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Figure 3-2. The early steps in the PgI pathway.
Two proposed models: (A) PgIC accepts UDP-Bac. (B) PgIC accepts UDP-HexNAc.
The Pgl g1ycosyltraosferases
The Und-PP-Bac intermediate is elaborated by PgIA, PglJ, PgIH and PglI to form the
Und-PP-heptasaccharide. The current model postulates that PgIA transfers the first GalNAc
residue to bacillosamine to form the disaccharide. PglJ catalyzes the subsequent GalNAc transfer
to afford the trisaccharide, PgIH is responsible for the third GalNAc transfer and PglI catalyzes
the fmal step of the biOSYnthesisby transferring the branching glucose residue (Figure 3-3).2
Infonnation on how the trisaccharide is elaborated to the hexasaccharide and the exact role of
PgIH remains in question. Three probable hyPOtheses have been presented: PglH transfers a
single GalNAc followed by two yet to be identified glycosyltransferases, PglH has polymerase
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activity and transfers the remaining three GalNAc residues or PgIH and PglJ act alternately to
create the hexasaccharide.I, 2
Cytoplasm
Periplasm
• Bacillosamine
_ N-Acetylgalactosamine
• Glucose
UDP..--..
PgU
Und-PP Undecaprenyl-pyrophosphate
Figure 3-3. The PgI glycosyltransferases.
Elongation of the Und-PP-Bac intermediate by PgI A, J, H and I to form the heptasaccharide.
These four glycosyltransferases have very similar sizes and topologies. They have a
molecular weight around 40 kD and do not include any predicted transmembrane domains
(TMHMM, ExPASY). They bear little homology to the Alg enzymes in the yeast dolichol
pathway, which are all integral membrane proteins.lO However, they do share significant
homology with the enzymes involved in the synthesis of the O-antigen sugar core. I I
We are interested in complementing the existing mutational analysis data with in vitro
biochemical data to define the precise roles of the PgI glycosyltransferases so as to develop a
tractable system for investigating the sequential biosynthetic assembly process that occurs at the
membrane interface. Furthermore, the biochemical validation of these transferases will help to
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complete the picture of heptasaccharide assembly, setting the stage for usmg these
glycosyltransferases to create native and novel substrates for the bacterial-glycosylation
machinery, and providing specific targets for the development of inhibitors that may reduce C.
jejuni pathogenicity.
Results and Discussion
PglC
PgIC was overexpressed, purifed using Ni2+ -affinity chromatography and confirmed by
SDS-PAGE (Coomassie-stained) and Western-blot analysis (Figure 3-4). The proposed UDP-
Bac substrate for PgIC was chemically synthesized via the coupling of bacillosamine-phosphate
to UMP-morpholidate (Chapter 2). Und-P was synthesized from undecaprenol using a previously
published procedure, which utilizes phosphoramidite chemistry.12, 13
Figure 3-4. Ni-NT A purified PgIC.
(A) Coomasie-stained polyacrylamide gel. (B) Anti- T7 -Tag western-blot analysis. ,Molecular
weight markers (lane 1). PgIC (lane 2).
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In one of the postulated models for PglC activity, the enzyme is proposed to facilitate the
transfer of bacillosamine-phosphate from UDP-Bac to Und-P to form Und-PP-Bac. This Und-
PP-Bac intermediate is then elaborated by PglA, which uses UDP-GalNAc to transfer an al,3-
GalNAc residue to form the GalNAc-al,3-Bac-a-l-PP-Und disaccharide intermediate (Scheme
3-1).
Me O 
AcHN- .UN
AH O-P-O N' 0 +
iflnP-Ra 6- 6-
OH OH
PglC
NHAc
/x\ AcHN~
0- 0/ x/-X' ,o-P-O-P-O-
- I-UDP-GaINAc
PgIA
UDP
HO OH O NHAc
0- 0
0 0
Scheme 3-1. Reactions catalyzed by PglC and PglA.
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A typical assay for glycosyltransferase activity involves monitoring the transfer of
radiolabeled glycan from the aqueous-soluble UDP-derivative to the organic-soluble Und-PP-
derivative. Since radiolabeled UDP-Bac is not readily available through our current synthetic
route, the activity of PgIC is observed indirectly by coupling the transformation that it effects
with that of PgIA, which adds a radiolabeled GalNAc moiety to the product of the PgIC reaction.
UDP-GaINAc is commercially available in radiolabeled form and by coupling the PgIC and
~glA reactions, the enzyme activity can be monitored by standard radiolabeled assay methods. A
schematic of this assay is displayed in Figure 3-5.
Quench aliquots
ASSAY
ANALYSIS
Count Organic
ORGANIC
3H-Iabeled Und-PP-Bac-GaINAc
Figure 3-5. Radiolabeled assay procedure for PgIC.
When synthetic UDP-Bac and Und-P are incubated with PgIC, PgIA and 3H-UDP-
GaINAc, a net transfer of radioactivity to the organic layer is observed with time (Figure 3-6).
This indicates that both PgIC and PglA are acting in concert to produce the radiolabeled
GaINAc-al,3-Bac-a-l-PP-Und disaccharide, which partitions into the organic layer. Control
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reactions in which either PglA or PglC were absent, show no net transfer of radioactivity, hence
indicating that both enzymes are required for the biosynthesis of the disaccharide product.
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Figure 3-6. PglC accepts UDP-Bac.
Plot of Und-PP-Bac-GalNAc product formation over time with UDP-Bac, UDP-GalNAc and
Und-P substrates. Solid line, PglC and PglA. Dotted line, PglA only. Dashed line, PglC only.
In order to further characterize the product from this combined PglC/PglA reaction, the
glycan was hydrolyzed from the undecaprenyl-pyrophosphate carrier by acid hydrolysis. The
reducing terminus was then labeled with a fluorophore, 2-aminobenzamide (2AB) via a reductive
amination (Scheme 3-2).
. . tH- ,-
a 6RH \ e b
HO .0 HO " O o
-L "H _OH NAcHN
O-3-04-o- OH
3 o
Scheme 3-2. Acid hydrolysis and 2-aminobenzamide-labeling scheme.a
aReagents and condition: a) TFA, n-propanol, 50 C; b) 2-aminobenzamide, sodium
cyanoborohydride, DMSO, 60 C.
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2
The resulting 2AB-labeled disaccharide was isolated on a GlykoSepN normal-phase
column and analyzed by MALDI-MS. The HPLC trace shows a peak that elutes at TR = 22
minutes (Figure 3-7 A) and when subjected to mass-spectral analysis a [M + Na]+ m/z of 592.27+
is observed, which corresponds to the sodium ion adduct of the disaccharide 2AB-Bac-GalNAc
(where 2AB is 2-aminobenzamide) (Figure 3-7 B).
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Figure 3-7. HPLC and MALDI-MS analysis of the PglC/PglA reaction.
(A) HPLC analysis of the 2-AB labeled disaccharide. (B) MALDI-MS analysis of the 2-AB
labeled disaccharide. Peak at 592.27 denotes the sodium adduct of the 2AB-labeled disaccharide.
We were interested in clarifying the exact role of PglC in the Pgl pathway. The
radioactive assay results, coupled with the HPLC and MALDI-MS characterization (Figure 3-7)
provide convincing evidence that UDP-Bac is indeed the substrate for PglC. However, it was
necessary to completely rule out the second hypothesis in which UDP-GalNAc or GlcNAc is the
substrate for PglC. Since both these UDP-derivatives are commercially available in radiolabeled
form, they could be directly assayed as substrates for PglC. When compared to the transfer of
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radioactivity to the organic phase in the case of UDP-Bac (Figure 3-8 A), there is no
radioactivity transferred to the organic phase during the timeframe of the experiment for UDP-
GlcNAc and UDP-GalNAc (Figure 3-8 B). This establishes that PglC does not accept UDP-
GalNAc or UDP-GlcNAc but does accept UDP-Bac to afford the transfer to Und-P to form Und-
PP-Bac. PglC also accepts UDP-6-hydroxybacillosamine (synthesized by M. M. Chen, Imperiali
Lab) (Figure 3-8 C) and hence does show some flexibility in the UDP-sugar donor.
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Figure 3-8. UDP-sugar substrate specificity of PglA.
(A) Radiolabeled product formation with UDP-Bac. (PglC/PglA coupled assay) (B) No
radiolabeled product is formed with UDP-GalNAc or UDP-GlcNAc. (PglC direct assay). (C)
Radiolabeled product formation with UDP-Bac-6-OH (PglC/PglA coupled assay).
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The Pgl glycosyltransferases
PgIA, PgIH, PglI, and PglJ were overexpressed, purified uSIng Ne+ affinity
chromatography, and confirmed by SDS-PAGE (Coomassie-stained) and Western blot analysis
(Figure 3-9).
A
2 25
19
14
-
;..4 .-_ ...
Figure 3-9. Ni-NTA purified glycosyltranferases.
(A) Coomasie stained-polyacrylamide gel. (B) Anti-T7 Western Blot analysis. Molecular weight
<..
markers (lane 1). PgIA, 43 kD (lane 2). PgIH, 41 leD (lane 3). PglI, 36 kD (lane 4). PglJ, 41 kD
(lane 5).
Various combinations of the purified enzymes were incubated in the presence of the
synthetic Und-PP-Bac (Chapter 2), UDP-Glucose, and UDP-GalNAc. The undecaprenyl-
pyrophosphate-linked saccharide products were isolated from the reaction mixture by extraction
into organic solvent, and hydrolyzed to remove the Und-PP moiety. The free saccharide was then
fluorescently labeled by reductive amination (2-aminobenzamide/sodium cyanoborohydride) for
HPLC analysis.
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PglA
When PglA alone is reacted, a peak with a retention time of 22 minutes is observed in the
HPLC analysis (Figure 3-10 A). When this peak is collected and subjected to mass spectral
analysis a [M + Na]+ m/z of 592.27+ is observed, which corresponds to the sodium ion adduct of
the disaccharide 2AB-Bac-GalNAc (where 2AB is 2-aminobenzamide) (Figure 3-10 B). PglH,
PglI, and PglJ all failed to show activity with the undecaprenyl-pyrophosphate-linked
monosaccharide (data not shown).
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Figure 3-10. HPLC and MALDI-MS analysis of the PglA reaction.
(A) HPLC analysis of the 2-AB labeled disaccharide. (B) MALDI-MS analysis of the 2-AB
labeled disaccharide. Peak at 592.27 denotes the sodium adduct of the 2AB-labeled disaccharide.
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To examine the undecaprenyl-pyrophosphate-linked glycan specificity, two non-native
glycosyl acceptors were prepared via chemical synthesis: Und-PP-Bac-6-OH and Und-PP-
GlcNAc (Chapter 2). Und-PP-GlcNAc shows product formation that is several-fold less efficient
than the Und-PP-Bac while Und-PP-6-hydroxybacillosamine, which contains a C-6 hydroxyl
group, is accepted significantly more efficiently than Und-PP-GlcNAc (Figure 3-11). These data
are consistent with cellular studies, which show flexibility in PglA activity as GlcNAc is found
in place of bacillosamine when the Pgl cluster is functionally reconstituted in E. coilI 4 .
3DU
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NHAc NHAc HO
HO Me Hoj OH H OH
X ~AcHN~~AcH NAcHN
o 0 0-00 0
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Und-PP-Bac Und-PP-Bac-6-OH Und-PP-GcNAc
Figure 3-11. Undecaprenyl-pyrophosphate-linked glycan specificity of PglA.
Plot of Und-PP-disaccharide formation over time using PglA, UDP-GalNAc and the three Und-
PP-monosaccharides shown. Solid line, Und-PP-Bac. Dashed line, Und-PP-Bac-6-OH. Dotted
line, Und-PP-GlcNAc.
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We were also interested in exploring the polyisoprene-specificity of PglA. In Chapter 2,
the synthesis of two different polyisoprenyl-pyrophosphate-linked compounds, geranylgeranyl-
PP-Bac-6-OH and dolichyl-PP-Bac-6-OH was discussed. When PglA was assayed with both of
these polyisoprenyl-pyrophosphate-linked compounds, it was found that PglA accepts the
dolichyl-linked substrate, but not the shorter geranylgeranyl-linked substrate (Figure 3-12).
NHAc
HO OH
Geranylgeranyl-PP-Bac-6-OH 
AcHNW
' o_8 o 0_o oI II, ~O-P-O-P-O-
60
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Figure 3-12. Polyisoprene specificity of PglA.
Plot of polyisoprenyl-pyrophosphate-linked disaccharide formation over time using PglA, UDP-
GalNAc and the three polyisoprenyl-pyrophosphate-linked monosaccharides shown. Solid line,
Undecaprenyl-PP-Bac-6-OH. Dashed line, Dolichyl-PP-Bac-6-OH. Dotted line, Geranylgeranyl-
PP-Bac-6-OH.
103
PglJ
When PglA and PglJ are combined and the products analyzed by HPLC, a peak at 31
minutes is observed, which has a [M + Na]+ m/z of 795.25 (Figure 3-13). This corresponds to the
sodium ion adduct of the trisaccharide 2AB-Bac-GalNAc-GalNAc and is consistent with PglJ
adding a single GalNAc residue. PglJ is very specific for this step as the combination of PglA
and PglH failed to yield anything larger than the disaccharide (data not shown). These results are
complementary with the in vivo studies, which demonstrated build up of a disaccharide
intermediate when PglJ was genetically knocked out. 15
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Figure 3-13. HPLC and MALDI-MS analysis of the PglJ reaction.
(A) HPLC analysis of the 2-AB-labeled trisaccharide. (B) MALDI-MS analysis of the 2-AB
labeled trisaccharide. Peak at 795.25 denotes the sodium adduct of the 2AB-labeled
trisaccharide.
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PglH
When PglA, PglH, and PglJ are combined, HPLC analysis reveals a peak with a
dramatically increased retention time of 51 minutes (Figure 3-13 A). By mass spectral analysis,
this peak has a [M + Na]+ m/z of 1403.26, which corresponds to the hexasaccharide 2AB-Bac-
(GalNAc)5 (Figure 3-13 B). In a parallel experiment, when trisaccharide is prepared using PglA
and PglJ and then reacted singly with PglH, a hexasaccharide is also observed (data not shown).
Taken together, these two studies reveal that PglH is adding the three remaining GalNAc
residues.
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Figure 3-14. HPLC and MALDI-MS analysis of the PglH reaction.
(A) HPLC analysis of the 2-AB labeled hexasaccharide. (B) MALDI-MS analysis of the 2-AB
labeled hexasaccharide. Peak at 1403.26 denotes the sodium adduct of the 2AB-labeled
hexasaccharide.
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PglI is proposed to add the final branching glucose to complete the heptasaccharide
glycosyl donor biosynthesis. When PglI is purified by Ni-NTA chromatography in the presence
of Triton X-100, and subjected to SDS-PAGE analysis, two major bands are observed by
Coomassie-staining and Western-blot analysis (Figure 3-9). The lower molecular weight band
corresponds well to the predicted molecular weight of PglI, while the higher band indicates the
presence of protein oligomerization. When added in combination with the other transferases, PglI
purified in this manner failed to show any glucosyl transferase activity (data not shown).
However, when a bacterial membrane fraction prepared from cells that overexpress PglI is
combined with PglA, PglJ and PglH a new peak at 56 minutes is observed (Figure 3-14 A). This
peak has a [M + Na]+ m/z of 1567.08 that corresponds to the full heptasaccharide (Figure 3-14
B). Control studies with bacterial membranes prepared using the same over-expression
conditions, but using a plasmid that did not have the PglI gene insert, did not show transferase
activity confirming that PglI is responsible for the Glc transfer (data not shown).
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Figure 3-15. HPLC and MALDI-MS analysis of the PglI reaction.
(A) HPLC analysis of the 2-AB-labeled heptasaccharide. (B) MALDI-MS analysis of the 2-AB-
labeled heptasaccharide. Peak at 1567.08 denotes the sodium adduct of the 2AB-labeled
heptasaccharide.
Conclusion
The processes by which nature assembles complex saccharides is of fundamental
biological importance. In the C. jejuni system, a heptasaccharide is assembled in a stepwise
fashion on an undecaprenyl-pyrophosphate carrier, in a sequential process that involves several
glycosyltransferases and a glycophosphoryltransferase.
PglC is a glycophosphoryltransferase that acts in the early steps of the biosynthesis of the
undecaprenyl-pyrophosphate-linked heptasaccharide, catalyzing the transfer of bacillosamine-
phosphate to undecaprenyl-phosphate to form Und-PP-Bac. In order to study the activity of PglC
in vitro, significant quantities of UDP-Bac are necessary. Purification from the natural source is
not a realistic option due to the low cellular levels of UDP-Bac, and the extreme pathogenicity of
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C. jejuni, which calls for specialized handling procedures. On the other hand, using the chemical
synthesis route presented in Chapter 2, access to the desired compound in milligram quantities is
possible.
The in vitro biochemical analysis of PglC has revealed that UDP-Bac is the preferred
substrate, while UDP-GlcNAc or UDP-GalNAc are not utilized under the conditions examined.
This evidence strongly suggests that the later model (Figure 3-2 B) in which a UDP-HexNAc is
converted to bacillosamine on the undecaprenyl carrier is not viable. Instead, the enzymes PglF,
PglE, and PglD) likely convert UDP-HexNAc to UDP-Bac, which is then a substrate for PglC.
Favorably, PglC also accepts the UDP-Bac-6-OH derivative, suggesting that the additional N-
acetyl group is a major determinant in substrate recognition. Since the synthesis of Bac-6-OH is
considerably more facile than that of bacillosamine, this compound represents a suitable
alternative for IJDP-Bac for future investigations into this process.
The coupling of PglC with PglA shows that PglC works in concert with the other
enzymes, and current research focuses on preparation of the undecaprenyl-pyrophosphate-linked
heptasaccharide starting from undecaprenyl-phosphate. Furthermore, the confirmation of PglC
activity in vitro adds crucial clarification to the details of the early steps of heptasaccharide
assembly, and is an important milestone in the validation of the pgl pathway.
The glycosyltranferases PglA, J, H and I are crucial to the Pgl pathway. PglA is the first
glycosyltransferase to act on the Und-PP-Bac substrate to yield the disaccharide. Although in
vivo reconstitution studies in E. coli suggested that PglA had a relaxed substrate specificity, 14
our studies revealed that PglA has strong preference for bacillosamine over GIcNAc in vitro
consistent with the observation that only bacillosamine is observed in C. jejuni in vivo.3
Interestingly, the intermediate 6-hydroxybacillosamine is accepted almost as well as
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bacillosamine indicating that the additional N-acetyl group at C-4 is the most important
determinant in the specificity of PglA. PglA also accepts a dolichyl-pyrophosphate-linked glycan
as the acceptor suggesting that PglA is not hindered by the larger chain length or a-isoprene
saturation of the dolichol chain compared to the native undecaprenol. Interestingly, PglA does
not accept the geranylgeranyl-pyrophosphate-linked glycan suggesting that although PglA does
not include any transmembrane domains, it does interact with the membrane bound regions of
the substrate.
PglJ transfers a single sugar while PglH has a polymerase activity adding the three
remaining GalNAc residues. Defining the roles of PglJ and PglH was essential for a complete
understanding of the glycan assembly process. In vivo studies were not able to account for the
complete assembly of hexasaccharide, and concluded with three possible scenarios. 15 The studies
presented herein clearly indicate that PglH precisely transfers the three terminal GalNAc residues
independent of the PglI glucosyl transferase activity, and structural studies are currently
underway to investigate this interesting behavior. Finally, PglI is considerably more hydrophobic
than the other transferases. In particular, the protein has a modest probability of having a C-
terminal transmembrane domain (TMHMM, ExPASY), and when purified in the presence of
detergents it shows oligomeric behavior by SDS-PAGE, which is indicative of a poorly
stabilized protein. Consequently, when this preparation was used for transferase studies, no
activity was observed. However, when a bacterial membrane preparation with PglI was
generated it revealed very good activity, highlighting the important role played by native lipids
in the stability and activity of the enzyme.
Remarkably, when the various transferases are combined, the intermediate saccharides
are not observed; the transfer is complete. This indicates that the sequential activities of the
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pathway have been reconstituted and suggests that the enzymes closely interact with each other.
Biophysical studies are currently underway to characterize this behavior. Having the exact roles
of PglA, PglJ, PglH, and PglI clearly defined helps to complete the picture of glycan assembly in
C. jejuni, and sets the stage for using this pathway to probe the more fundamental questions
surrounding multi-enzyme processes as well as engineering the enzymes to create unnatural
saccharides.
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Experimental
Cloning of the Pgl enzymes
PglC, A, J, H and I were amplified by PCR from C. jejuni genomic DNA (ATCC
700819D, designation NCTC 11168) using Pfu Turbo (Stratagene) polymerase, with the
oligonucleotides:
PglCBamHI (CGCGGATCCATGTATGAAAAAGTTTTTAAAAGAATTTTTG)
PglCXho I (CCGCTCGAGGTTCTTGCCATTAAATTTCTCTGTTGTAAC)
PglABamH I (CGCGGATCCATGAGAATAGGATTTTTATCACATGCA)
PglAXho I (TACATTCTTAATTACCCTATCATAAAG)
PglHBamH I (CGCGGATCCATGATGAAAATAAGCTTTATTATCGCAAC),
PglHXho I (CCG-CTCGAGGGCATTTTTAACCCTCGGCTATAAGCTTA),
PgllBamH I (CGCGGATCCATGCCTAAACTTTCTGTTATAGTACCAAC),
PgllXho I (CCG(CTCGAGATTTTTGCATAAAG-CCACCCGAATTTTTG),
PglJBamH I (CGCGGATCCATGCAAAAATTAGGCATTTTTATTT-ATTC) and PglJXho I
(CCGCTCGAGCTCCTAATAAATATTTCAAAGCATCGCGT).
The PCR product was digested with BamH I and Xho I and cloned into the same sites of
vector pET-24a (Novagen). The final gene construct encoded a protein product with a N-
terminal T7-Tag and a C-terminal His-Tag.
Protein expression
Starting from a 5 mL overnight culture, PglC, PglA, PglH, PglI, or PglJ were grown at
37°C in LB broth to an OD6 00 of 0.6-0.8. At that point, the temperature was reduced to 16°C and
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protein production was induced by the addition of IPTG (1 mM). After 24 hours, the cells were
harvested by centrifugation (5000 x g) and frozen at -80°C until needed.
Protein purification
All steps were performed at 4°C. Cell pellets of E. coli strains expressing PglC, PglA,
PglH, PglI, or PglJ were thawed and resuspended in 5% of the original culture volume in buffer
L (50 mM Tris-acetate [pH 8.0], 20 mM imidazole). The cells were then subjected to sonication,
followed by the addition of Triton X-100 (1%), and shaking for 10 minutes. Cellular debris and
membrane proteins were removed by centrifugation (142,414 x g) for one hour, and the
supernatant was loaded on to a column containing Ni-NTA agarose equilibrated with buffer L.
After washing with 10 column volumes of buffer W (50 mM Tris-acetate [pH 8.0], 45 mM
imidazole), the purified protein was eluted with buffer E (50 mM Tris-acetate [pH 8.0], 250 mM
imidazole). Fractions containing at least 500 jtg/mL protein were used for enzyme assays, and
no further purification of the proteins was undertaken.
Preparation of PglI membrane fraction
All steps were performed at 4°C. The cell pellet of PglI was thawed and resuspended in
5% of the original culture volume in buffer M (50 mM Tris-acetate [pH 8.0], 1 mM EDTA). The
cells were then subjected to sonication, unbroken cells were removed by centrifugation at 5,697
x g for 15 minutes, and the membrane fraction was collected by centrifugation at 142,414 x g for
60 minutes. The pellet was washed once with buffer M, centrifuged again, and resuspended in
0.25% of the original culture volume in buffer M. The final suspension was aliquoted and stored
at -80°C.
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PglC radioactive enzyme assay using UDP-Bac and UDP-6-hydroxybacillosamine
To a tube containing 0.06 mg of dried Und-P, 3 pL of DMSO and 7 gL of 14.3% (v/v)
Triton X-100 were added. After vortexing and sonication (water bath), 70 pL of H20, 4.5 ,uL of 1
M Tris-acetate pH 8.0, 1 pL 1 M MgCl2, 5 pL PglC, and 5 iL PglA were added. For the two
control reactions, the PglA or PglC samples were replaced with buffer E. The reaction was
initiated by the addition of 4.5 L of a 53 M solution of UDP-Bac or UDP-6-hydroxy
bacillosamine, and 22 MM UDP-GalNAc (2.02 nCi/nmol). Reactions were run at room
temperature and 20 L aliquots were taken at 1.5, 3, 4.5, and 6 minutes. Reactions were
quenched by addition to a tube containing 400 pL of 2:1 chloroform: methanol and 200 pL of
pure solvent upper phase (PSUP, [15 mL chloroform/240 mL methanol/1.83 g potassium
chloride in 235 mL water]). After vortexing briefly the layers were allowed to separate and the
aqueous layer removed. The organic layer was washed two times with 400 uL of PSUP and dried
under a stream of nitrogen. The residue was redissolved in 200 pL of Solvable (Perkin-Elmer) by
vigorous vortexing followed by the addition of 5 mL of Formula 989 scitillation fluid (Perkin-
Elmer). The tubes were allowed to rest for 1 hour and counted in a scintillation counter (5
minutes per sample).
PglC Enzyme assay for HPLC and MALDI-MS analysis
To a tube containing 0.06 mg of dried Und-P, 3 pL of DMSO and 7 pL of 14.3% (v/v)
Triton X-100 were added. After vortexing and sonication (water bath), 15 pL H2 0, 4 pL 1 M
Tris-Acetate pH 8.0, 1 pL 1 M MgCl2, and 5 pL of PglC were added. The reaction was initiated
by the addition of 4.5 pL of a 53 M solution of UDP-Bac or UDP-6-hydroxy bacillosamine, and
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22 tM UDP-GalNAc. The reaction was run at room temperature for 120 minutes and quenched
by addition to a tube containing 800 pIL of 2:1 chloroform: methanol and 160 jiL of PSUP.
After vortexing for 20 seconds, the tubes were centrifuged briefly and the organic layer (bottom)
containing product was removed and dried.
PglA, J, H and I enzyme assays for HPLC and MALDI-MS analysis
80 tL of buffer A (50 mM Tris-Acetate pH 7.0, 3 mM dithiothreitol, 5 mM MgCl 2 , 1%
(v/v) NP-40, 250 mM sucrose) was added to a tube containing 0.06 mg of dried Und-PP-Bac,
UDP-GalNAc (4 mM final concentration), and/or UDP-Glucose (0.4 mM final concentration).
The mixture was vortexed vigorously and sonicated (water bath). Next 5 tL each of the desired
enzymes were added and if necessary, buffer E was added to bring the total volume to 100 iL.
Reactions were run at room temperature for 120 minutes and quenched by addition to a tube
containing 800 p.L of 2:1 chloroform: methanol and 160 [tL of pure solvent upper phase. After
vortexing for 20 seconds, the tubes were centrifuged briefly and the organic layer (bottom)
containing product was removed and dried.
PglA radioactive enzyme assay
To a tube containing 0.06 mg of dried Und-PP-Bac, Und-PP-6-hydroxybacillosamine or
Und-PP-GlcNAc, 3 [tL of DMSO, and 7 tL of 14.3% (v/v) Triton X-100 were added. After
vortexing and sonication (water bath), 77 1tL of H2 0, 5 !iL of 1 M Tris-Acetate pH 8.0, 1 ptL 1 M
MgCl2, and 1 L PglA (660 ~tg/mL) were added. The reaction was initiated by the addition of 6
[tL of UDP-GalNAc (2.25 ,uCi/nmol). 15 gtL aliquots were taken at 2.5, 5, 10, and 15 minutes.
Und-PP-6-hydroxybacillosamine and Und-PP-GlcNAc were prepared via the coupling of Und-P
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with the corresponding sugar phosphate similar to the procedure used in the synthesis of Und-
PP-Bac.1 6-hydroxy bacillosamine is an intermediate in the synthetic route to bacillosaminet and
GlcNAc-phosphate was synthesized according to a previously reported procedure. 16
HPLC and MALDI-MS analysis of saccharides
The saccharide sample was hydrolyzed by dissolving the dried sample in n-propanol:2M
TFA (1:1), heating to 50°C for 15 minutes, and then evaporating to dryness. The hydrolyzed
sugars were then labeled with 2-aminobenzamide. To prepare the labeling reagent, a solution of
2-aminobenzamide (5mg) in 100 [tL acetic acid:DMSO (1:2.3) was prepared. This dye solution
was added to 6 mg of sodium cyanoborohydride and aliquots of 5 ItL of this reagent were added
to dried samples of hydrolyzed, desalted glycans, and heated to 60°C for 2-4 hours. Post-
labeling clean-up was accomplished using GlykoClean S cartridges (ProZyme Inc.) according to
the manufacturer's instructions. The labeled glycans were separated on a normal phase
analytical HPLC column (GlykoSepN, ProZyme, Inc.) using 50 mM ammonium formate, pH 4.4
(Solvent A) and acetonitrile (Solvent B) as eluents. A gradient of 20-52% solvent A over 80
minutes was used at a flow rate of 0.4 mL/min. The peaks were detected using a fluorescence
detector (ex = 330 nm, Xem = 420 nm) and collected and characterized with MALDI-MS using a
matrix composed of DHB (2,5-dihydrobenzoic acid) in acetonitrile/water with Nafion
perfluorinated resin (Aldrich) and trifluoroacetic acid as additives.
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Chapter 4:
Investigating the activity of PglB, the oligosaccharyl transferase of Campylobacterjejuni
A significant portion of the work described in this chapter has been published in:
Glover, K. J.*; Weerapana, E.*, Numao, S., Imperiali, B. Chemo-enzymatic synthesis of
glycopeptides using PglB, a bacterial oligosaccharyl-transferase from Campylobacter jejuni.
Chem. Biol. 2005, in press.
*These authors contributed equally to this work.
Dr. K. J. Glover performed all the cloning, protein expression and purification described in this
chapter. All the radioactive and HPLC assays were a collaborative effort.
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Introduction
Oligosaccharyl transferase (OT) is the enzyme responsible for the transfer of an
oligosaccharide from a polyisoprenyl-pyrophosphate-linked glycan donor to the asparagine side
chain within the Asn-Xaa-Ser/Thr sequon of nascent proteins.1 In eukaryotes, the OT complex
2,3
comprises 8 membrane-bound protein subunits. 3 The complexity of this system has hindered
in-depth investigation into the catalytic mechanism of this enzyme. Recent genetic and
biochemical studies in yeast have demonstrated that the Stt3p protein is an essential component
of the OT complex.4' 5 Homologs of STT3 are found in eukaryotic and archaeal systems (Table 4-
1), but until recently, no homologs were found in bacteria. The recent discovery of a STT3
homolog, pglB, in the genome of C. jejuni suggested the presence of an N-linked protein
glycosylation system in this bacterium.6
Domain Species Conserved sequence
Archaeal Pyrococcus abyssi (976 aa) ATATSWWDYGYWIE
Archaeal Pyrococcus horikoshii (976 aa) ATATSWWDYGYWIE
Archaeal Archaeoglobusfulgidus (593 aa) YAVLSWWDYGYWIL
Eukaryal Saccharomyces cerevisiae (718 aa) SKVAAWWDYGYQIG
Eukaryal Arabidopsis thaliana (779 aa) DKVASWWDYGYQTT
Eukaryal Mus musculus (823 aa) ARVMSWWDYGYQIA
Eukaryal Drosophila melanogaster (774 aa) ARVMSWWDYGYQIA
Eukaryal Anopheles gambiae (806 aa) ARVMSWWDYGYQIA
Eukaryal Caenorhabditis elegans (757 aa) ARVMSWWDYGYQIA
Eukaryal Schizosaccharomyces pombe (752 aa) TKVMSWWDYGYQIA
Eukaryal Toxoplasma gondii (723 aa) ARIMSWWDYGYQAT
Eukaryal Leishmania major (833 aa) ARVLAWWDYGYQI T
Bacterial Campylobacterjejuni (713 aa) DYVVTWWDYGYPVR
Archaeal Methanobacterium thermoautotrophicum (845aa) TVVMSWWDFGHLFA
Archaeal Pyrococcusfuriosus (743 aa) DIVLTWWDWGHFVT
Archaeal Pyrococcus horikoshii (758 aa) DVILAWWDWGHFIT
Archaeal Methanococcusjannaschii (933 aa) SVITCWWDNGHIYT
Table 4-1. Alignment of conserved residues from putative oligosaccharyl transferase homologs
from archaeal, bacterial and eukaryal domains. (Figure adapted from Wacker et al.)7
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Figure 4-1 shows a hydropathy plot of PglB and Stt3p (TMHMM, ExPasy), which clearly
demonstrates that the predicted membrane topology is highly conserved. PglB comprises a large
hydrophobic domain located at the N-terminus that accounts for approximately 2/3 of the
protein. This region is proposed to include 10 to 12 transmembrane domains. In contrast, the C-
terminal domain is highly hydrophilic and contains the WWDYGY motif (Table 4-1), which is
highly conserved among the Stt3 protein family.
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Figure 4-1. Membrane topology of PglB and Stt3p.
Hydropathy plot of (A) PglB and (B) Stt3p, showing that the membrane topology is highly
conserved (TMHMM, ExPASY).
The substrate for the PglB-catalyzed oligosaccharide transfer is the undecaprenyl-
pyrophosphate-linked heptasaccharide that is biosynthesized on the cytosolic side of the
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periplasmic membrane (Chapter 3). A C. jejuni, pglB mutant strain shows changes in
immunoreactivity that is in agreement with the phenotype expected for reduced glycosylation.7
When the PgI cluster is reconstituted in E.coli, two Campylobacter-derived proteins AcrA and
PEB3 are shown to be glycosylated with the heptasaccharide structure. However, if the highly
conserved WWDYGY sequence in PgIB is mutated, the proteins are produced in unglycosylated
form.7 These data suggest a direct involvement of PgIB in the generation of N-linked
glycoproteins in C.jejuni.
Cytoplasm
•-•
Und-PP
Bacillosamine
N-Acetylgalactosamine
Glucose
Undecaprenyl-pyrophosphate
Figure 4-2. Glycoprotein biosYnthesis by PgIB.
C. jejuni glycosylation occurs at the Asn-Xaa-Serffhr acceptor sequence.8 Both serine
and threonine can serve as the hydroxyl amino acid in the acceptor sequence and proline as
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residue X prevents glycosylation. Not all potential sites are glycosylated indicating that the N-X-
S/T sequon is necessary but not sufficient for glycosylation to occur.8 These observations are in
agreement with the parallel process of eukaryotic glycosylation.1
The native substrate for PglB is the undecaprenyl-pyrophosphate-linked heptasaccharide
containing bacillosamine as the first sugar. However, if E. coli cells are engineered so that the N-
glycosylation pathway and the lipopolysaccharide biosynthesis pathway converge, PglB is
shown to transfer O-polysaccharide from the undecaprenyl-pyrophosphate carrier to an acceptor
protein.9 A variety of O-antigen glycan structures are transferred, demonstrating the substrate
flexibility of PglB. When individual enzymes in the Pgl pathway are genetically knocked-out,
truncated saccharides are transferred to protein.10 This suggests that PglB also displays flexible
specificity with respect to the length of the glycan it transfers.
The requirement for the canonical consensus peptide sequence and the polyisoprenyl-
pyrophosphate-linked glycan substrate in bacterial glycosylation suggests that the mechanism of
oligosaccharide transfer in C. jejuni and eukaryotes is very similar. It is proposed that PglB
fulfills the oligosaccharyltransferase-function in the prokaryote and Stt3 represents the catalytic
subunit of the eukaryotic enzyme complex. Since the mechanism of action of the eukaryotic OT
complex is poorly understood due to its significant complexity, PglB provides a simpler model
system for studying this intriguing reaction in more depth.
Results and Discussion
In this chapter, work done towards establishing a system for demonstrating and studying
PglB activity in vitro is described. This in vitro system utilizes an E. coli membrane-fraction
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overexpressing PgIB in the presence of a truncated polyisoprenyl-pyrophosphate-linked glycan
donor and a peptide acceptor derived from known C.jejuni glycoproteins.
Substrates for N-Iinked glycosylation in vitro
In order to define the optimal peptide substrate, sequence alignments were performed
with two known periplasmic proteins, PEB3 and AcrA, which have been established to be
glycosylated in C. jejuni.7 AcrA is glycosylated at Asn123, while PEB3 is glycosylated at
;\sn90.IO, II When those regions are aligned, the first three amino acids preceding the Asn are
strictly conserved. However the residue after the Asn appears to be variable. The next two
residues, Ser and Lys are also highly conserved in these two proteins. In order to create the
consensus sequence for glycosylation, all conserved residues were retained to create the
KDFNVSKA-octapeptide sequence, which was prepared with a free N-terminus and a C-
terminal amide by standard solid-phase peptide synthesis (Figure 4-3).
PEB3 (N90)
AcrA (N123) It D P H RS It A L
Consensus
Figure 4-3. A peptide substrate for PgIB.
Sequence alignment of residues flanking the glycosylation sites of PEB3 and AcrA and the
resulting consensus peptide.
The polyisoprenyl-pyrophosphate-linked sugar substrate for PgIB was obtained chemo-
enzymatically, using the glycosyltransferase PgIA, which adds a GalNAc to the synthetically-
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obtained Und-PP-Bac in high yield (also accepts Und-PP-GlcNAc and Und-PP-6-
hydroxybacillosamine to a lesser extent) (Chapter 3). Und-PP-Bac is obtained via chemical
synthesis (Chapter 2) and radiolabeled-disaccharide substrate can be readily prepared by using
commercially available UDP-3H-GalNAc as the substrate for the PglA reaction (Scheme 4-1 A).
The disaccharide was selected as the minimal glycan donor for PglB based upon precedent from
the yeast OT, which readily accepts a truncated disaccharide substrate in vitro." 3 If the PglB
reaction proceeds as anticipated, a glycosylated peptide containing the tritium-labeled
disaccharide will be formed (Figure 4-1 B).
NHAc
HO UDP-3H-GalNAc UDP
_ l / V t
PglA
3HO33H OH
HIO "J /O NHAc
HMe KDFNVSKA
t5 AcHN~ Pg
I70-oeP0 OUnd-
/ 0 0
Scheme 4-1. Overview of PglA and PglB reactions.
(A) Synthesis of radiolabeled undecaprenyl-linked disaccharide using PglA, synthetic
undecaprenyl-pyrophosphate bacillosamine, and tritiated UDP-GalNAc.
(B) Overview of desired PglB reaction using the polyisoprenyl-pyrophosphate-linked
disaccharide and the peptide based on the consensus sequence.
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Preparation of PglB
Two PgIB constructs were prepared. The native, 83 kD PgIB protein was cloned into a
vector such that the final construct was a T7oTag-PgIB-(His)6 (T7oTag is for antibody
recognition). In addition, since the bacterial, fungal, and yeast OTs all contain a highly
conserved, 6-residue signature sequence WWDYGY (Figure 4-4 A) a second homologous
construct, in which two of these residues were mutated, was also prepared. According to the
work of Aebi and co-workers, if the WWDYGY signature sequence is mutated to WAA YGY,
PglB is no longer active in vivo.7 Both proteins were over-expressed in E. coli and a bacterial
membrane preparation of each was used for activity assays. The anti- T7 western-blot analysis
shown in Figure 4-4 B confirms that both the wild type and mutant are expressed in E. coli.
A
Wild Type
Mutant
B
2
......... ~ I
Figure 4-4. Overexpression of PgIB, wild-type and mutant.
(A) Sequence alignment of the highly conserved OT hex a-peptide motif. The PgIB mutant has
two alanine substitutions within this motif.
(B) Anti-T7.Tag Western blot of bacterial membranes overexpressing PgIB and the mutant
counterpart. Lane 1, Wild type; Lane 2, Mutant.
Both the mutant and wild-type PgIB proteins were assayed for oligosaccharyl transferase
activity. The assay used was one that was already established for assaying yeast microsomes for
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OT activity.3,12 Briefly, PgIB is added to a solution containing the peptide and glycan substrates.
An aqueous/organic phase separation partitions the peptide into the aqueous phase, while the
tritiated undecaprenyl-pyrophosphate-linked saccharide starting material remains in the organic
phase. If oligosaccharyl transferase activity is observed there will be a net transfer of
radioactivity from the organic phase into the aqueous phase (Figure 4-5).
Quench aliquots
ASSAY
RIIB
Peptide substrate
3H-GafNAc-Bac-PP-Und
ANALYSIS
Count Aqueous
AQUEOUS
3H-Iabeled glycopeptide
ORGANIC
3H-GaINAc-Bac-PP-Und
Figure 4-5. Radiolabeled assay procedure for PgIB.
The results from this assay are shown in Figure 4-6. These data clearly show that the wild
type PgIB readily transfers radioactive carbohydrate to an aqueous soluble fraction whereas the
mutant shows no comparable activity. Furthermore, the constant slope of the mutant-PgIB rate
profile confirms that there is negligible hydrolysis of the Und-PP-Bac pyrophosphate within the
timeframe of the experiment.
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Figure 4-6. Radiolabeled assay data for PglB.
Plot of glycopeptide product formation as a function of time. Solid line, Wild type. Dashed line,
Mutant.
In order to further confirm the presence of glycopeptide, the peptide products of reactions
run for extended periods (12 hours) were subjected to HPLC analysis. With wild-type PglB, the
peptide product elutes from the reverse-phase column at TR = 17.5 minutes (Figure 4-7 A), while
the peptide product from a similar incubation using the mutant PglB elutes at TR = 18.0 minutes
(Figure 4-7 C). When these peaks are collected and subjected to mass spectral analysis, a mass
corresponding to the glycopeptide is observed for the wild type (Figure 4-7 B) while the mutant
analysis shows only the unglycosylated peptide (Figure 4-7 D). The presence of single peaks in
the mass spectra shows that the glycopeptide product is not modified by host transferases or
proteases. Interestingly, the presence of only a single product in the mass spectrum coupled with
the appearance of a single HPLC peak suggests that there is complete conversion to
glycopeptide.
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Figure 4-7. HPLC analysis of the PglB reaction.
Reverse-phase HPLC traces of peptide and glycopeptide products. (These experiments were
performed with the more synthetically accessible 6-hydroxybacillosamine derivative).
(A) HPLC trace of peptide after PglB wild type reaction.
(B) MALDI-MS ofglycopeptide product.
(C) HPLC trace of peptide after PglB mutant reaction.
(D) MALDI-MS of unglycosylated peptide product.
Furthermore if radiolabeled glycan substrate is used, an abundant radioactive peak at a
similar retention time as the glycopeptide (Figure 4-8 A), confirms that the radioactivity in the
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aqueous layer is a result of radiolabeled glycopeptide and not a hydrolysis product, which would
elute very early (TR < 4 minutes) from the reverse-phase column (Figure 4-8 A arrow). In
addition, the assay including the mutant PglB, does not show an abundant radioactive peak
(Figure 4-8 B) further confirming that it is deficient in transferase activity.
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Figure 4-8. Radiolabeled HPLC analysis of the PglB reaction.
Radioactive HPLC traces of peptide and glycopeptide products. (These experiments were
performed with the more synthetically accessible 6-hydroxybacillosamine derivative).
(A) Radioactive HPLC trace of wild type PglB reaction.
(B) Radioactive HPLC trace of mutant PglB reaction.
Utilization of diverse undecaprenyl-pyrophosphate-linked glycans by PglB
Three disaccharide substrates were prepared using a chemo-enzymatic approach. As
presented previously, synthetic Und-PP-bacillosamine, Und-PP-6-hydroxybacillosamine and
Und-PP-GlcNAc were reacted with PglA and UDP-GalNAc to form the corresponding
radiolabeled disaccharides (Chapter 3). These polyisoprene-linked disaccharides were then
129
assayed with PglB to determine the specificity of PglB for the saccharide proximal to the
pyrophosphate moiety. The results from this assay are shown in Figure 4-9. In these studies, it
appears that PglB will accept the unnatural 6-hydroxybacillosamine and GlcNAc analogs,
although the bacillosamine substrate appears to be the most efficient of the three. These data
agree with in vivo studies, which have shown that PglB can transfer several structurally different
O-antigen saccharides to protein. 9
H
0 0'
O-P-O-P-O-
H-GaNAc-al,3-Bac-PP-Und
3HGalNAc-al ,3_BacPPUn d
8000
6000
a000C4000
2000
0
i1 3-R-hvdrmxvhcr-PP- nd
3H
0 5 10 15 20 25 30 35 3HOH
Time (min) O , 
ANHO<
~~- ',o> ~o 7o- -o O
3 H-GalNAc-a1,3-GIcNAc-PP-Und
Figure 4-9. Undecaprenyl-pyrophosphate linked disaccharide (3 H-GalNAc-X-PP-Und)
specificity of PglB. Solid line, X= bacillosamine; Dashed line, X= GlcNAc; Dotted line, X= 6-
hydroxybacillosamine.
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The native substrate for PglB is a heptasaccharide, but we have shown that PglB readily
accepts a disaccharide in vitro. Mutagenesis studies of proteins in the Pgl pathway have resulted
in the transfer of truncated saccharides to protein, strongly suggesting that PglB has low
specificity for the substrate length when functionally reconstituted in E. coli. 10 In vitro we can
access truncated substrates using various combinations of glycosyltransferases in the pgl
pathway. With PglA we can access the disaccharide (GalNAc-Bac), with PglA and J, we form
the trisaccharide (GalNAc2-Bac), with PglA, J and H, we form hexasaccharide (GalNAc5-Bac)
and finally, with PglA, J, H and I we form the heptasaccharide (GalNAc2(Glc)GalNAc3-Bac)
(Chapter 3). Studies with these intermediate sugars in vitro, demonstrate that PglB readily
accepts these substrates (Figure 4-10), further reinforcing the observations made by Linton et
al.'0 in the in vivo system. Since radioactive bacillosamine is not currently available to us using
our synthetic scheme, a similar study on the transfer of monosaccharide could not be performed.
However, using HPLC analysis and mass spectral analysis, it was shown that PglB also accepts
the Und-PP-linked monosaccharide, bacillosamine, in addition to the di-, tri-, hexa- and hepta-
saccharide substrates (data not shown).
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Figure 4-10. PglB accepts glycans of varying length.
Utilization of various undecaprenyl-pyrophosphate linked saccharide intermediates. The more
readily available 6-hydroxybacillosamine substrate was used for this study in place of the native
bacillosamine. The variation in the levels of DPM incorporation reflects the different amounts of
polyisoprenyl-phosphate-linked sugar substrate in each reaction; conclusions about the relative
reaction rates cannot be made.
(A) 3H-GalNAc-Bac-PP-Und.
(B) GalNAc-3H-iGalNAc-Bac-PP-Und.
(C) (GalNAc) 4-3H-GalNAc-Bac-PP-Und.
(D) (Glc)-(GalNAc)4-3H-GalNAc-Bac-PP-Und.
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Polyisoprene specificity of PglB
In order to study the specificity of PglB towards the polyisoprene that acts as the carrier
for the glycan, two substrates, dolichyl-PP-Bac-6-OH and geranylgeranyl-PP-Bac-6-OH were
synthesized (Chapter 2). Dolichol is of longer chain length (15-20 isoprene units) compared to
the native undecaprenyl (11 isoprene units) and also contains a saturated a-isoprene unit.
Geranylgeraniol is of shorter chain length (4 isoprene units) and different geometry compared to
undecaprenol. Using PglA, the radiolabeled dolichyl-PP-Bac-6-OH-GalNAc substrate was
accessed. Using the standard radioactive assay, it appears that PglB accepts this dolichol-linked
substrate, albeit at lower efficiency than the native undecaprenyl-linked substrate (Figure 4-11).
600
500
4000 400
300
200
2 4 6 8 10 12 14 16 18
Time
Figure 4-11. PglB accepts the dolichyl-pyrophosphate-linked disaccharide.
Radiolabeled glycopeptide formation using dolichyl-PP-Bac-6-OH-GalNAc as the substrate.
Solid line, Dol-PP-Bac-6-OH with PglB. Dashed line, Dol-PP-Bac-6-OH, no PglB.
PglA does not accept the shorter chain geranylgeraniol, hence it was not possible to
chemo-enzymatically access the radiolabeled disaccharide substrate for the PglB assay.
However, since PglB accepts the polyisoprenyl-pyrophosphate-linked monosaccharide substrate,
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the geranylgeranyl-pyrophosphate-Bac-6-OH was incubated with PglB and the product analyzed
by HPLC. Mass spectral analyses of the resulting HPLC product peaks show that the Bac-6-OH
monosaccharide is transferred to protein (Figure 4-12). Hence it appears that PglB accepts the
geranylgeranyl-bound glycan substrate as well as the longer chain, a-saturated dolichyl-
pyrophosphate-linked substrate.
NHAc 8000
.t 6000
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Figure 4-12. PglB accepts geranylgeranyl-PP-Bac-6-OH.
HPLC and MALDI-MS analysis of the geranylgeranyl-PP-Bac-6-OH and PglB reaction. Peak at
m/z 1152.6 corresponds to sodium adduct of glycopeptide.
Peptide specificity of PglB
Next, the oligosaccharyl transferase activity of PglB on the octapeptide was compared
with the known tripeptide acceptor (Bz-NLT-NHMe), commonly used for the yeast OT system.'
12 As the results from the radioactive assay demonstrate, clearly, Bz-NLT-NHMe is a poor
acceptor in the bacterial system (Figure 4-13 A). The Bz-NLT-NHMe peptide was subjected to
HPLC analysis similar to the consensus peptide discussed above. The HPLC trace (Figure 4-13
B) shows the presence of 2 peaks, which were confirmed by mass spectral analysis to be the
glycopeptide (TR== 27.0 min, Figure 4-13 C) and the unglycosylated counterpart (TR = 29.0 min,
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data not shown). The presence of a significant amount of unglycosylated peptide, when subjected
to the exact reaction conditions as the consensus peptide, together with the low rate of transfer
observed in Figure 4-13A, strongly suggests that PglB has additional determinants for the
peptide substrate beyond the minimal tripeptide consensus sequence that is well recognized in
eukaryotes. 8 Further studies into the peptide specificity of PglB are currently in progress.
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Figure 4-13. Peptide substrate specificity of PglB.
(A) Radioactive Assay of product formation. Solid line, octapeptide consensus sequence
(KDFNVSKA); Dashed line, tripeptide consensus for yeast OT (Bz-NLT-NHMe). 6-
hydroxybacillosamine was used in this study in place of the native bacillosamine substrate. (B)
HPLC trace of Bz-NLT-NHMe reaction. (C) MALDI-MS of Bz-NLT-NHMe glycopeptide (peak
at TR = 27.0 min).
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Conclusion
The experiments described here afford the first in vitro observation of oligosaccharyl
transferase activity of PglB. By using a combination of chemical synthesis and enzymology we
were able to prepare various glycan and peptide substrates for this remarkable enzyme. The
results demonstrate that PglB has a relaxed substrate specificity accepting peptide substrates in
place of full-length proteins, making it potentially useful for the preparation of artificial
glycopeptides. Furthermore, the observation that PglB can transfer undecaprenyl-pyrophosphate-
linked saccharides of various lengths (2-7 saccharides) adds to the promise of using PglB in the
synthesis of diverse glycopeptide products. However, PglB does require determinants in the
peptide sequence beyond the canonical N-X-S/T tripeptide and with this in vitro assay in place,
further studies to determine the role of the amino acid binding determinants can be readily
undertaken. Although the experiments described in this work strongly suggest that PglB is solely
responsible for oligosaccharyl transferase activity, the presence of an accessory protein(s) in E.
coli cannot be ruled out due to the use of a bacterial membrane fraction. Currently, work is
underway to purify PglB to homogeneity, which will unambiguously demonstrate whether it
alone is responsible for the oligosaccharyl transferase activity. Furthermore, detailed
investigations into the poorly understood mechanism of oligosaccharyl transferases are more
feasible using PglB as opposed to the multi-subunit eukaryotic complexes. Lastly, the
development of powerful inhibitors of this enzyme would be valuable in the quest for antibiotics
for C. jejuni-induced gastrointestinal disorders.
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Experimental Procedures
Expression of PglB
Starting from a 5 mL overnight culture, E. coli strains expressing PglB were grown at 37°C in
LB broth to an OD)600 of 0.6-0.8. At that point, the temperature was reduced to 16°C and protein
production was induced by the addition of IPTG (1 mM). After 24 hours, the cells were
harvested by centrifugation (5000 x g) for 30 minutes, washed once with 0.9% NaCl solution,
recentrifuged (5000 x g) for 30 minutes and frozen at -80°C until needed.
Preparation of PglB membrane fraction
All steps were performed at 4°C. The E.coli cell pellets expressing PglB (wild type and mutant)
were thawed and resuspended in 5% of the original culture volume in buffer M (50 mM Tris-
acetate [pH 8.0], 1 mM EDTA). The cells were then subjected to sonication (3 x 15 s), unbroken
cells were removed by centrifugation at 5,697 x g for 15 minutes, and the membrane fraction
was collected by centrifugation at 142,414 x g for 60 minutes. The pellet was washed once with
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buffer M, centrifuged again, and resuspended in 0.25% of the original culture volume in buffer
M. The final suspension was aliquoted and stored at -80°C.
Preparation of undecaprenyl-pyrophosphate-linked disaccharides using PglA
To a tube containing 0.06 mg of dried Und-PP-Bac, Und-PP-6-hydroxybacillosamine or Und-
PP-GlcNAc, 3 ptL of DMSO, and 7 tiL of 14.3% (v/v) Triton X-100 were added. After vortexing
and sonication (water bath), 58 L of H2 0, 4 ptL of 1 M Tris-Acetate pH 8.5, 1 [tL 1 M MgCl 2 ,
and 20 ,tL PglA (660 pg/mL) were added. The reaction was initiated by the addition of 7.5 [tL
of UDP-GalNAc (55 nCi/nmol). After 120 minutes, the reaction was quenched in 1.6 mL of 2:1
chloroform:methanol and extracted three times with 320 ~tL of pure solvent upper phase (15 mL
chloroform: 240 mL methanol: 235 mL water: 1.83 g KCl). The organic layer was aliquoted and
dried under a stream of nitrogen (-20,000-30,000 DPM/tube).
Peptide Synthesis
Peptides were synthesized by automated peptide synthesis (Applied Biosystems ABI 431A
peptide synthesizer) using standard Fmoc peptide synthesis conditions on PAL-PEG-PS resin.
The resulting peptides were cleaved from the resin using trifluoroacetic acid and purified by
preparative reverse phase high-pressure liquid chromatography using a standard
acetonitrile/water gradient.
PglB Assay
To a tube of the labeled disaccharide, 10 pL DMSO, 100 pL of 2x assay Buffer (100mM
HEPES, pH 7.5, 280 mM sucrose, 2.4% v/v Triton-X100), 2 [tL of 1M MnCl2 and 28 ptL of
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water was added. Reactions were initiated by the addition of 10 ptL of a 2 mM stock of the
peptide in DMSO. 40 jiL of the reaction mixture was removed at various time points and
quenched into 1 mL of 3:2 chloroform: methanol + 200 ptL of 4 mM MgCl2. The aqueous layer
was extracted and the organic layer was washed twice with 600 pL of pure solvent upper phase.
The aqueous layers were combined, mixed with 5 mL of scintillation fluid (EcoLite, MP
Biomedicals) and subjected to scintillation counting (2 minutes per tube).
HPLC analysis of glycopeptides
A 40 ptL reaction aliquot was quenched as above and the aqueous layer was dried under vacuum.
The residue was resuspended in 50 pL of water and injected on a reverse-phase C18 column and
eluted under a standard water/acetonitrile gradient. Fractions were collected every minute, mixed
with scintillation fluid (EcoLite, MP Biomedicals) and subjected to scintillation counting (2
minutes per tube).
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Chapter 5
Design and synthesis of peptidomimetic inhibitors of oligosaccharyl transferase
A significant portion of the work described in this chapter has been published in:
Weerapana, E.; Imperiali, B. Peptides to peptidomimetics: towards the design and synthesis of
bioavailable inhibitors of oligosaccharyl transferase. Org. Biomol. Chem., 2003, 1, 93-99
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Introduction
Protein glycosylation plays a key role in numerous cellular processes including immune
response, intracellular targeting, intercellular recognition and protein folding and stability.'
Asparagine-linked glycosylation in eukaryotes is a major class of protein modification mediated
by a single enzyme, oligosaccharyl transferase (OT) that is localized in the lumen of the
2
endoplasmic reticulum (ER).
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Scheme 5-1. The reaction catalyzed by oligosaccharyl transferase.
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The multimeric membrane-bound OT enzyme facilitates the co-translational transfer of a
dolichol-pyrophosphate-linked tetradecasaccharide (GlcNAc2Man9Glc3) to an asparagine side
chain in the Asn-Xaa-Thr/Ser consensus sequence within a nascent polypeptide chain as shown
in Scheme 5-1.3 This step constitutes the first committed step in N-linked glycosylation and the
resulting glycoprotein is further processed by various glycosidases and glycosyltransferases in
the ER and Golgi to create a diverse array of oligosaccharide units.4 The availability of OT-
specific inhibitors that function in vivo may ultimately provide insight into this vital protein
modification reaction.
Previous studies in the Imperiali group have yielded inhibitors with low nanomolar
affinity for OT (Figure 5-1). These inhibitors are based on the Asn-Xaa-Thr/Ser (1) consensus
sequence of the natural substrate. To ensure that a short peptide could be used as a substrate for
OT, the capped tripeptide, Bz-Asn-Leu-Thr-NHMe (2) was synthesized and determined to be a
substrate for the enzyme (KM 20 [tM). 3 The first generation of OT inhibitors was based on this
truncated substrate and was discovered by systematically replacing the asparagine residue in the
tripeptide with several asparagine mimics. This study resulted in a substrate mimic Bz-Dab-Leu-
Thr-NHMe (diaminobutyric acid, Dab) (3) that is a weak competitive inhibitor of OT.5 Therefore
replacing the amide of the asparagine with an isosteric amine containing side chain (3 vs. 4)
results in a compound that binds to the enzyme but is not turned over. Studies extending from
this initial discovery exploited binding interactions between OT and residues beyond the
consensus sequence through the synthesis of a small library of peptides that included different
combinations of amino acids C-terminal to the tripeptide sequence. This study yielded a
hexapeptide Bz-Dab-Ala-Thr-Val-Thr-Nph-NH 2 (Nph = p-nitrophenylalanine) (4) that is a
potent in vitro inhibitor of yeast (Saccharomyces cerevisiae) OT (K = 69 nM).6 Additionally,
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peptides that are structurally constrained to an Asx-turn conformation show enhanced affinity for
the enzyme.3 For example, the linear hexapeptide inhibitor (4) demonstrates a two-fold increase
in potency when constrained via a side-chain to backbone macrocyclization (5).
-
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Figure 5-1. Previous peptide-based inhibitors of OT
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Inhibitors based upon these initial discoveries yielded potent OT inhibitors, yet none
displayed any activity in vivo. This is due to the fact that peptides exhibit poor membrane
permeation and limited proteolytic stability and are not optimal for studies under cell-based
conditions. Hence it is desirable to obtain non-peptidic, bioavailable inhibitors of OT that would
enable the study of N-linked glycosylation and its role in cellular processes in vivo.
Currently, the only inhibitor of N-linked protein glycosylation to function within a
cellular environment is the microbial product tunicamycin (Figure 5-2). Tunicamycin is a
bisubstrate analog that inhibits the GlcNAc-1-P glycophosphoryltransferase, Alg 7, which is
responsible for the first committed step in the assembly of the dolichol-pyrophosphate-linked
oligosaccharide donor.7 Since this transformation occurs numerous steps prior to the reaction
catalyzed by OT, the effect of the inhibitor on the actual glycosylation step is not immediate, nor
does it have the potential to reveal the specific consequences of blocking N-linked glycosylation.
The focus of this study is the generation of rationally designed, non-peptidic inhibitors that
specifically target OT in vivo.
0
0 OH / HHO OH
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Figure 5-2. Tunicamycin: A microbial natural product that inhibits N-linked glycosylation.
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The linear hexapeptide Bz-Dab-Ala-Thr-Val-Thr-Nph-NH 2 (4) was used as the prototype
for designing an inhibitor of OT that would function in vivo. The readily modifiable and modular
peptide platform provided a foundation for the rational design of a peptidomimetic inhibitor. Our
aim was to design and synthesize a potent inhibitor of OT that includes reduced amide bond
content to minimize proteolysis and increase hydrophobicity to enhance cell permeability.
Toward this goal, we have modified the inhibitor structure via isosteric replacement of the
peptide backbone to afford a non-peptidic entity that demonstrates higher proteolytic stability
and increased lipophilicity, which would facilitate passive permeation of the cellular and
endoplasmic reticulum membranes. There has been no previous record of peptidomimetics or
pseudopeptides that act as potent inhibitors of OT. In this study we report the systematic
introduction of non-peptidic character to our previous inhibitors to yield several compounds with
nanomolar inhibition potency for OT.
Results and Discussion
Dipeptide Isosteres
We initiated this project with the goal of identifying a suitable dipeptide isostere to
replace the Val-Thr unit within our prototype hexapeptide, Bz-Dab-Ala-Thr-Val-Thr-Nph-NH 2
(4). Modifications to the consensus inhibitory sequence (Dab-Xaa-Thr) results in a dramatic
decrease in affinity, hence these residues were left unaltered in this study. In early investigations
into inhibitor design, the Val-Thr dipeptide unit was installed based on statistical studies on
glycosylation sites found in native proteins.8 Further studies showed that hydrophobic residues
are well tolerated in the positions occupied by the Val-Thr unit,9 hence this would be the ideal
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location for a lipophilic isostere. It is also believed that these residues can be altered without
deleterious effects to binding. In this study we evaluated the ability of a non-peptide based
scaffold to replace the Val-Thr dipeptide unit and orient the crucial residues for optimal
interaction with the OT exosites. The third residue in the C-terminal extension sequence, p-
nitrophenylalanine was introduced to allow facile concentration determination by absorption
spectroscopy.
The class of dipeptide isosteres that was the focus of this study is based on an
aminobenzoic acid framework. Similar scaffolds have been successfully incorporated within the
structures of Src SH2 domain antagonists, l° growth hormone-releasing peptide receptor
agonists and Ras farnesyl protein transferase inhibitors.1 2 These isosteres introduce rigidity and
hydrophobicity to the system as well as reducing the total amide bond content. We replaced the
Val-Thr unit with a variety of spacers that incorporated 3-or 4-aminobenzoic acid and 3- or 4-
aminomethylbenzoic acid.
All the unprotected aminobenzoic acids (9, 11 and 13, Scheme 5-2) were commercially
available except for 3-amino(methyl)benzoic acid (7), which was synthesized from 3-
cyanobenzoic acid (6) by catalytic hydrogenation. The amine or aniline groups of the building
blocks were protected as the Alloc (allyloxy carbonyl) derivative using allyl chloroformate, to
afford the corresponding protected spacer units (8, 10, 12 and 14).
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Scheme 5-2. Synthesis of alloc-protected aminobenzoic acid spacers for solid phase synthesis.a
aReagents and conditions: (a) H2, Pd/C, MeOH, 70%; (b) allyl chloroformate, 60-80% yield.
These spacer units were then incorporated into the peptide backbone using standard solid
phase coupling conditions (Scheme 5-3). The synthesis of these peptidomimetics involves the
solid phase peptide coupling of the corresponding Alloc protected aminobenzoic acid to the p-
nitrophenylalanine residue using -(7-azabenzotriazol-1-yl)-N,N,N', N'-tetramethyluronium
hexafluorophosphate (HATU) as a coupling agent. The coupling step was followed by alloc
deprotection using tetrakis(triphenylphosphine)palladium(0) and phenylsilane and subsequent
coupling of the threonine, alanine and diaminobutyric acid residues using standard peptide
synthesis protocols. In the final step, the entire construct was cleaved from the resin using 95%
trifluoroacetic acid (TFA).
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Scheme 5-3. Solid phase incorporation of aminobenzoic-acid spacers.a
aReagents and conditions: (a) alloc-protected aminobenzoic acid, HATU, DIPEA; (b) Pd(PPh3)4,
phenylsilane; (c) standard Fmoc-based solid-phase coupling of Fmoc-Thr(tBu)-OH, Fmoc-Ala-
OH, Fmoc-Dab(Boc)-OH with HATU and DIPEA followed by capping with benzoic anhydride,
pyridine; (d) cleavage from resin (95% TFA).
The four inhibitors synthesized via this method are illustrated in Figure 5-3. These
compounds were assayed for their in vitro potency as OT-inhibitors using solubilized yeast (S.
cerevisiae) microsomes. The prototype peptide inhibitor (4) has low nanomolar affinity for OT
(Ki = 62 nM). When the Val-Thr dipeptide of 4 was replaced with each of the four spacers, it was
found that the longer spacers, the 3-amino(methyl) (15) and 4-amino(methyl)-benzoic acid (16)
groups caused a significant drop in enzyme affinity. In contrast, the shorter spacers, the 3-amino
(17) and 4-aminobenzoic acid (18) showed a less dramatic effect on enzyme binding. In fact the
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3-aminobenzoic acid dipeptide isostere (17) (Ki = 84 nM) was the most effective mimic of the
Val-Thr unit with inhibitory activity similar to the parent peptidic inhibitor.
prototype peptide inhibitor
K = 62 nM
3-amino(methyl)benzoic acid isostere
Ki = 850 nM
4-amino(methyl)benzoic acid isostere
Ki = 1600 nM0
3-aminobenzoic acid isostere
Kj = 84 nM
1I
4-aminobenzoic acid isostere
Ki = 300 nM
I0
Figure 5-3. Inhibitors incorporating dipeptide isosteres in place of the Val-Thr dipeptide.
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The reduced amide bond content and increased rigidity of the 3-aminobenzoic acid
isostere has minimal effects on affinity for OT, confirming that the amide bond between the Val-
Thr unit can be replaced without deleterious consequences for inhibitor binding. Due to the high
affinity of compound 17 for OT, it was considered to be an excellent candidate for further
modification toward the goal of generating a more hydrophobic non-peptide inhibitor.
Further Modifications
Since the dipeptide isostere studies yielded a promising candidate for OT inhibition,
subsequent attempts were made to systematically reduce the hydrophilicity of compound 17. The
first site explored was the central residue within the Dab-Xaa-Thr sequence. Previous studies
have shown that a higher binding affinity is observed in the truncated tripeptide substrate when
this site is occupied by hydrophobic residues (Leu, Ala) whereas charged residues (Asp) are
disfavored.3 In order to confirm that this effect also applies to the interaction of the peptide
isostere with OT, the alanine was substituted with norvaline, an unnatural amino acid that
contains a longer hydrophobic side chain. This modification resulted in compound 19 that
displays a slightly improved affinity for OT (Figure 5-4).
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Figure 5-4. Replacement of Ala with Nva (norvaline).
In general, a minimal number of amide bonds are desirable so as to confer proteolytic
stability as well as lipophilicity.' 3 In accordance with this hypothesis, further modifications were
investigated to systematically reduce the number of amide bonds within the inhibitor structure
and determine which of these bonds are important for interaction with the enzyme. The initial
dipeptide isostere studies removed the amide between the Val-Thr unit with minimal effect on
binding. The next amide bond targeted was the amide C-terminal to the p-nitrophenylalanine
residue. Replacement of this amide was achieved by using a 4-nitrobenzylamine capping group
instead of the intact p-nitrophenylalanine residue. The resulting inhibitor 20 (Figure 5-5) shows a
3-fold loss in affinity, suggesting that there is a weak interaction between this terminal amide and
residues in the OT exosites.
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Figure 5-5. Further modifications to reduce the amide-bond character and the overall size of the
inhibitors.
A second factor that promotes cell permeability is the overall size of the molecule and
studies show that higher molecular weight compounds are less likely to be orally active and
therefore cell permeable relative to smaller entities.13 In accordance with this hypothesis, two
inhibitors, 21 and 22 (Figure 5-5) were synthesized with molecular weights in the 500 Da range
were synthesized. Inhibitor 21 eliminates the p-nitrophenylalanine residue that is used for
quantification purposes, but installs an N-terminal nitrobenzyl cap instead, to enable accurate
quantitation as described previously. Previous studies in the group have shown that substitution
of nitrobenzyl for benzyl at the N-terminal cap causes minimal effects in enzyme affinity.6 These
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two changes to the inhibitor structure resulted in compound 21 which exhibited a Ki of 620 nM,
a seven-fold decrease in enzyme affinity. This result indicates that the C-terminal p-
nitrophenylalanine provides valuable interactions with residues at the enzyme exosite, in addition
to supplying a quantification tool. Inhibitor 22 installs the nitrophenyl group adjacent to the
consensus sequence and excludes the Val-Thr dipeptide isostere. The resulting molecule is small
and contains only 4 amide bonds, factors that enhance its cell permeability and proteolytic
stability. The higher Ki value (900 nM) of this compound confirms that the Val-Thr dipeptide
and hence the aminobenzoic acid unit is essential for enzyme binding. It is believed that the rigid
structure of the aminobenzoic spacer orients the nitrophenyl group at the optimal distance for
favorable interactions as well as providing additional hydrophobic contacts.
The synthesis of inhibitors 20 and 22, containing the C-terminal nitrobenzyl group,
involved the use of an aldehyde-functionalized resin, to which the nitrobenzyl functionality was
introduced via a reductive amination using 4-nitrobenzylamine. A schematic of the synthetic
scheme used to access the C-terminal nitrobenzyl cap is shown in Scheme 5-4 for the synthesis
of inhibitor 20. After the nitrobenzyl group was installed, the alloc protected 3-aminobenzoic
acid spacer was coupled to the resulting resin-bound secondary amine using HATU as a coupling
agent. The peptide was then extended after deprotection of the alloc group using standard peptide
synthesis protocols and cleaved from the resin with TFA to yield 20.
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Scheme 5-4. Synthesis of C-terminal nitrobenzyl-capped inhibitor 20.a
aReagents and conditions: a) nitrobenzylamine, trimethyl orthoformate, dichloroethane; b)
sodium triacetoxyborohydride; c) Alloc-3-aminobenzoic acid, HATU, N,N-
diisopropyltheylaminc (DIPEA); d) Pd(PPh3)4, phenylsilane; e) standard solid phase peptide
coupling of Fmoc-Thr(tBu)-OH, Fmoc-Nva-OH, Fmoc-Dab(Boc)-OH, followed by capping with
benzoic anhydride and pyridine; f) cleavage from resin (95% TFA).
Of the changes that were made to increase the bioavailability of the initial lead compound
(19), the installation of the nitrobenzyl cap (20) had the least effect on enzyme affinity. This
compound displays significantly decreased amide bond character relative to the first generation
inhibitors. Further modifications were then performed on this inhibitor skeleton, to add more
'drug-like' character and increase enzyme affinity. To do this, we focused our attention on
hydrophobicity, which is an important aspect of bioavailability. 3 Throughout this study,
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theoretical water-octanol partition coefficients were calculated for each of the inhibitors using
the ACD/LogP software that calculates log P values based on an algorithm using a database of
over 14,600 compounds.14 These computed values of log P were used to obtain a rough estimate
of the relative hydrophobicity of the synthesized compounds. The values of log P for the
inhibitors discussed in this paper ranged from 1.19 to 5.04 (Table 5-1) and even the most
hydrophobic inhibitors were well behaved under the aqueous assay conditions at concentrations
up to 10 tM.
The most hydrophobic of the inhibitors synthesized was 23 (Figure 5-6), which
incorporated a nitrobenzyl group at the amine terminus of the Dab side chain. This modification
was chosen due to information suggesting the presence of aromatic amino acids at the site of
interaction of carbohydrate binding proteins.15' 16 It was hypothesized that the sugar-binding site
of OT comprises similar aromatic side chains and previous studies in the group demonstrated
that incorporating a naphthyl group at this position enhanced inhibition.17 Since p-nitrobenzyl
provided enhanced binding when incorporated at the C-terminus of the inhibitor, this same group
was chosen to modify the amine side chain of the diaminobutyric acid. We proposed that this
would place the p-nitrobenzyl group within the same binding pocket as the carbohydrate moiety
and should hypothetically exploit the aromatic n-stacking interactions at this site to enhance
binding affinity.
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Figure 5-6. Modification of the Dab side chain.
The synthesis of compound 23 used Fmoc-Dab(Alloc)-OH instead of the Boc-protected
unit used in the previous syntheses. This orthogonal protection scheme enabled the selective
deprotection of the Dab side chain using tetrakis(triphenylphosphine)palladium(0) and
phenylsilane. The nitrobenzyl moiety was installed via a reductive amination with
nitrobenzaldehyde and sodium triacetoxyborohydride (Scheme 5-5). The resulting inhibitor, 23,
shows a Ki value of 350 nM with no solubility problems under the aqueous assay conditions. The
added aromatic group does not increase affinity as desired, suggesting that the nitrobenzyl group
is not oriented optimally for re-stacking interactions at the active site.
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Scheme 5-5. Reductive amination with p-nitrobenzaldehyde.a
aReagents and conditions: (a) Pd(PPh3)4, phenylsilane; (b) p-nitrobenzaldehyde, sodium
triacetoxyborohydride; (c) cleavage from resin (95% TFA).
Cyclization into an Asx-turn
Molecular rigidity is proposed to play a role in cell permeation by locking out access to
degradative enzymes while retaining inhibitory potency against the target.18 Conformational
studies on different OT substrates have indicated that peptides constrained to an Asx-turn motif,
through side-chain to main-chain macrocyclization, are more competent substrates for OT as
compared to the corresponding linear analogs.5 The Asx-turn motif displays a "more open"
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peptide backbone when contrasted with the more common -turn structure. These turns are
characterized by an extensive hydrogen bonding network between the side chain of the
asparagine and the backbone amides (Figure 5-7). Since the peptide substrate for OT is
hypothesized to bind in an Asx-turn conformation, introducing this turn to the inhibitor structure
could potentially enhance binding affinity as well as increase the molecular rigidity of the
compound.
A B
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H HN H
H NOH'N 0X0 . H'N O
P-Turn Asx-Turn
Figure 5-7. Illustration of a typical Asx-turn (A) and a ,-turn (B).
Since the cyclized hexapeptide, cyclo(Hex-Dab-Cys)-Thr-Val-Thr-Nph-NH 2 (5) was
found to be twice as potent as its linear counterpart,3 it was decided that the macrocycle motif be
incorporated into the non-peptidic inhibitor that is the focus of this study. This cyclization,
together with a modified C-terminal cap, 4-nitrophenethylamine instead of nitrobenzylamine,
resulted in a 2-fold increase in enzyme affinity. This resulted in inhibitor 24 (Figure 5-8) that
possesses very little peptidic character, yet reasonable affinity for OT (Ki = 130nM), and is one
of the most hydrophobic and conformationally constrained inhibitors to demonstrate activity
against this enzyme. This inhibitor fulfils the requirements for bioavailability such as reduced
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amide bond character, increased hydrophobicity and rigidity as well as being smaller in size
relative to the parent peptidic compound (4).
H N NX0 S°
N
H 0- NO
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24
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Figure 5-8. Structure of the cyclized peptidomimetic inhibitor (24).
The synthesis of inhibitor 24 utilized an aldehyde-functionalized resin (2-(4-formyl-3-
methoxyphenoxy)ethyl polystyrene) that enables installation of the C-terminal 4-
nitrophenethylamine cap via a reductive amination as illustrated in Scheme 5-6. The Alloc-
protected 3-aminobenzoic acid moiety was coupled to the resulting secondary amine using
HATU as a coupling reagent. Subsequent Alloc deprotection was then followed by coupling of
threonine, 4-methoxytrityl (Mmt) protected cysteine, and diaminobutyric acid residues using
standard peptide synthesis procedure. The peptide was capped with 6-bromohexanoic acid, the
Mmt group was deprotected with 1% TFA and the cyclization between the resultant thiolate and
the 6-bromohexanoyl group was achieved in degassed DMF, using an excess of 1,1,3,3-
tetramethylguanidine as base.19 The inhibitor was then cleaved from resin using 95% TFA and
purified by HPLC.
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Scheme 5-6. Synthesis of the cyclized inhibitor (11).a
aReagents and conditions: a) nitrophenethylamine, trimethyl orthoformate, dichloroethane; b)
sodium triacetoxyborohydride; c) Alloc-3-aminobenzoic acid, HATU, N,N-
diisopropylethylamine (DIPEA); d) Pd(PPh3)4, phenylsilane; e) standard solid phase peptide
coupling of Fmoc-Thr(tBu)-OH, Fmoc-Cys(Mmt)-OH, Fmoc-Dab(Boc)-OH; f) 6-
bromohexanoic acid, benzotriazol- 1 -yloxytrispyrrolidinophosphonium hexafluorophosphate
(PyBOP), DIPEA; g) 1% TFA; h) 1,1,3,3-tetramethylguanidine; i) cleavage from resin (95%
TFA).
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Since these compounds would eventually be tested as potential inhibitors of OT within
mammalian cells, it was necessary to confirm that they inhibit mammalian as well as the yeast
(S. cerevisiae) OT. Hence assays were carried out as before, but using pig liver microsomes
instead of yeast, to determine the Ki for a representative mammalian OT. These studies show that
there is no significant difference in Ki values between the yeast and mammalian enzymes; hence
none of the inhibitors are selective for either species, although inhibition in yeast is generally
more potent. The results of these enzyme assays are summarized in Table 1.
Table 5-1. Ki values for yeast and porcine liver oligosaccharyl transferase inhibition.
Inhibitor Ki (nM) yeast OT Ki (nM) porcine OT log P Molecular
Weight
17 84 110 1.48 +/-0.88 705
19 69 180 2.55 +/- 0.88 733
20 220 710 3.13 +/-0.87 676
21 620 780 1.19 +/-0.83 586
22 900 600 1.79 +/- 0.85 557
23 350 760 5.04 +/-0.88 810
24 130 180 2.96 +/-0.84 686
LogP values are crude estimates calculated using the ACD/LogP softwarel s5
The OT inhibitors developed in these studies will be implemented into a cellular assay for
OT function to determine if they inhibit efficiently within a cellular environment. Their potency
in vivo will be detenrmined with the use of a high throughput assay system for analyzing OT
inhibition in a stable mammalian cell line (Chapter 6).
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Conclusion
Protein N-glycosylation is a crucial post-translational modification that is mediated by
the enzyme oligosaccharyl transferase (OT). Due to its multimeric, membrane bound nature,
there is no structural information available on the catalytic domain, and any studies into its
inhibition could provide valuable information regarding the structure and function of this elusive
enzyme. Moreover, inhibition of this enzyme within a cellular environment could be the means
of obtaining knowledge on the immediate biological implications of N-linked glycosylation.
Although potent inhibitors of OT exist, they all display peptidic character with poor proteolytic
stability and membrane permeability, which render them unsuitable for in vivo studies. For this
reason, this study describes efforts made towards the design and synthesis of a non-peptidic,
hydrophobic OT inhibitor that demonstrates affinity for the enzyme in the nanomolar range.
In order to follow a rational approach to peptidomimetic inhibitor design, the hexapeptide
Bz-Dab-Ala-Thr-Val-Thr-Nph-NH 2 (4) was used as the prototype. Studies on various Val-Thr
dipeptide mimetics established 3-aminobenzoic acid to be the most suitable isostere for this unit
with a Ki value that is almost identical to the parent peptide. Further modifications conferred
structural features on the inhibitor to improve its bioavailability. The amide bond character of the
inhibitor was significantly reduced, thus increasing the proteolytic stability of the molecules.
Since smaller size is favored for cell permeation, systematic deletion of units from the prototype
inhibitor yielded compounds with low molecular weight. Hydrophobicity as estimated from log
P values is also an important factor in cell permeation. Removal of hydrogen-bond donor groups
and the introduction of aromatic groups assist in increasing the log P values whilst maintaining
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solubility under the assay conditions. Finally, rigidity was introduced to the inhibitor by an
aminobenzoic acid scaffold as well as by cyclization into an Asx turn conformation.
This study yielded a family of non-peptidic inhibitors that display varying degrees of
hydrophobicity, size and rigidity as viable candidates for the in vivo inhibition of OT. In addition
to providing potential bioavailable inhibitors of OT, the structure-activity relationships that have
been defined in this study provide valuable clues to the nature of the interactions occurring at the
OT exosites. The prime candidate for cellular studies is inhibitor 24, which displays all the
properties that are desired of in vivo inhibitors whilst maintaining a very high affinity for the
enzyme (130 nM). The success of such a bioavailable inhibitor on a cellular level would enable
studies related to understanding the effects of depleting N-linked glycoproteins on downstream
biological processes.
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Experimental Procedures
General procedure for solid-phase peptide synthesis
All peptides unless otherwise noted, were synthesized by manual solid phase methods
using Fmoc-PAL PEG resin and using Fmoc (9-fluorenylmethoxycarbonyl) as the protecting
group for the ac-amino functionalities. Amino acids were coupled using either 1-
benzotriazolyloxytris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) or 0-(7-
azabenzotriazo1-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and DIPEA to
generate the activated ester. The resin was swelled in dichloromethane (5 min.) and DMF (5
min.) prior to use. Couplings to the resin were performed in the following order: removal of the
Fmoc group (20% piperidine solution in DMF, 3 x 5 min.), wash (DMF, 5 x 1 min.), coupling
(amino acid/PyBC)P/DIPEA, 1:2:2 in DMF, 1 hour) and rinse (DMF 2 x 1 min., CH 2Cl2 2 x 1
min.). All amino acids were obtained commercially as the N-a-Fmoc-protected derivatives with
the following side-chain protection: Dab(Boc), Dab(Alloc), Cys(Mmt), Thr(t-Bu). At the
conclusion of the peptide synthesis, the peptides were capped with a large excess (10 eq) of
benzoic anhydride and pyridine (10 eq). Cleavage from resin was performed with trifluoroacetic
acid (TFA): C 2Cl2: triisopropylsilane: H20 (90:5:2.5:2.5). The mixture was then filtered to
remove the resin and concentrated under a stream of nitrogen. The resulting pellet was triturated
with cold ether and redissolved in DMSO. The DMSO solution was then diluted into a solution
of 1:1 water:acetonitrile and the peptides were purified by preparative HPLC (C18) with a
gradient of increasing acetonitrile/0.1%TFA (solvent A) in water/0.1%TFA (solvent B): the
standard gradient used in this study was 93:7 A:B to 0:100 A:B in 35 mins. Elution from the
column was monitored by UV absorbance at 280 nm and 228 nm and the product peak was
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collected and lyophilized. All peptide identities were confirmed by electrospray mass
spectrometry (ESI-MS) and the peptide solutions were quantified by UV absorbance at 280 nm
(E280 = 12,800 M- 1 cm-1 for thep-nitrophenyl group).
Bz-Dab-Ala-Thr-(3-amino(methyl)benzoic acid)-Nph-NH2 (15)
/NO 2
H | H 
N-~ ~2 N,,, N N
- H H I H 
uHO'" 
NH3
+ 15
Fmoc-PAL-PEG PS resin was used and the nitrophenylalanine residue was coupled using
standard Fmoc-based peptide synthesis methods. After Fmoc-deprotection, alloc protected 3-
amino(methyl)benzoic acid was added in excess (4 eq) with HATU (4 eq) and
diisopropylethylamine (DIPEA) (8 eq). The coupling was allowed to proceed overnight, after
which alloc deprotection was performed with tetrakis(triphenylphosphine)Palladium (0) (0.2 eq)
and phenylsilane (25 eq) in CHCl2. Three 20-minute deprotections were performed under an N2
atmosphere. Foc-Thr(tBu)-OH coupling was performed using HATU as above, and the
subsequent alanine and diaminobutyric acid residues were coupled using standard procedure.
The peptide was capped with benzoic anhydride, cleaved from resin and purified by HPLC.
HPLC tR= 21.60 min (C 18 , 7-100% B in 28 min)
LRMS calcd for 15 (C35H43N8O9g+) requires m/z 719.76. Found 719.5 (ESI+)
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Bz-Dab-Ala-Thr-(4-amino(methyl)benzoic acid)-Nph-NH2 (16)
NH2
16
The standard procedure outlined above was used, where alloc protected 4-
amino(methyl)benzoic acid was coupled to the nitrophenylalanine on PAL-PEG PS resin.
HPLC tR= 22.60 min (C18, 7-100% B in 28 min)
LRMS calcd for 16 (C35H43N809+) requires m/z 719.76. Found 719.5
Bz-Dab-Ala-Thr-(3-aminobenzoic acid)-Nph-NH 2 (17)
N.
17
The standard procedure outlined above was used, where alloc protected 3-aminobenzoic
acid was coupled to the nitrophenylalanine on PAL-PEG PS resin.
HPLC tR= 21.43 min (C18, 7-100% B in 28 min)
LRMS calcd for 17 (C34H41N809+) requires m/z 705.74. Found 705.5
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Bz-Dab-Ala-Thr-(4-aminobenzoic acid)-Nph-NH 2 (18)
0
NH3 + 18
The standard procedure outlined above was used, where alloc protected 4-aminobenzoic
acid was coupled to the nitrophenylalanine on PAL-PEG PS resin.
HPLC tR= 19.22 min (C1 8, 7-100% B in 28 min)
LRMS calcd for 18 (C34H41N809+) requires m/z 705.74. Found 705.1
Synthesis of Bz-Dab-Nva-Thr-(3-aminobenzoic acid)-Nph-NH2 (19)
The standard procedure for the synthesis of inhibitor 15 was applied here, except that
Fmoc-Ala-OH was replaced with the commercially available unnatural amino acid Fmoc-Nva-
OH (norvaline).
HPLC tR= 20.26 min (C18, 7-100% B in 28 min)
LRMS calcd for 19 (C36H45N809+) requires m/z 733.79. Found 733.3
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Synthesis of Bz-Dab-Nva-Thr-(3-aminobenzoic acid)-NH-CH 2-Ph-NO2 (20)
0
20
This peptide was synthesized on 2-(4-formyl-3-methoxyphenoxy)ethyl polystyrene
(FMPE) resin available from Novabiochem, which is an aldehyde-functionalized resin. The resin
was swollen in trimethylorthoformate (TMOF) and dichloroethane (DCE) 3:2 for 20mins. 4-
nitrobenzylamine (10 eq) was added to the resin and stirred under N2 for 3 hours, then 10 eq of
sodium triacetoxyborohydride was added and the mixture shaken overnight. Alloc-protected 3-
aminobenzoic acid (4 eq) was coupled to the resulting secondary amine using HATU and
DIPEA. Fmoc-Thr(t-Bu)-OH, Fmoc-Nva-OH and Fmoc-Dab(Boc)-OH were coupled using
standard procedure. The peptide was capped with benzoic anhydride and purified by HPLC as
before.
HPLC tR= 23.85 min (C18, 7-100% B in 28 min)
LRMS calcd for 20 (C34H4lN708+) requires m/z 676.73. Found 676.4
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Synthesis of Bz(NO2)-Dab-Nva-Thr-(3-aminobenzoic acid)-NH2 (21)
H2
21
Alloc-protected 3-aminobenzoic acid was coupled to PAL-PEG-PS resin, followed by the
coupling of Fmoc-Thr(t-Bu)-OH, Fmoc-Nva-OH and Fmoc-Dab(Boc)-OH using standard
peptide synthesis procedure. The peptide was capped with 4-nitrobenzoic (2 eq) acid,using
PyBOP (2 eq) as the coupling reagent and DIPEA (4eq).
HPLC tR= 23.02 min (C18, 7-100% B in 28 min)
LRMS calcd for 21 (C2 7H36N7 08 +) requires m/z 586.62. Found 586.4
Synthesis of Bz-Dab-Nva-Thr-NH-CH 2 -Ph-NO2 (22)
22
The procedure was the same as for inhibitor 20 above, except that Fmoc-Thr(tBu)-OH
was coupled to the resin after the reductive amination, instead of 3-aminobenzoic acid. The
peptide was cleaved and purified as before.
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HPLC tR- 23.20 min (C18, 7-100% B in 28 min)
LRMS calcd for 22 (C2 7H36N607+ ) requires m/z 557.62. Found 557.3
Synthesis of Bz-Dab(4-nitrobenzyl)-Nva-Thr-(3-aminobenzoic acid)-NH-CH 2-CH2-Ph-NO2
(23)
FMPE resin was used to couple the 4-nitrobenzylamine as before. The residues, alloc-3-
aminobenzoic acid, Fmoc-Thr(tBu)-OH, Fmoc-Nva-OH and Fmoc-Dab(alloc)-OH were coupled
using standard procedure outlined previously. The peptide was capped with benzoic anhydride
and pyridine as before. The orthogonal alloc protection on the Dab side chain was removed with
Pd(PPh3) 4 and phenylsilane as before and a mixture of DCE:TMOF (3:2) with 10% acetic acid
was added to the resin. 4-nitrobenzaldehyde (10 eq) was added to the resin and shaken for 5
hours. The reagent mixture was drained and the resin washed with TMOF. NaBH(OAc3) (0leq)
was added and the resin stirred under N2 overnight. The resin was washed with TMOF, DCE and
dichloromethane and cleaved and purified as before.
HPLC tR= 27.70 min (C18, 7-100% B in 28 min)
LRMS calcd for 23 (C4 1H46 N80 10 ) requires m/z 810.85. Found 811.3
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Synthesis of cyc[Hex-Dab-Cys]-Thr-(3-aminobenzoic acid)-NH-CH 2-CH2 -Ph-NO2 (24)
0, 
0
XNH 0
H3N HO No'NNo2
24
This peptide was synthesized on FMPE resin swollen with TMOF and DCE. 4-
nitrophenethylamine (10 eq) was added to the resin and stirred under N2 for 3 hours, then 10 eq
of sodium triacetoxyborohydride was added and the mixture shaken overnight. Alloc-protected
3-aminobenzoic acid (4 eq) was coupled to the resulting secondary amine using HATU and
DIPEA. After alloc deprotection as before, Fmoc-Cys(Mmt)-OH and Fmoc-Dab(Boc)-OH were
coupled using standard peptide coupling procedure described above. The peptide was capped
with 6-bromohexanoic acid and the Mmint protecting group was removed using 1% TFA in
CH2C12. Cyclization was effected between the thiolate of the cysteine and the 6-bromohexanoyl
group in degassed DMF using a large excess of 1,1,3,3-tetramethylguanidine as a base (24
hours). The peptide was cleaved and purified as before.
HPLC tR= 23.90) min (C18, 7-100% B in 28 min)
LRMS calcd for 24 (C4 1H46N801o+) requires m/z 686.80. Found 686.3
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Determination of Ki values
In a typical yeast OT assay, [3 H]DPPC (dolichol pyrophosphate chitobiose) (50,000 dpm,
60 Ci/mmol) was aliquoted from a chloroform/methanol stock solution into a microcentrifuge
tube, and residual solvent removed under a gentle stream of nitrogen. Mixtures of increasing
amounts of inhibitor (in 10 pl of DMSO) and a constant amount of enzyme in buffer were
incubated on ice for 30 min. This incubation time was required to ensure pre-equilibration of the
inhibitor with the enzyme. The reaction was initiated by adding 10 pL of a solution of Bz-Asn-
Leu-Thr-NHMe (4 Kin) (2 mM for yeast and 10 mM for pig liver microsomes) substrate in
DMSO. Aliquots (40 gL) of the reaction mixture were quenched after 2, 4, 6 and 8 min, and the
aqueous phase containing the radioactive N-glycosylated peptide was extracted and quantified
using a scintillation counter. Preliminary experiments employed a broad range of inhibitor
concentrations for each peptide to afford a rough estimate of the IC50. Three concentrations were
then selected to give between 30-70% inhibition. All experiments were run in duplicate and in
each case the Ki was determined using the following equation:
[I] X (1- i)
where i represents the fraction inhibition, [I] is the concentration of inhibitor, and [S] is the
concentration of Bz-Asn-Leu-Thr-NHMe. This assessment of Ki assumes competitive inhibition
for all the peptides under investigation.
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Chapter 6
Evaluation of peptidomimetic inhibitors of oligosaccharyl transferase in cell-based systems
177
Introduction
Oligosaccharyl transferase (aT) is a multimeric membrane bound protein that facilitates
the co-translational transfer of a dolichol-pyrophosphate-linked tetradecasaccharide to the
asparagine side chain of a nascent protein within the Asn- Xaa- Thr/Ser consensus sequence.)
This intriguing enzyme is located in the lumen of the endoplasmic reticulum (Figure 6-1).
golgi
Figure 6-1. The oligosaccharyl transferase complex is located in the lumen of the rough
endoplasmic reticulum. (Figure taken from httu://202.195.138.253/vcx/chaotcr2/2-2.htm),
An inhibitor that targets aT within a cellular context has the potential to provide
valuable information on the effect of glycosylation on downstream biological processes. N-
linked glycosylation is one of the key post-translational protein modification processes that
plays a role in immune response, intracellular targeting, intercellular recognition and protein
folding and stability? Currently the only inhibitor of N-linked glycosylation that functions in
vivo is tunicamyein.3 This microbial product is a bisubstratc-analog that inhibits the first
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committed step in the assembly of the dolichol-pyrophosphate-linked oligosaccharide donor.
Since this transfonrmation occurs numerous steps prior to the reaction catalyzed by OT, the
effect of the inhibitor on the actual protein-glycosylation step is not immediate, nor does it
have the potential to reveal the specific consequences of blocking N-linked glycosylation. For
these reasons, a specific inhibitor of OT that functions in vivo has several important
applications.
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Figure 6-2. Peptidomimetic inhibitors of oligosaccharyl transferase.4
An inhibitor that targets OT in vivo needs to permeate both the plasma membrane and
the endoplasmic reticulum membrane. The inhibitor also has to show a high degree of
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stability to proteolytic degradation by cytoplasmic proteases. In Chapter 5, research towards
increasing the non-peptide like character of previously synthesized peptide-based inhibitors is
discussed. In those studies, the peptide backbone was modified through the incorporation of
dipeptide isosteres to yield a small library of peptidomimetic structures with high affinity for
OT (representatives of this library are shown in Figure 6-2).4 In this chapter, these
peptidomimetic inhibitors are investigated for their cell permeability and cell lysate stability
properties, as well as their ability to inhibit N-linked glycosylation in vivo using a novel high-
throughput assay.
Results and Discussion
Cell lysate stability
One of the major advantages of using a peptidomimetic inhibitor rather than a peptide-
based inhibitor is the reduced amide-bond character that affords greater proteolytic stability.5'
6 We were interested in comparing the cell lysate stability of our peptidomimetics with the
parent peptide-based inhibitor (4) to verify this prediction.
In order to explore the cell lysate stability, solutions of 20 iM of either the peptide
inhibitor (4) or the peptidomimetic inhibitor (20) were incubated in Chinese Hamster Ovary
(CHO) cell lysate for 24 hours and the resulting mixture analyzed by HPLC (Figure 6-3).
After exposure to proteases in cell lysate, several degradation peaks were apparent on the
HPLC trace of the hexapeptide 4. The peptidomimetic 20, however, was present as mainly a
single peak with negligible degradation products. Hence it is apparent that the reduced amide-
bond character of the peptidomimetic, as well as the incorporation of non-native amino acid
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scaffolds within the structure, renders the resulting compound considerably less susceptible to
protease degradation.
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Figure 6-3. Cell lysate stability.
I
..................
I
HP~C traces demonstrating the cell lysate stability of the peptide and peptidomimetic
inhibitors. (A) Peptide (4). (B) Peptidomimetic (20). Arrows designate peak corresponding to
non-degraded peptide or peptidomimetic.
]8]
Cell permeability
In order to explore the cell permeability of the inhibitors, analogs of the peptide and
peptidomimetic structure were synthesized with a fluorophore label. In order to minimize the
effect of the fluorophore on the properties of the inhibitors, a nitrobenzoxadiazolyl (NBD)
moiety was chosen. NBD has a relatively small size, a polar character, and a small dipole
moment and as such would not be expected to interfere with peptide-membrane interactions.7
8 Two NBD-labeled compounds were synthesized, utilizing an N-a-Fmoc-Dap(NBD)-OH
amino acid building block (Dap = diaminopropionic acid) that has been previously
synthesized.9 This fluorescent amino acid was incorporated into the peptide and
peptidomimetic structures using standard Fmoc-based solid-phase peptide synthesis methods
to afford the two compounds 25 and 26 (Figure 6-4).
NO9
.NO2
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N
0
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NO2HN
N
< N H 0 N,,02
(Y H 0H H 
NH3
+
NBD-peptidomimetic
26
Figure 6-4. NBD labeled structures. (A) Peptide (25). (B) Peptidomimetic (26).
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These NBD-labeled compounds were incubated with CHO cells at 20 jtM for 2 hours
and visualized under a fluorescence microscope to determine if the peptide and
peptidomimetic are able to permeate the cell membrane. These fluorescence studies showed
no fluorescence inside the cells for both the NBD-labeled peptide and peptidomimetic
compounds (25 and 26) indicating that the peptidomimetic, although more hydrophobic than
the peptide, was still unable to permeate the lipophilic cell membrane.
The peptidomimetic inhibitor (26) incorporates several aromatic moieties in its
backbone and has reduced amide-bond character that enhances its hydrophobicity. However,
the presence of the charged amine on the diaminobutyric acid (Dab) side chain may encumber
the ability of the peptidomimetic to interact with the lipophilic cell membrane.6 To investigate
if the charge on the Dab side chain was hampering cell permeability, a further NBD-tagged
construct was synthesized where the free amine on the Dab side chain was capped with the
NBD fluorophore (27). The resulting aryl amine has a lower pKa relative to the primary amine
and is hence neutral at physiological pH (Figure 6-5).
Figure 6-5. Peptidomimetic construct (27) with the NBD-capped Dab side chain.
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This compound was synthesized on solid-phase using an Alloc-protected Dab amino
acid derivative, which was orthogonally deprotected using tetrakistriphenylphosphine
palladium (0) and elaborated with NBD-chloride to yield the NBD-capped inhibitor 27
(Scheme 6-1).10
N
0
v5~O
a, b
H
O)- N
0
ONN
N- 
I c
27
Scheme 6-1. Synthesis of the NBD-labeled peptidomimetic 27.a
aReagents and conditions: (a) Pd(PPh3)4, phenylsilane, CH2Cl2; (b) NBD-Cl
(nitrobenzoxadiazolyl chloride), DIPEA, DMF; (c) cleavage from resin (95% TFA).
184
e
When compound 27 was incubated with CHO cells as before and visualized under the
fluorescence microscope, the cells were brightly fluorescent (Figure 6-6). This compound
permeates the cell membrane very efficiently, suggesting that the charged amine on the Dab
side chain was indeed hindering the ability of the inhibitor to permeate the cell membrane.
Figure 6-6. Cellular uptake studies with the NBD-Iabeled peptidomimetic 27.
Coumarin-based prodrug approach
The fluorescence uptake experiments suggest that the charged amine on the Dab side
chain prevents cell permeation. This charged amine is, however, crucial for interaction with
the OT active site, as inhibitors without this charge show no activity in vitro. Hence, it is
necessary to transiently mask the side chain using a prodrug approach to inhibitor design. The
prodrug strategy involves derivatizing certain polar functional groups transiently and
bioreversibly to 'mask' the undesirable physicochemical characteristics of these groups
without permanently altering the pharmacological properties of the molecule. I I This strategy
has been very successful in cases where a carboxyl or a hydroxyl group is derivatized into an
'.
ester group that is readily hydrolyzed in vivo by esterases.12, 13 In the case of amine
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functionalities, the task becomes more complicated as there are few chemical methods
available to derivatize an amino group bioreversibly due to the inherent chemical stability of
an amide linkage relative to that of an ester. 14
The coumarin-based prodrug system takes advantage of the facile lactonization of cis-
coumarinic acid and its derivatives. In such a strategy, a latent nucleophile can be unmasked
using an esterase triggering mechanism that, in turn, initiates the cyclization reaction to
release the parent drug (Figure 6-7). 15-17 Similar coumarinic derivatives have been
successfully utilized in the synthesis of opioid peptides, 18 and peptidomimetic glycoprotein
IIb/IIIa antagonists, 17, 19 and have shown increased membrane permeability.
x x x
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Figure 6-7. Mechanism of release of the coumarin-based prodrug, X inhibitor.
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Scheme 6-2. Synthesis of the Coumarin-based prodrug precursor (31).a
aReagents and conditions: (a) LDA/THF, -78 °C; (b) Ac 2 0, Et 3N; (c) H2, Lindlar's catalyst,
EtOH.
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The synthesis of the coumarin precursor was previously described in the literature,7 and
involves a 4-step procedure starting with benzofuran-2-carboxylic acid (28) (Scheme 6-2).
Lithium diisopropylamine (LDA) treatment produces 3-(2-hydroxyphenyl)propynoic acid
(29). Esterification of the phenol with acetic anhydride yields the phenolic ester (30). The
final step involves a catalytic hydrogenation of the alkyne with Lindlar's catalyst to yield the
cis double bond in the coumarin precursor (31).
OMe
d, U, 
32
I d
4
33
Scheme 6-3. Synthesis and esterase-cleavage of the coumarin-based prodrug.a
aReagents and conditions: (a) Pd(PPh3)4, phenylsilane; (b) 31, HATU, DIPEA, DMF; (c)
cleavage from resin (95% TFA); (d) cellular esterases.
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This precursor is then coupled to the free amine on the Dab side chain on solid phase to
afford the final prodrug 32 after cleavage with 95% TFA (Scheme 6-3). A dinitrobenzoyl cap
was installed at the N-terminus to enable visualization in cells using a commercial antibody
that specifically recognizes dinitrobenzene. 20 Upon exposure to cellular esterases, the
coumarin masking group is released to reveal the active inhibitor 33.
Incubation of the coumarin-based prodrug 32 in CHO-cell lysate showed minimal
cleavage of the coumarin after 12 hours by HPLC analysis. Since the rate limiting step is the
esterase-catalyzed cleavage of the acetate that triggers cyclization, it appears that the
coumarin-bound inhibitor 32 is a poor substrate for these cellular esterases. Since there is
negligible active inhibitor 33 formed after 12 hours, it is unlikely that this prodrug approach
will be successful in targeting OT inhibitors into cells and hence this approach was
abandoned.
Caged inhibitor
Another method, similar to the coumarin-based prodrug approach, to transiently mask a
functionality, is the use of a photo-labile protecting group. Similar methods have been
successful in the investigation of nitric oxide synthase, carbonic anhydrase and other signaling
pathways.2 -23 Upon incubation with the protected form for several hours, the cells would be
illuminated to cleave the photo-labile group and release free inhibitor within the cell. A
nitroveratryloxycarbonyl (NVoc) group was chosen as the 'cage' and incorporated into the
inhibitor framework on solid phase to afford compound 34 (Scheme 6-4).24 25
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Scheme 6-4. Synthesis and photolysis of the NVoc-labeled inhibitor.a
aReagents and conditions: (a) Pd(PPh3 )4, phenylsilane; (b) NVoc-Cl, DIPEA, DMF; (c)
cleavage from resin (95% TFA); (d) illuminate at = 365 nm.
Cleavage of the NVoc protecting group was tested in vitro, by illuminating a solution of
the caged inhibitor (34) using a transilluminator and monitoring the release of the inhibitor
(20) using HPLC analysis. Within 5 minutes, almost 70% cleavage of the NVoc group had
occurred (Figure 6-8). This compound could be used as a potential inhibitor by incubating
with cells, illuminating the cells at 365 nm to remove the NVoc protection and monitoring the
activity of the inhibitor.
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Figure 6-8. Photolysis of the NYoc group (progress monitored by HPLC).
Secreted Alkaline Phosphatase (SeAP) Assay
In order to study the effectiveness of OT inhibitors in vivo, it was necessary to develop
an assay to monitor N-linked glycosylation within cells. Since we now have a series of
potential candidates for inhibition in vivo, it was desirable to design an assay system that is
high-throughput and amenable to screening several compounds concurrently.
The assay that we developed is based on a stably-transfected CHO cell line expressing a
reporter-recombinant glycoprotein, SeAP (Secreted Alkaline Phosphatase). SeAP is a...
glycoprotein that contains several N-linked glycosylation sites,26,27and previous studies on
insect cells have shown that pre-treating cells with tunicamycin results in a dramatic decrease
in the amount of SeAP secreted into the media.27This sparked the idea of a possible use for
SeAP to monitor levels of glycosylation in cells. Inhibiting N-linked glycosylation would
result in a decrease in SeAP activity and this activity can be easily detected in the
extracellular media through a fluorescence, chemiluminescence or UV-based absorbance
assay.
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The Kompala group at DC Boulder (Department of Chemical Engineering) has
developed a stably transfected CHO cell line that produces SeAP when activated with a
hormone, dexamethasone.28-3o An MMTV-promoter replaces the SV40-promoter found in the
commercially available plasmid, resulting in lO-times greater protein production. The ability
to induce protein production is also an advantage as the cells can be incubated with inhibitors
prior to initiating protein production.
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Figure 6-9. Schematic of the SeAP assay with and without inhibitors of N-linked
glycosylation.
We obtained this cell line from the Kompala Group and started cell growth in a-MEM
supplemented with Geneticin to select for cells containing the SeAP plasmid. The cells are
then grown in a 96-well plate and incubated overnight with inhibitors after which SeAP
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production is induced with the addition of dexamethasone. After 24 hours, a sample of the
media is removed from each well and subjected to the addition of methylumbelliferyl
phosphate (MUP). MUP is a coumarin derivative that is not fluorescent, but upon the action
31
of the phosphatase, the phosphate is cleaved to yield a fluorescent coumarin derivative.3
Hence, control cells that do not contain inhibitor will produce fully glycosylated SeAP that is
released into the media resulting in a high fluorescence reading. On the other hand, cells that
are exposed to an inhibitor of N-linked glycosylation will produce unglycosylated SeAP that
is not properly folded and hence not secreted. Thus there will be lower levels of SeAP in the
extracellular milieu in the presence of inhibitor, resulting in a lower fluorescence reading
(Figure 6-9).
In order to validate the principal behind the SeAP assay, tunicamycin was used as a
positive control. Cells exposed to tunicamycin show reduced protein glycosylation, hence less
SeAP is secreted into the media, resulting in a lower fluorescence signal. This observation
was verified by incubating the cells with increasing amounts of tunicamycin and monitoring
SeAP production. As shown in Figure 6-10, as the amount of tunicamycin is increased, there
is a stepwise decrease in the fluorescence signal, indicating that there is reduced SeAP in the
media.
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Figure 6-10. SeAP assay with increasing concentrations of tunicamycin.
Inhibitor library.
All of the inhibitors synthesized were tested using the SeAP assay. The inhibitors
shown in Figure 6-11 are all in vitro inhibitors of OT with Ki values in the low to high-
nanomolar range. These inhibitors display a variety of physical characteristics differing in
size, hydrophobicity and amide-bond content. Several of the inhibitors have been verified to
permeate the cell membrane and are shown to be stable to proteolytic digestion. It is as yet
unknown if any or all of these compounds are able to permeate the membrane of the
endoplasmic reticulum and bind to the peptide-binding site of the membrane-bound OT
complex.
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Figure 6-11. Library of peptide and peptidomimetic inhibitors tested in the SeAP assay.
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Naphthyl based inhibitor
All of the inhibitors illustrated in Figure 6-11 were assayed in the SeAP system at 50
[tM concentration. Only one inhibitor yielded a positive result and this was compound 35,
which bears a naphthyl group in the backbone. This compound was synthesized on solid
phase, by the coupling of Alloc-protected 6-amino-2-naphthoic acid to the resin. Alloc
deprotection was then followed by standard peptide-coupling chemistry to yield 35 (Scheme
6-5).
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Scheme 6-5. Solid-phase synthesis of the naphthyl-based inhibitor (36).a
aReagents and conditions: a) nitrobenzylamine, trimethyl orthoformate, dichloroethane; b)
sodium triacetoxyborohydride; c) Alloc-6-amino-3-naphthoic acid, HATU, DIPEA; d)
Pd(PPh3)4, phenylsilane; e) standard solid phase peptide coupling of Fmoc-Thr(tBu)-OH, Fmoc-
Nva-OH, Fmoc-Dab(Boc)-OH, followed by capping with benzoic anhydride and pyridine; f)
cleavage from resin (95% TFA).
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Similar to the SeAP assay with tunicamycin, the fluorescence data for the naphthyl-
based inhibitor displayed a stepwise decrease in fluorescence upon addition of increasing
inhibitor (Figure 6-12). Even at levels as low as 8 tM of inhibitor, there is a significant
decrease in the amount of SeAP in the media, which is a very promising indication of an
inhibitor that functions in vivo. This naphthyl-based inhibitor has a Ki of 900 M in vitro,
which is relatively poor compared to some of the other inhibitors in the library. However, this
compound has a log P value that is 4.01 +/- 1.16, which is higher than any other member of
the library.32 These data suggests that this naphthyl-based inhibitor functions in vivo due to its
extreme hydrophobicity and its ability to cross the lipophilic cell membrane more efficiently
than the other members of the library.
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Figure 6-12. SeAP data for the naphthyl-based inhibitor 35.
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Metabolic Labeling Assay.
Although the SeAP assay functions well as a high-throughput assay to screen a library
of compounds concurrently, it is a "negative read-out" assay, which is not optimal. Hence we
propose using the SeAP assay as a first-round high-throughput screen for inhibitors of
glycosylation, then following up with a more labor intensive secondary assay on the "hits"
from the SeAP assay in order to further confirm the data.
The secondary assay that was used relies on the same cell line as before. Instead of
simply monitoring the formation of SeAP by fluorescence analysis of the media, we probed
for both glycosylated and unglycosylated forms of SeAP using a metabolic
labeling/immunoprecipitation approach. The cells were plated and incubated with inhibitor as
before and SeAP production was induced with dexamethasone. The media from the wells was
collected and the cells lysed to release all proteins sequestered inside. The combined cell
media and lysate mixtures were treated with an antibody specific to SeAP. This antibody
binds both glycosylated and unglycosylated SeAP in the solution, and protein G beads are
used to pull down this antibody-protein complex (Figure 6-13). The proteins released from the
G-beads by boiling are separated by SDS-page electrophoresis, which should show
glycosylated SeAP in the control lanes with no inhibitor, but unglycosylated SeAP in those
cells treated with inhibitor. The unglycosylated band should run noticeably faster than the
glycosylated band.
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Figure 6-13. Schematic of the metabolic labeling/immunoprecipitation assay.
Our first few attempts at this assay used a commercially available anti-human placental
alkaline phosphatase antibody. However, we discovered that this antibody and all others that
are commercially available are conformational antibodies that recognize only the fully-folded
protein. Since the unglycosylated SeAP that we are monitoring is unfolded, we were unable to
visualize a band corresponding to unglycosylated protein. In order to circumvent this
problem, we custom synthesized an antibody to SeAP based on a 15 amino acid sequence that
is present in an exposed-loop region of SeAP. With this antibody in hand, attempts to
definitively prove that inhibitor 35 is affecting N-linked glycosylation can be undertaken.
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Conclusion
In order to investigate the downstream effects of glycosylation on protein function, it is
vital to obtain an inhibitor of N-linked glycosylation that functions in a cellular milieu.
Although tunicamycin, a microbial natural product, does act in vivo, it acts several metabolic
steps prior to the actual glycosylation step, hence its effect is not immediate. For these
reasons, it would be ideal to obtain an inhibitor that directly targets OT in vivo.
As discussed in Chapter 5, peptide-based inhibitors of OT were modified to yield
several peptidomimetic structures that demonstrated low nanomolar affinity for the enzyme.
Through cell lysate incubations, we demonstrate that a representative member of the
peptidomimetic library (compound 20) displays greater proteolytic stability compared to the
peptide counterpart (4). Several prodrug and caging strategies are used to transiently mask the
charge on the amine of the Dab side chain, which hinders cell permeability. These studies
afforded several inhibitors as potential candidates for in vivo inhibition of OT, and also
provided insight into the properties that make compounds more cell-permeable and stable to
proteases.
In order to monitor glycosylation in cells, a novel, high-throughput assay based on the
activity of a secreted glycoprotein, SeAP, was developed. This assay allows inhibitor
screening in a 96-well format, providing a fast read-out that reveals the cellular activity of the
inhibitors. Using this SeAP assay, a hydrophobic inhibitor, based on a naphthyl scaffold (35),
emerged as a successful candidate. Ongoing and future work involves the development of a
secondary assay to directly visualize the production of unglycosylated protein in the presence
of this inhibitor, so as to unambiguously prove that it is targeting N-linked glycosylation.
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Experimental
General procedure for solid-phase peptide synthesis
All peptides, unless otherwise noted, were synthesized by manual solid-phase methods
using Fmoc-PAL PEG resin and using Fmoc (9-fluorenylmethoxycarbonyl) as the protecting
group for the -amino functionalities. Amino acids were coupled using either 1-
benzotriazolyloxytris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) or 0-(7-
azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and DIPEA
to generate the activated ester. The resin was swelled in dichloromethane (5 min.) and DMF
(5 min.) prior to use. Couplings to the resin were performed in the following order: removal
of the Fmoc group (20% piperidine solution in DMF, 3 x 5 min.), wash (DMF, 5 x 1 min.),
coupling (amino acid/PyBOP/DIPEA, 1:2:2 in DMF, 1 hour) and rinse (DMF, 2 x 1 min.,
CH2Cl2, 2 x min.). All amino acids were obtained commercially as the N-a-Fmoc-protected
derivatives with the following side-chain protection: Dab(Boc), Dab(Alloc), Thr(t-Bu). At the
conclusion of the peptide synthesis, the peptides were capped with a large excess (10 eq) of
benzoic anhydride and pyridine (10 eq). Cleavage from resin was performed with
trifluoroacetic acid (TFA): CH2Cl2: triisopropylsilane: H20 (90:5:2.5:2.5). The mixture was
then filtered to remove the resin and concentrated under a stream of nitrogen. The resulting
pellet was triturated with ice-cold ether and redissolved in DMSO. The DMSO solution was
then diluted into a solution of 1:1 water:acetonitrile and the peptides were purified by
preparative HPLC (C18) using a gradient of increasing acetonitrile/0.1%TFA (solvent A) in
water/0.1%TFA (solvent B): the standard gradient used in this study was 93:7 A:B to 0:100
A:B in 35 mins. Elution from the column was monitored by UV absorbance at 280 nm and
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228 nm, and the product peak was collected and lyophilized. All peptide identities were
confirmed by electrospray mass spectrometry (ESI-MS) and the peptide solutions were
quantified by UV absorbance at 280 nm (E280 = 12,800 M-1 cm-l for thep-nitrophenyl group).
Synthesis of Bz-Dab-Dap(NBD)-Thr-Val-Thr-Nph-NH2 (25)
0
I~~~~~~~~~~~~~~
NH3
+
Fmoc-PAL-PEG PS resin was used and Fmoc-Nph-OH, Fmoc-Thr(tBu)-OH, Fmoc-Val-OH,
and Fmoc-Dab(Boc)-OH were coupled using standard Fmoc-based peptide synthesis. A
Fmoc-Dap(NBD)-OH amino acid that was previously synthesized in the group by Dr.
Eugenio Vazquez was used to install the NBD fluorophore. This coupling was performed
using standard procedure. The peptide was capped with benzoic anhydride, cleaved from resin
and purified by HPLC.
HPLC tR= 24.11 min (C1 8, 7-100% B in 28 min)
LRMS calcd for 25 (C42H54N 3 0 14+) requires m/z 964.9. Found 964.3 (ESI+)
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Synthesis of Bz-Dab-Dap(NBD)-Thr-(3-aminobenzoic acid)-NH-CH2-Ph-NO2 (26)
N02
S N
N
NO2
H
N N
0
This peptide was synthesized on 3-(4-formyl-3-methoxyphenoxy)ethyl polystyrene (FMPE)
resin available from Novabiochem. The resin was swelled in trimethylorthoformate (TMOF)
and dichloroethane (DCE) 3:2 for 20 minutes. 4-nitrobenzylamine (10 eq) was added to the
resin and stirred under N2 for 3 hours, then 10 eq of sodium triacetoxyborohydride was added
and the mixture shaken overnight. Alloc-protected 3-aminobenzoic acid was added in excess
(4 eq) with HATU (4 eq) and diisopropylethylamine (DIPEA) (8 eq). The coupling was
allowed to proceed overnight, after which alloc deprotection was performed with
tetrakis(triphenylphosphine) palladium (0) (0.2 eq) and phenylsilane (25 eq) in CHCl2. Three
20-minute deprotections were performed under an N2 atmosphere. Fmoc-Thr(tBu)-OH
coupling was performed using HATU as above, and the subsequent Fmoc-Dap(NBD)-OH and
Fmoc-Dab(Boc)-OH residues were coupled using standard procedure.
HPLC tR= 26.29 min (C18, 7-100% B in 28 min)
LRMS calcd for 26 (C38H4 0N110 11+) requires m/z 826.8. Found 826.2 (ESI+)
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Synthesis of Bz-Dab(NBD)-Nva-Thr-(3-aminobenzoic acid)-NH-CH 2-Ph-NO2 (27)
i4N J N
0
The procedure for the synthesis of compound 26 was followed except that after the coupling
of Fmoc-Thr(tBu)-OH, Fmoc-Nva-OH was coupled. This was followed by the coupling of
Fmoc-Dab(Alloc)-OH. The peptide was capped with benzoic anhydride as before. The alloc
side chain on the Dab residue was removed with tetrakis(triphenylphosphine) palladium (0)
(0.2 eq) and phenylsilane (25 eq) in CHCl2. Three 20-minute deprotections were performed
under a N2 atmosphere. The side chain on the Dab was capped with 4 eq. of
nitrobenzoxadiazolyl chloride (NBD-Cl) and 4 eq. of diisopropylethylamine (DIPEA) in
DMF. The reaction was allowed to proceed for 2 hours and the compound was cleaved from
the resin and purified by HPLC as before.
HPLC tR= 29.02 min (C18, 7-100% B in 28 min)
LRMS calcd for 27 (C4 0H4 2N1 Ol 1) requires m/z 838.3. Found 839.6 (ESI+)
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Synthesis of the coumarin-based prodrug (3,5-DNB-Dab(Coum)-Nva-Thr-(3-
aminobenzoic acid)-NH-CH2 -Ph-NO2) (32)
NO2
H IIN , '.
The procedure for the synthesis of compound 27 was followed. After the coupling of Fmoc-
Dab(alloc)-OH, the peptide was capped with 3,5-dinitrobenzoyl chloride (4 eq.) and DIPEA
(4 eq.) in DMF. The alloc side chain on the Dab residue was removed as described before
with tetrakis(triphenylphosphine) palladium (0) (0.2 eq) and phenylsilane (25 eq) in CH2Cl2.
The coumarinic acid precursor was synthesized as described in the literature17 and coupled to
the Dab side chain using HATU and DIPEA. The compound was then cleaved from the resin
and purified by HPLC as before.
HPLC tR= 29.51 min (C18 , 7-100% B in 28 min)
LRMS calcd for 32 (C45H47N9015+) requires m/z 953.3. Found 954.2 (ESI+)
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Synthesis of the caged inhibitor (Bz-Dab(NVoc)-Nva-Thr-(3-aminobenzoic acid)-NH-
CH2 -Ph-NO 2 ) (34)
NO2
The procedure for the synthesis of compound 27 was followed. After deprotection of the alloc
protection on the Dab side chain, the nitroveratryloxycarbonyl (NVoc) group was installed by
coupling the free amine to NVoc-chloride (2 eq.) with DIPEA (4 eq.). The peptide was
cleaved from resin and purified as before.
HPLC tR= 30.41 min (C18, 7-100% B in 28 min)
LRMS calcd for 34 (C48H48N120 17+) requires m/z 1065.0. Found 1065.3 (ESI+)
Synthesis of Naphthyl-based inhibitor (Bz-Dab-Nva-Thr-(6-amino-2-naphthoic acid)-
NH-CH 2-Ph-NO 2 ) (36)
H
N,
0 <
I
NH3
+
This inhibitor was synthesized by performing a reductive amination on FMPE resin with 4-
nitrobenzylamine as described previously. This was followed by the coupling of alloc-
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protected 6-amino-2-naphthoic acid to the resulting resin-bound secondary amine using
HATU (4 eq.) and DIPEA (4 eq.). The alloc protection is removed with
tetrakis(triphenylphosphine) palladium (0) (0.2 eq) and phenylsilane (25 eq) in CH2C12. The
remaining amino acids are then coupled using standard procedure.
HPLC tR= 30.41 min (C18, 7-100% B in 28 min)
LRMS calcd for 34 (C38H44N708+) requires m/z 726.8. Found 726.9 (ESI+)
Cell lysate stability assay.
CHO K1 cells were grown on a 6-well plate until they reached 80% confluency. The media
was removed from the wells and the cells lysed with 1 mL of PBS containing 1% Triton X-
100. After agitating the cells in the lysis buffer for 15 minutes, the lysate was transferred to an
eppendorf tube and centrifuged to remove cell debris. Solutions of the peptide (4) and
peptidomimetic (20) in DMSO were added to 1 mL of lysate to a final concentration of 20 [tM
(1% final volume of DMSO). The lysates were incubated at 35 °C for 24 hours, filtered to
remove any precipitate and analyzed by analytical HPLC (C18) using a gradient of increasing
acetonitrile/0.1%TFA in water/0.1%TFA (93% to 0% water in 35 mins.). Elution of the
peptide was detected by UV absorbance at both 228 nm and 280 nm. A blank run of lysate
with no inhibitor was used as a control to determine which of the peaks were due to the
exogenous compounds added to the lysate.
Cell permeability assays
CHO K1 cells were plated on glass slides (2E6 cells/well) and allowed to grow for 4-6 hours.
The inhibitors (in DMSO) were then added with complete media (200 L with 1% final
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volume of DMSO) and the cells incubated overnight. The media was removed and the cells
washed thoroughly with PBS + 0.5% FBS and observed under the fluorescent microscope
with a filter set corresponding to the absorption and emission wavelengths of NBD ( = 481
nm, Xem = 541 nm).
Cell ysate incubation of the coumarin-based prodrug
CHO K1 cell lysate was prepared as before using PBS + 1% Triton X-100. 50 !IM of the
Coumarin-based prodrug was incubated in the cell lysate and cleavage of the prodrug moiety
was monitored by HPLC (C18). Aliquots of the lysate mixture were removed at 1 hour, 2 hour,
5 hour and 15 hour time points and injected on the HPLC. Cleavage of the coumarin was
monitored by observing the peaks at X = 228 nm and X = 280 nm.
Photolysis of NVoc-protected inhibitor
The concentrated inhibitor stock (in DMSO) was diluted into PBS buffer to a final
concentration of 50 M. The samples were then irradiated with a UVP UV Transilluminator,
365 nm, 7330 [tW/cm2 at the surface, in vessels with a path length of 1 mm. The samples
were irradiated for 2 min. and 5 min. and the extent of photolysis monitored by injecting the
samples on the HPLC.
SeAP Assay
MMapG CHO cells were grown in a-MEM supplemented with 10 % FBS, 4 mg/ml Geneticin
and Penn/Strep. To run the assay, the cells were plated in a 96-well plate at 1E6 cells/ml in
200 tL of CD-CHO serum-free media (Gibco/Invitrogen) supplemented with 1% FBS. The
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cells were allowed to settle for 4 hours and inhibitors (in DMSO) were added (2.5% final
DMSO concentration). The cells were incubated overnight in the presence of inhibitors. The
media was then removed and replaced with fresh media containing fresh inhibitors and 1 mM
dexamethasone. The cells were then incubated for 24 hours, after which they were assayed for
SeAP activity. 5 [tL from each well was transferred to a black well plate, and 95 [tL of methyl
umbelliferyl phosphate (MUP) solution was added. The MUP solution is premixed and is a 1
jiM solution of MUP in 2 mM diethanolamine. The plate was then incubated in the dark at 35-
40 °C and the fluorescence recorded using a HTS 7000 BioAssay Reader (Perkin-Elmer). ex
= 360 nm, ,m = 430 nm.
Metabolic Labeling Assay:
This assay is performed in a 24-well plate with 500 tL of media. The night before,
MMapG CHC) cells were plated at 3E5 cells/well in 500 pL of media (-MEM, 5% dialyzed
FBS, penn/strep, 100 pM MSX). Inhibitors were added at this time. 24 hours later, the media
was removed from cells and washed with PBS. 500 jtL per well of Met-/Cys- DMEM (+5%
FBS, Penn/Strep, MSX) was added. Inhibitor was added along with 5 gL of Trans S-35 label.
The cells were incubated for 5 hours at 37 °C in the CO2 incubator. The media was transferred
to an eppendorf tube, spun to remove cell debris and the supemrnatant ransferred to a fresh
tube. The cells were lysed with 300 pL PBS + 1% Triton X and added to the cell media. A 4-
uL portion of antibody (anti-human placental alkaline phosphatase, 3 g/ml) was added
together with 50 ,uL of 1 M Tris-Cl pH 7.5. The media was incubated at 4 °C for 1 hour, then
30 ,uL of well-resuspended protein-G beads were added and incubated for another hour. The
beads were pelleted and washed 3 times with 500 jtL wash buffer (1X PBS with 0.5% Triton-
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X) and after the final wash the beads were taken up in 15 tL Laemmeli running buffer. The
samples were boiled and the supernatant loaded on a 15% SDS-PA gel using pre-stained
markers and C-14 labeled markers. After running the gel, it was dried on a gel-dryer and read
on a Phospholmager after exposing for 24 hours.
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Appendix
NMR data
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Benzyl 2-acetamido-3,6-di-O-benzoyl-2-deoxy-3-D-galactopyranoside (6)
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Benzyl 2-acetamido-4-azido-3,6-di-O-benzoyl-2,4-deoxy-p-D-glucopyranoside (7)
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Benzyl 2-acetamido-4-azido-2,4-deoxy-j3-D-glucopyranoside (8)
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Benzyl 2-acetamido-4-azido-6-tosyloxy-2,4-deoxy-J3-D-glucopyranoside (9)
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Benyzl 2-acetamido-4-azido-6-iodo-2,4,6-deoxy-,3-D-glucopyranoside (10)
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Benzyl 2,4-acetamido-3-O-acetyl-2,4,6-deoxy-p3-D-glucopyranoside (11)
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Benzyl 2,4-acetamido-2,4,6-deoxy-f3-D-glucopyranoside (12)
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Benzyl 2,4-acetamido-3-O-benzoyl-2,4,6-deoxy-3-D-glucopyranoside (13)
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2-4-acetamido-3-O-benzoyl-2,4,6-deoxy-D-glucopyranoside (14)
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Dibenzylphospho-2,4-acetamido-3-O-benzoyl-2,4,6-deoxy-a-D-gluocopyranoside (15)
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Dibenzylphospho-2,4-acetamido-3-O-benzoyl-2,4,6-deoxy-a-D-gluocopyranoside (15)
(continued)
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Dibenzylphospho-2,4-acetamido-3-O-benzoyl-2,4,6-deoxy-a-D-glucopyranoside (2)
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Dibenzylphospho-2,4-acetamido-3-O-benzoyl-2,4,6-deoxy-a-D-glucopyranoside (2)
(continued)
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Uridin-5'-yl (2,4-diacetamido-2,4,6-trideoxy-a-D-glycopyranosyl) diphosphate (3)
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Undecaprenyl-pyrophosphate bacillosamine (4)
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Benzyl 2,4-acetamido-3,6-O-benzoyl-2,4-deoxy-p3-D-gluocpyranoside (20)
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2,4-acetamido-3,6-O-acetyl-2,4-deoxy-p3-D-glucopyranoside (21)
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Dibenzylphospho-2,4-acetamido-3,6-O-benzoyl-2,4-deoxy-a-D-glucopyranoside (22)
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Dibenzylphospho-2,4-acetamido-3,6-O-benzoyl-2,4-deoxy-a-D-glucopyranoside (22)
(continued)
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Phospho-2,4-acetamido-3,6-O-benzoyl-2,4-deoxy-a-D-glucopyranoside (23)
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Phospho-2,4-acetamido-3,6-O-benzoyl-2,4-deoxy-a-D-glucopyranoside (23)
(continued)
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Undecaprenyl-pyrophosphate 6-hydroxybacillosamine (18)
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Undecaprenyl-pyrophosphate N-acetylglucosamine (19)
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Geranylgeranyl-PP-Bac-6-OH (24)
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Geranylgeranyl-PP-Bac-6-OH (24) (continued)
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Dolichol-pyrophosphate Bac-6-OH (25)
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